

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
001 ALAN AMINO	ALT/SGPT	CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE	20	%								
2024-781	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	22	14.545	1.588	10.92	12.000	17.000				
2024-781	8 OX.OF NADH	220 Medica E.	130 MEDICA	10	17.400	1.200	6.90	14.000	21.000				
2024-781	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	84	19.964	1.911	9.57	16.000	24.000				
2024-781	11 MOD. IFCC	184 INTEGRA	93 ROCHE	17	14.647	1.185	8.09	12.000	18.000				
2024-781	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	32	14.188	0.634	4.47	11.000	17.000				
2024-781	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	30	17.552	1.868	10.64	14.000	21.000				
2024-781	11 MOD. IFCC	203 ROCHE	93 ROCHE	43	15.310	1.012	6.61	12.000	18.000				
2024-781	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	18	18.294	0.892	4.88	15.000	22.000				
2024-781	12 IFCC witho	203 ROCHE	93 ROCHE	14	15.571	1.678	10.78	12.000	19.000				
2024-781	13 ALA &aKETO	165 VITROS	155 ALTV	135	13.037	0.884	6.78	10.000	16.000				
2024-782	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	22	197.381	7.007	3.55	158.000	237.000				
2024-782	8 OX.OF NADH	220 Medica E.	130 MEDICA	10	181.500	5.954	3.28	145.000	218.000				
2024-782	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	84	209.313	4.953	2.37	167.000	251.000				
2024-782	11 MOD. IFCC	184 INTEGRA	93 ROCHE	17	192.059	4.988	2.60	154.000	230.000				
2024-782	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	32	176.645	3.815	2.16	141.000	212.000				
2024-782	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	30	231.033	16.384	7.09	185.000	277.000				
2024-782	11 MOD. IFCC	203 ROCHE	93 ROCHE	43	194.929	4.501	2.31	156.000	234.000				
2024-782	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	18	229.056	6.205	2.71	183.000	275.000				
2024-782	12 IFCC witho	203 ROCHE	93 ROCHE	14	195.692	4.065	2.08	157.000	235.000				
2024-782	13 ALA &aKETO	165 VITROS	155 ALTV	135	183.812	4.587	2.50	147.000	221.000				
2024-783	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	22	282.864	12.422	4.39	226.000	339.000				
2024-783	8 OX.OF NADH	220 Medica E.	130 MEDICA	10	256.800	7.600	2.96	205.000	308.000				
2024-783	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	84	295.060	8.696	2.95	236.000	354.000				
2024-783	11 MOD. IFCC	184 INTEGRA	93 ROCHE	17	273.176	6.391	2.34	219.000	328.000				
2024-783	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	32	250.742	5.465	2.18	201.000	301.000				
2024-783	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	30	331.267	23.056	6.96	265.000	398.000				
2024-783	11 MOD. IFCC	203 ROCHE	93 ROCHE	43	278.163	7.704	2.77	223.000	334.000				

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-783	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	18	326.333	6.254	1.92	261.000	392.000	
2024-783	12 IFCC witho	203	ROCHE	93	ROCHE	14	277.643	5.511	1.98	222.000	333.000	
2024-783	13 ALA &aKETO	165	VITROS	155	ALTV	135	254.940	6.243	2.45	204.000	306.000	
001	ALAN AMINO ALT/SGPT	CLIA TEST ID #: 255				EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-784	5 ENZ. 37 C	197	ARCHITECT	1	ABBOTT	22	123.667	4.098	3.31	99.000	148.000	
2024-784	8 OX.OF NADH	220	Medica E.	130	MEDICA	10	114.500	3.106	2.71	92.000	137.000	
2024-784	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	84	133.337	3.581	2.69	107.000	160.000	
2024-784	11 MOD. IFCC	184	INTEGRA	93	ROCHE	17	121.588	3.362	2.76	97.000	146.000	
2024-784	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	32	110.813	3.097	2.79	89.000	133.000	
2024-784	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	30	145.633	8.487	5.83	117.000	175.000	
2024-784	11 MOD. IFCC	203	ROCHE	93	ROCHE	43	123.071	3.327	2.70	98.000	148.000	
2024-784	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	18	145.056	2.321	1.60	116.000	174.000	
2024-784	12 IFCC witho	203	ROCHE	93	ROCHE	14	122.000	3.703	3.04	98.000	146.000	
2024-784	13 ALA &aKETO	165	VITROS	155	ALTV	135	117.195	2.982	2.54	94.000	141.000	
2024-785	5 ENZ. 37 C	197	ARCHITECT	1	ABBOTT	22	69.524	2.302	3.31	56.000	83.000	
2024-785	8 OX.OF NADH	220	Medica E.	130	MEDICA	10	66.500	4.387	6.60	53.000	80.000	
2024-785	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	84	77.337	2.262	2.92	62.000	93.000	
2024-785	11 MOD. IFCC	184	INTEGRA	93	ROCHE	17	67.765	2.414	3.56	54.000	81.000	
2024-785	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	32	62.469	1.695	2.71	50.000	75.000	
2024-785	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	30	81.897	4.054	4.95	66.000	98.000	
2024-785	11 MOD. IFCC	203	ROCHE	93	ROCHE	43	69.357	1.730	2.49	55.000	83.000	
2024-785	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	18	82.167	2.062	2.51	66.000	99.000	
2024-785	12 IFCC witho	203	ROCHE	93	ROCHE	14	69.571	1.879	2.70	56.000	83.000	
2024-785	13 ALA &aKETO	165	VITROS	155	ALTV	135	65.679	2.024	3.08	53.000	79.000	
002	ALBUMIN	CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-781	3 DYE BI-B.G	165	VITROS	63	KODAK	146	1.764	0.070	3.97	1.600	1.900	
2024-781	3 DYE BI-B.G	184	INTEGRA	93	ROCHE	26	2.020	0.057	2.80	1.800	2.200	
2024-781	3 DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	33	1.884	0.051	2.69	1.700	2.100	
2024-781	3 DYE BI-B.G	191	RX-SERIES	126	RANDOX	32	1.941	0.093	4.80	1.700	2.100	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-781	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	12	1.800	0.041	2.27	1.600	2.000
2024-781	3	DYE BI-B.G	203	ROCHE	93	ROCHE	58	2.028	0.121	5.97	1.800	2.200
2024-781	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	17	1.906	0.042	2.18	1.700	2.100
2024-781	3	DYE BI-B.G	220	Medica E.	130	MEDICA	10	1.830	0.090	4.92	1.600	2.000
2024-781	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	89	1.675	0.043	2.59	1.500	1.800
2024-781	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	89	1.613	0.069	4.27	1.500	1.800
2024-781	5	DYE B-HABA	197	ARCHITECT	1	ABBOTT	11	1.800	0.074	4.10	1.600	2.000
002	ALBUMIN	CLIA TEST ID #: 265		EVALUATION CRITERIA: TARGET VALUE 10 %								
2024-782	3	DYE BI-B.G	165	VITROS	63	KODAK	146	3.458	0.104	3.02	3.100	3.800
2024-782	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	26	3.600	0.136	3.77	3.200	4.000
2024-782	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	33	3.488	0.074	2.12	3.100	3.800
2024-782	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	32	3.532	0.106	3.00	3.200	3.900
2024-782	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	12	3.375	0.060	1.76	3.000	3.700
2024-782	3	DYE BI-B.G	203	ROCHE	93	ROCHE	58	3.618	0.129	3.55	3.300	4.000
2024-782	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	17	3.524	0.064	1.83	3.200	3.900
2024-782	3	DYE BI-B.G	220	Medica E.	130	MEDICA	10	3.610	0.192	5.32	3.200	4.000
2024-782	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	89	3.154	0.103	3.25	2.800	3.500
2024-782	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	89	3.200	0.000	0.00	2.900	3.500
2024-782	5	DYE B-HABA	197	ARCHITECT	1	ABBOTT	11	3.400	0.095	2.80	3.100	3.700
2024-783	3	DYE BI-B.G	165	VITROS	63	KODAK	146	4.221	0.131	3.11	3.800	4.600
2024-783	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	26	4.238	0.127	3.00	3.800	4.700
2024-783	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	33	4.148	0.093	2.23	3.700	4.600
2024-783	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	32	4.203	0.133	3.17	3.800	4.600
2024-783	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	12	4.083	0.069	1.68	3.700	4.500
2024-783	3	DYE BI-B.G	203	ROCHE	93	ROCHE	58	4.288	0.102	2.38	3.900	4.700
2024-783	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	17	4.218	0.104	2.47	3.800	4.600
2024-783	3	DYE BI-B.G	220	Medica E.	130	MEDICA	10	4.330	0.168	3.87	3.900	4.800
2024-783	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	89	3.850	0.050	1.30	3.500	4.200
2024-783	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	89	3.853	0.118	3.07	3.500	4.200

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-783	5	DYE B-HABA	197	ARCHITECT	1	ABBOTT	11	4.091	0.100	2.43	3.700	4.500
002	ALBUMIN	CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-784	3	DYE BI-B.G	165	VITROS	63	KODAK	146	2.747	0.095	3.44	2.500	3.000
2024-784	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	26	2.946	0.084	2.86	2.700	3.200
2024-784	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	33	2.800	0.078	2.78	2.500	3.100
2024-784	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	32	2.872	0.128	4.46	2.600	3.200
2024-784	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	12	2.742	0.049	1.80	2.500	3.000
2024-784	3	DYE BI-B.G	203	ROCHE	93	ROCHE	58	2.968	0.126	4.24	2.700	3.300
2024-784	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	17	2.847	0.061	2.13	2.600	3.100
2024-784	3	DYE BI-B.G	220	Medica E.	130	MEDICA	10	2.910	0.170	5.84	2.600	3.200
2024-784	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	89	2.625	0.043	1.65	2.400	2.900
2024-784	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	89	2.516	0.080	3.16	2.300	2.800
2024-784	5	DYE B-HABA	197	ARCHITECT	1	ABBOTT	11	2.745	0.099	3.60	2.500	3.000
2024-785	3	DYE BI-B.G	165	VITROS	63	KODAK	146	2.268	0.069	3.05	2.000	2.500
2024-785	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	26	2.496	0.076	3.04	2.200	2.700
2024-785	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	33	2.356	0.070	2.99	2.100	2.600
2024-785	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	32	2.413	0.111	4.61	2.200	2.700
2024-785	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	12	2.300	0.000	0.00	2.100	2.500
2024-785	3	DYE BI-B.G	203	ROCHE	93	ROCHE	58	2.509	0.110	4.37	2.300	2.800
2024-785	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	17	2.388	0.032	1.35	2.100	2.600
2024-785	3	DYE BI-B.G	220	Medica E.	130	MEDICA	10	2.360	0.111	4.72	2.100	2.600
2024-785	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	89	2.076	0.075	3.63	1.900	2.300
2024-785	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	89	2.150	0.050	2.33	1.900	2.400
2024-785	5	DYE B-HABA	197	ARCHITECT	1	ABBOTT	11	2.300	0.074	3.21	2.100	2.500
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-781	3	COLORIMET.	184	INTEGRA	93	ROCHE	21	26.381	1.987	7.53	18.000	34.000
2024-781	3	COLORIMET.	203	ROCHE	93	ROCHE	39	26.184	1.144	4.37	18.000	34.000
2024-781	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	10	24.000	2.793	11.64	17.000	31.000
2024-781	6	KINETIC 37	165	VITROS	63	KODAK	146	40.097	2.217	5.53	28.000	52.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-781	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	33	19.970	2.713	13.59	14.000	26.000
2024-781	10	IFCC	203	ROCHE	93	ROCHE	10	25.000	1.549	6.20	18.000	33.000
2024-781	10	IFCC	219	ATELLICA	143	SIEMENS	18	26.389	1.671	6.33	18.000	34.000
2024-781	11	Modified I	38	SIEMENS DI	143	SIEMENS	81	27.679	3.993	14.43	19.000	36.000
2024-781	11	Modified I	191	RX-SERIES	126	RANDOX	25	22.200	2.020	9.10	16.000	29.000
2024-781	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	23.500	2.102	8.94	16.000	31.000
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-782	3	COLORIMET.	184	INTEGRA	93	ROCHE	21	173.143	9.249	5.34	121.000	225.000
2024-782	3	COLORIMET.	203	ROCHE	93	ROCHE	39	173.053	5.544	3.20	121.000	225.000
2024-782	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	10	160.200	12.742	7.95	112.000	208.000
2024-782	6	KINETIC 37	165	VITROS	63	KODAK	146	140.338	7.993	5.70	98.000	182.000
2024-782	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	33	136.000	17.199	12.65	95.000	177.000
2024-782	10	IFCC	203	ROCHE	93	ROCHE	10	173.300	13.536	7.81	121.000	225.000
2024-782	10	IFCC	219	ATELLICA	143	SIEMENS	18	172.944	8.866	5.13	121.000	225.000
2024-782	11	Modified I	38	SIEMENS DI	143	SIEMENS	81	181.375	8.907	4.91	127.000	236.000
2024-782	11	Modified I	191	RX-SERIES	126	RANDOX	25	143.640	9.641	6.71	101.000	187.000
2024-782	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	155.417	12.169	7.83	109.000	202.000
2024-783	3	COLORIMET.	184	INTEGRA	93	ROCHE	21	240.571	10.613	4.41	168.000	313.000
2024-783	3	COLORIMET.	203	ROCHE	93	ROCHE	39	241.658	7.760	3.21	169.000	314.000
2024-783	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	10	224.700	22.826	10.16	157.000	292.000
2024-783	6	KINETIC 37	165	VITROS	63	KODAK	146	157.310	9.468	6.02	110.000	205.000
2024-783	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	33	190.394	24.469	12.85	133.000	248.000
2024-783	10	IFCC	203	ROCHE	93	ROCHE	10	240.200	5.653	2.35	168.000	312.000
2024-783	10	IFCC	219	ATELLICA	143	SIEMENS	18	242.833	12.194	5.02	170.000	316.000
2024-783	11	Modified I	38	SIEMENS DI	143	SIEMENS	81	255.775	10.608	4.15	179.000	333.000
2024-783	11	Modified I	191	RX-SERIES	126	RANDOX	25	198.160	13.965	7.05	139.000	258.000
2024-783	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	218.500	16.132	7.38	153.000	284.000
2024-784	3	COLORIMET.	184	INTEGRA	93	ROCHE	21	113.571	5.534	4.87	80.000	148.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-784	3	COLORIMET.	203	ROCHE	93	ROCHE	39	113.763	4.029	3.54	80.000	148.000
2024-784	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	10	105.700	8.889	8.41	74.000	137.000
2024-784	6	KINETIC 37	165	VITROS	63	KODAK	146	111.778	5.973	5.34	78.000	145.000
2024-784	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	33	88.727	11.469	12.93	62.000	115.000
2024-784	10	IFCC	203	ROCHE	93	ROCHE	10	110.500	3.041	2.75	77.000	144.000
2024-784	10	IFCC	219	ATELLICA	143	SIEMENS	18	112.944	5.411	4.79	79.000	147.000
2024-784	11	Modified I	38	SIEMENS DI	143	SIEMENS	81	119.443	5.575	4.67	84.000	155.000
2024-784	11	Modified I	191	RX-SERIES	126	RANDOX	25	96.800	6.823	7.05	68.000	126.000
2024-784	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	101.750	7.833	7.70	71.000	132.000
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275		EVALUATION CRITERIA: TARGET VALUE 30 %								
2024-785	3	COLORIMET.	184	INTEGRA	93	ROCHE	21	70.571	3.983	5.64	49.000	92.000
2024-785	3	COLORIMET.	203	ROCHE	93	ROCHE	39	70.263	2.643	3.76	49.000	91.000
2024-785	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	10	65.600	6.484	9.88	46.000	85.000
2024-785	6	KINETIC 37	165	VITROS	63	KODAK	146	80.814	4.416	5.46	57.000	105.000
2024-785	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	33	54.818	7.383	13.47	38.000	71.000
2024-785	10	IFCC	203	ROCHE	93	ROCHE	10	68.700	2.238	3.26	48.000	89.000
2024-785	10	IFCC	219	ATELLICA	143	SIEMENS	18	69.722	4.240	6.08	49.000	91.000
2024-785	11	Modified I	38	SIEMENS DI	143	SIEMENS	81	73.924	4.508	6.10	52.000	96.000
2024-785	11	Modified I	191	RX-SERIES	126	RANDOX	25	60.400	4.060	6.72	42.000	79.000
2024-785	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	63.417	4.924	7.76	44.000	82.000
004	AMYLASE	CLIA TEST ID #: 285										
2024-781	3	ENZYM. 37C	165	VITROS	63	KODAK	88	30.517	1.173	3.84	21.000	40.000
2024-781	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	24	21.625	0.753	3.48	15.000	28.000
2024-781	9	ENZ/COL.37	203	ROCHE	93	ROCHE	26	25.120	0.765	3.05	18.000	33.000
2024-781	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	16.563	1.321	7.98	12.000	22.000
2024-781	11	KINETIC	219	ATELLICA	143	SIEMENS	12	27.667	0.943	3.41	19.000	36.000
2024-782	3	ENZYM. 37C	165	VITROS	63	KODAK	88	113.977	6.226	5.46	80.000	148.000
2024-782	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	24	159.000	4.397	2.77	111.000	207.000
2024-782	9	ENZ/COL.37	203	ROCHE	93	ROCHE	26	158.960	2.457	1.55	111.000	207.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-782	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	122.188	6.654	5.45	86.000	159.000
2024-782	11	KINETIC	219	ATELLICA	143	SIEMENS	12	178.833	3.262	1.82	125.000	232.000
004	AMYLASE		CLIA TEST ID #: 285			EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-783	3	ENZYM. 37C	165	VITROS	63	KODAK	88	157.302	6.658	4.23	110.000	204.000
2024-783	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	24	223.875	4.833	2.16	157.000	291.000
2024-783	9	ENZ/COL.37	203	ROCHE	93	ROCHE	26	222.846	3.393	1.52	156.000	290.000
2024-783	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	170.875	9.539	5.58	120.000	222.000
2024-783	11	KINETIC	219	ATELLICA	143	SIEMENS	12	251.750	5.387	2.14	176.000	327.000
2024-784	3	ENZYM. 37C	165	VITROS	63	KODAK	88	74.103	5.481	7.40	52.000	96.000
2024-784	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	24	102.792	1.658	1.61	72.000	134.000
2024-784	9	ENZ/COL.37	203	ROCHE	93	ROCHE	26	103.520	1.603	1.55	72.000	135.000
2024-784	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	80.313	5.774	7.19	56.000	104.000
2024-784	11	KINETIC	219	ATELLICA	143	SIEMENS	12	116.167	1.344	1.16	81.000	151.000
2024-785	3	ENZYM. 37C	165	VITROS	63	KODAK	88	48.287	4.804	9.95	34.000	63.000
2024-785	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	24	61.750	1.199	1.94	43.000	80.000
2024-785	9	ENZ/COL.37	203	ROCHE	93	ROCHE	26	63.923	1.299	2.03	45.000	83.000
2024-785	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	48.188	3.661	7.60	34.000	63.000
2024-785	11	KINETIC	219	ATELLICA	143	SIEMENS	12	71.083	1.891	2.66	50.000	92.000
005	ASP. AMINO AST/SGOT		CLIA TEST ID #: 295			EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-781	1	ASPAR&KETO	165	VITROS	63	KODAK	143	44.063	1.747	3.96	35.000	53.000
2024-781	1	ASPAR&KETO	220	Medica E.	130	MEDICA	10	36.300	1.847	5.09	29.000	44.000
2024-781	5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	89	38.875	2.016	5.19	31.000	47.000
2024-781	11	MOD. IFCC	184	INTEGRA	93	ROCHE	19	38.526	1.313	3.41	31.000	46.000
2024-781	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	33	34.219	1.268	3.71	27.000	41.000
2024-781	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	30	44.933	3.203	7.13	36.000	54.000
2024-781	11	MOD. IFCC	203	ROCHE	93	ROCHE	41	39.125	1.706	4.36	31.000	47.000
2024-781	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	18	44.882	1.182	2.63	36.000	54.000
2024-781	12	IFCC witho	203	ROCHE	93	ROCHE	14	38.286	1.623	4.24	31.000	46.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2024-781	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	12	36.667	1.841	5.02	29.000	44.000			
005 ASP. AMINO	AST/SGOT	CLIA TEST ID #: 295	EVALUATION CRITERIA: TARGET VALUE 20 %									
2024-782	1 ASPAR&KETO	165 VITROS	63 KODAK	143	269.373	10.134	3.76	215.000	323.000			
2024-782	1 ASPAR&KETO	220 Medica E.	130 MEDICA	10	202.200	7.264	3.59	162.000	243.000			
2024-782	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	89	224.364	6.894	3.07	179.000	269.000			
2024-782	11 MOD. IFCC	184 INTEGRA	93 ROCHE	19	226.053	7.437	3.29	181.000	271.000			
2024-782	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	33	194.313	6.858	3.53	155.000	233.000			
2024-782	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	30	261.067	20.324	7.78	209.000	313.000			
2024-782	11 MOD. IFCC	203 ROCHE	93 ROCHE	41	226.850	8.604	3.79	181.000	272.000			
2024-782	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	18	252.611	5.717	2.26	202.000	303.000			
2024-782	12 IFCC witho	203 ROCHE	93 ROCHE	14	225.000	7.211	3.20	180.000	270.000			
2024-782	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	12	213.167	9.898	4.64	171.000	256.000			
2024-783	1 ASPAR&KETO	165 VITROS	63 KODAK	143	394.972	18.310	4.64	316.000	474.000			
2024-783	1 ASPAR&KETO	220 Medica E.	130 MEDICA	10	280.300	8.186	2.92	224.000	336.000			
2024-783	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	89	313.830	9.796	3.12	251.000	377.000			
2024-783	11 MOD. IFCC	184 INTEGRA	93 ROCHE	19	310.789	9.423	3.03	249.000	373.000			
2024-783	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	33	268.879	11.316	4.21	215.000	323.000			
2024-783	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	30	358.333	29.698	8.29	287.000	430.000			
2024-783	11 MOD. IFCC	203 ROCHE	93 ROCHE	41	313.075	12.827	4.10	250.000	376.000			
2024-783	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	18	347.778	8.664	2.49	278.000	417.000			
2024-783	12 IFCC witho	203 ROCHE	93 ROCHE	14	310.071	9.647	3.11	248.000	372.000			
2024-783	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	12	296.333	12.919	4.36	237.000	356.000			
2024-784	1 ASPAR&KETO	165 VITROS	63 KODAK	143	171.161	6.541	3.82	137.000	205.000			
2024-784	1 ASPAR&KETO	220 Medica E.	130 MEDICA	10	136.000	4.050	2.98	109.000	163.000			
2024-784	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	89	149.659	4.250	2.84	120.000	180.000			
2024-784	11 MOD. IFCC	184 INTEGRA	93 ROCHE	19	150.895	4.909	3.25	121.000	181.000			
2024-784	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	33	130.000	5.399	4.15	104.000	156.000			
2024-784	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	30	172.467	13.961	8.10	138.000	207.000			

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-784	11 MOD. IFCC	203	ROCHE	93	ROCHE	41	150.900	5.643	3.74	121.000	181.000	
2024-784	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	18	168.389	3.058	1.82	135.000	202.000	
2024-784	12 IFCC witho	203	ROCHE	93	ROCHE	14	147.857	3.962	2.68	118.000	177.000	
2024-784	13 NADH wo P5	197	ARCHITECT	1	ABBOTT	12	142.000	5.874	4.14	114.000	170.000	
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295				EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-785	1 ASPAR&KETO	165	VITROS	63	KODAK	143	106.085	3.799	3.58	85.000	127.000	
2024-785	1 ASPAR&KETO	220	Medica E.	130	MEDICA	10	85.400	2.417	2.83	68.000	102.000	
2024-785	5 ENZYMA.37C	38	SIEMENS DI	143	SIEMENS	89	93.955	3.720	3.96	75.000	113.000	
2024-785	11 MOD. IFCC	184	INTEGRA	93	ROCHE	19	94.947	2.665	2.81	76.000	114.000	
2024-785	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	33	82.156	2.959	3.60	66.000	99.000	
2024-785	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	30	108.600	8.212	7.56	87.000	130.000	
2024-785	11 MOD. IFCC	203	ROCHE	93	ROCHE	41	94.950	3.294	3.47	76.000	114.000	
2024-785	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	18	106.667	2.404	2.25	85.000	128.000	
2024-785	12 IFCC witho	203	ROCHE	93	ROCHE	14	94.071	2.711	2.88	75.000	113.000	
2024-785	13 NADH wo P5	197	ARCHITECT	1	ABBOTT	12	89.750	3.789	4.22	72.000	108.000	
006 BILIRUBIN, TOTAL		CLIA TEST ID #: 305										
2024-781	1 BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	0.156	0.045	29.12	0.120	0.190	
2024-781	4 J-G WITH B	38	SIEMENS DI	143	SIEMENS	87	0.073	0.028	38.24	0.060	0.090	
2024-781	4 J-G WITH B	38	SIEMENS DI	143	SIEMENS	87	0.097	0.034	34.70	0.080	0.120	
2024-781	4 J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	31	0.100	0.008	7.80	0.080	0.120	
2024-781	4 J-G WITH B	191	RX-SERIES	126	RANDOX	23	0.073	0.028	38.24	0.060	0.090	
2024-781	4 J-G WITH B	191	RX-SERIES	126	RANDOX	23	0.132	0.097	73.01	0.110	0.160	
2024-781	5 J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	0.100	0.000	0.00	0.080	0.120	
2024-781	7 DIAZO-DYPH	165	VITROS	63	KODAK	144	0.119	0.048	40.45	0.100	0.140	
2024-781	13 AZOBIL.	184	INTEGRA	93	ROCHE	11	0.100	0.068	68.49	0.080	0.120	
2024-781	13 AZOBIL.	203	ROCHE	93	ROCHE	37	0.151	0.021	14.03	0.120	0.180	
2024-781	14 VANADATE	219	ATELLICA	143	SIEMENS	18	0.164	0.022	13.66	0.130	0.200	
2024-781	18 COLORIMETR	184	INTEGRA	93	ROCHE	10	0.126	0.040	31.98	0.100	0.150	
2024-781	18 COLORIMETR	203	ROCHE	93	ROCHE	18	0.156	0.019	12.06	0.120	0.190	
2024-781	19 DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	0.100	0.000	0.00	0.080	0.120	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
006 BILIRUBIN, TOTAL		CLIA TEST ID #: 305	EVALUATION CRITERIA: TARGET VALUE 20 %									
2024-782	1 BICHR.NO B	194 BIOLIS-24S	154 (IDG)	10	2.586	0.187	7.22	2.070	3.100			
2024-782	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS	87	3.118	0.152	4.86	2.490	3.740			
2024-782	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS	87	2.918	0.214	7.32	2.330	3.500			
2024-782	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN	31	3.103	0.075	2.42	2.480	3.720			
2024-782	4 J-G WITH B	191 RX-SERIES	126 RANDOX	23	3.163	0.221	6.98	2.530	3.800			
2024-782	4 J-G WITH B	191 RX-SERIES	126 RANDOX	23	2.918	0.214	7.32	2.330	3.500			
2024-782	5 J-G NO BK.	197 ARCHITECT	1 ABBOTT	10	2.895	0.292	10.10	2.320	3.470			
2024-782	7 DIAZO-DYPH	165 VITROS	63 KODAK	144	2.989	0.169	5.65	2.390	3.590			
2024-782	13 AZOBIL.	184 INTEGRA	93 ROCHE	11	2.720	0.083	3.05	2.180	3.260			
2024-782	13 AZOBIL.	203 ROCHE	93 ROCHE	37	2.679	0.122	4.56	2.140	3.210			
2024-782	14 VANADATE	219 ATELLICA	143 SIEMENS	18	3.252	0.190	5.84	2.600	3.900			
2024-782	18 COLORIMETR	184 INTEGRA	93 ROCHE	10	2.790	0.227	8.15	2.230	3.350			
2024-782	18 COLORIMETR	203 ROCHE	93 ROCHE	18	2.728	0.154	5.66	2.180	3.270			
2024-782	19 DIAZO W BL	197 ARCHITECT	1 ABBOTT	10	2.817	0.195	6.92	2.250	3.380			
2024-783	1 BICHR.NO B	194 BIOLIS-24S	154 (IDG)	10	3.718	0.225	6.06	2.970	4.460			
2024-783	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS	87	4.363	0.257	5.89	3.490	5.240			
2024-783	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS	87	4.610	0.213	4.62	3.690	5.530			
2024-783	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN	31	4.438	0.099	2.22	3.550	5.330			
2024-783	4 J-G WITH B	191 RX-SERIES	126 RANDOX	23	4.363	0.257	5.89	3.490	5.240			
2024-783	4 J-G WITH B	191 RX-SERIES	126 RANDOX	23	4.650	0.285	6.12	3.720	5.580			
2024-783	5 J-G NO BK.	197 ARCHITECT	1 ABBOTT	10	4.230	0.425	10.05	3.380	5.080			
2024-783	7 DIAZO-DYPH	165 VITROS	63 KODAK	144	4.303	0.254	5.91	3.440	5.160			
2024-783	13 AZOBIL.	184 INTEGRA	93 ROCHE	11	4.002	0.138	3.46	3.200	4.800			
2024-783	13 AZOBIL.	203 ROCHE	93 ROCHE	37	3.948	0.157	3.98	3.160	4.740			
2024-783	14 VANADATE	219 ATELLICA	143 SIEMENS	18	4.804	0.160	3.32	3.840	5.760			
2024-783	18 COLORIMETR	184 INTEGRA	93 ROCHE	10	4.009	0.193	4.82	3.210	4.810			
2024-783	18 COLORIMETR	203 ROCHE	93 ROCHE	18	4.001	0.180	4.50	3.200	4.800			
2024-783	19 DIAZO W BL	197 ARCHITECT	1 ABBOTT	10	4.073	0.273	6.70	3.260	4.890			

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
006	BILIRUBIN, TOTAL	CLIA TEST ID #: 305	EVALUATION CRITERIA: TARGET VALUE 20 %									
2024-784	1	BICHR.NO B	194 BIOLIS-24S	154	(IDG)	10	1.582	0.102	6.45	1.270	1.900	
2024-784	4	J-G WITH B	38 SIEMENS DI	143	SIEMENS	87	1.840	0.102	5.52	1.470	2.210	
2024-784	4	J-G WITH B	38 SIEMENS DI	143	SIEMENS	87	1.708	0.176	10.31	1.370	2.050	
2024-784	4	J-G WITH B	186 BECK. COUL	76	AU-BECKMAN	31	1.887	0.042	2.21	1.510	2.260	
2024-784	4	J-G WITH B	191 RX-SERIES	126	RANDOX	23	1.849	0.124	6.72	1.480	2.220	
2024-784	4	J-G WITH B	191 RX-SERIES	126	RANDOX	23	1.708	0.176	10.31	1.370	2.050	
2024-784	5	J-G NO BK.	197 ARCHITECT	1	ABBOTT	10	1.748	0.168	9.61	1.400	2.100	
2024-784	7	DIAZO-DYPH	165 VITROS	63	KODAK	144	1.803	0.120	6.66	1.440	2.160	
2024-784	13	AZOBIL.	184 INTEGRA	93	ROCHE	11	1.619	0.059	3.63	1.300	1.940	
2024-784	13	AZOBIL.	203 ROCHE	93	ROCHE	37	1.576	0.080	5.05	1.260	1.890	
2024-784	14	VANADATE	219 ATELLICA	143	SIEMENS	18	1.933	0.115	5.93	1.550	2.320	
2024-784	18	COLORIMETR	184 INTEGRA	93	ROCHE	10	1.623	0.081	4.97	1.300	1.950	
2024-784	18	COLORIMETR	203 ROCHE	93	ROCHE	18	1.595	0.099	6.20	1.280	1.910	
2024-784	19	DIAZO W BL	197 ARCHITECT	1	ABBOTT	10	1.725	0.151	8.78	1.380	2.070	
2024-785	1	BICHR.NO B	194 BIOLIS-24S	154	(IDG)	10	0.822	0.075	9.15	0.660	0.990	
2024-785	4	J-G WITH B	38 SIEMENS DI	143	SIEMENS	87	0.818	0.074	9.00	0.650	0.980	
2024-785	4	J-G WITH B	38 SIEMENS DI	143	SIEMENS	87	0.905	0.072	7.97	0.720	1.090	
2024-785	4	J-G WITH B	186 BECK. COUL	76	AU-BECKMAN	31	0.985	0.021	2.09	0.790	1.180	
2024-785	4	J-G WITH B	191 RX-SERIES	126	RANDOX	23	0.818	0.074	9.00	0.650	0.980	
2024-785	4	J-G WITH B	191 RX-SERIES	126	RANDOX	23	0.953	0.133	13.98	0.760	1.140	
2024-785	5	J-G NO BK.	197 ARCHITECT	1	ABBOTT	10	0.899	0.105	11.71	0.720	1.080	
2024-785	7	DIAZO-DYPH	165 VITROS	63	KODAK	144	0.911	0.092	10.10	0.730	1.090	
2024-785	13	AZOBIL.	184 INTEGRA	93	ROCHE	11	0.797	0.030	3.71	0.640	0.960	
2024-785	13	AZOBIL.	203 ROCHE	93	ROCHE	37	0.763	0.053	6.92	0.610	0.920	
2024-785	14	VANADATE	219 ATELLICA	143	SIEMENS	18	0.974	0.060	6.20	0.780	1.170	
2024-785	18	COLORIMETR	184 INTEGRA	93	ROCHE	10	0.797	0.052	6.57	0.640	0.960	
2024-785	18	COLORIMETR	203 ROCHE	93	ROCHE	18	0.772	0.045	5.82	0.620	0.930	
2024-785	19	DIAZO W BL	197 ARCHITECT	1	ABBOTT	10	0.884	0.101	11.45	0.710	1.060	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
010	CALCIUM, TOTAL	CLIA TEST ID #: 345	EVALUATION CRITERIA: TARGET VALUE	1.00									
2024-781	3	ARSEN.-III	165 VITROS	63	KODAK	162	5.676	0.145	2.55	4.700	6.700		
2024-781	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	35	5.694	0.133	2.34	4.700	6.700		
2024-781	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	32	5.972	0.289	4.83	5.000	7.000		
2024-781	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	11	5.755	0.099	1.72	4.800	6.800		
2024-781	3	ARSEN.-III	220 Medica E.	99	STAMBIO	12	5.167	0.325	6.29	4.200	6.200		
2024-781	5	CALC-NONFL	197 ARCHITECT	1	ABBOTT	10	5.740	0.250	4.35	4.700	6.700		
2024-781	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	90	5.815	0.228	3.92	4.800	6.800		
2024-781	8	CRESOLPHT.	184 INTEGRA	93	ROCHE	13	5.746	0.199	3.45	4.700	6.700		
2024-781	8	CRESOLPHT.	203 ROCHE	93	ROCHE	11	5.791	0.124	2.14	4.800	6.800		
2024-781	8	CRESOLPHT.	219 ATELLICA	143	SIEMENS	17	5.535	0.161	2.90	4.500	6.500		
2024-781	15	CA-NM-BAPT	184 INTEGRA	93	ROCHE	15	5.753	0.141	2.45	4.800	6.800		
2024-781	15	CA-NM-BAPT	203 ROCHE	93	ROCHE	46	5.773	0.121	2.10	4.800	6.800		
2024-782	3	ARSEN.-III	165 VITROS	63	KODAK	162	8.770	0.180	2.05	7.800	9.800		
2024-782	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	35	8.766	0.164	1.87	7.800	9.800		
2024-782	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	32	8.997	0.407	4.52	8.000	10.000		
2024-782	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	11	8.682	0.170	1.95	7.700	9.700		
2024-782	3	ARSEN.-III	220 Medica E.	99	STAMBIO	12	8.433	0.429	5.08	7.400	9.400		
2024-782	5	CALC-NONFL	197 ARCHITECT	1	ABBOTT	10	8.610	0.266	3.09	7.600	9.600		
2024-782	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	90	8.509	0.238	2.80	7.500	9.500		
2024-782	8	CRESOLPHT.	184 INTEGRA	93	ROCHE	13	8.746	0.199	2.27	7.700	9.700		
2024-782	8	CRESOLPHT.	203 ROCHE	93	ROCHE	11	8.727	0.114	1.30	7.700	9.700		
2024-782	8	CRESOLPHT.	219 ATELLICA	143	SIEMENS	17	8.665	0.350	4.04	7.700	9.700		
2024-782	15	CA-NM-BAPT	184 INTEGRA	93	ROCHE	15	8.820	0.304	3.44	7.800	9.800		
2024-782	15	CA-NM-BAPT	203 ROCHE	93	ROCHE	46	8.682	0.182	2.09	7.700	9.700		
2024-783	3	ARSEN.-III	165 VITROS	63	KODAK	162	10.053	0.200	1.99	9.100	11.100		
2024-783	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	35	10.106	0.228	2.26	9.100	11.100		
2024-783	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	32	10.187	0.353	3.46	9.200	11.200		

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2024-783	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	11	10.055	0.188	1.87	9.100	11.100	
2024-783	3	ARSEN.-III	220 Medica E.	99	STAMBIO	12	10.100	0.365	3.62	9.100	11.100	
2024-783	5	CALC-NONFL	197 ARCHITECT	1	ABBOTT	10	9.970	0.307	3.08	9.000	11.000	
2024-783	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	90	9.739	0.254	2.61	8.700	10.700	
2024-783	8	CRESOLPHT.	184 INTEGRA	93	ROCHE	13	9.985	0.175	1.75	9.000	11.000	
2024-783	8	CRESOLPHT.	203 ROCHE	93	ROCHE	11	9.991	0.156	1.57	9.000	11.000	
2024-783	8	CRESOLPHT.	219 ATELLICA	143	SIEMENS	17	10.065	0.397	3.94	9.100	11.100	
2024-783	15	CA-NM-BAPT	184 INTEGRA	93	ROCHE	15	10.079	0.230	2.29	9.100	11.100	
2024-783	15	CA-NM-BAPT	203 ROCHE	93	ROCHE	46	9.978	0.171	1.71	9.000	11.000	
010 CALCIUM, TOTAL		CLIA TEST ID #: 345		EVALUATION CRITERIA: TARGET VALUE 1.00								
2024-784	3	ARSEN.-III	165 VITROS	63	KODAK	162	7.424	0.168	2.26	6.400	8.400	
2024-784	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	35	7.400	0.166	2.24	6.400	8.400	
2024-784	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	32	7.700	0.350	4.55	6.700	8.700	
2024-784	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	11	7.418	0.164	2.21	6.400	8.400	
2024-784	3	ARSEN.-III	220 Medica E.	99	STAMBIO	12	7.133	0.361	5.07	6.100	8.100	
2024-784	5	CALC-NONFL	197 ARCHITECT	1	ABBOTT	10	7.320	0.240	3.28	6.300	8.300	
2024-784	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	90	7.347	0.221	3.00	6.300	8.300	
2024-784	8	CRESOLPHT.	184 INTEGRA	93	ROCHE	13	7.438	0.234	3.14	6.400	8.400	
2024-784	8	CRESOLPHT.	203 ROCHE	93	ROCHE	11	7.436	0.143	1.93	6.400	8.400	
2024-784	8	CRESOLPHT.	219 ATELLICA	143	SIEMENS	17	7.318	0.241	3.29	6.300	8.300	
2024-784	15	CA-NM-BAPT	184 INTEGRA	93	ROCHE	15	7.427	0.184	2.48	6.400	8.400	
2024-784	15	CA-NM-BAPT	203 ROCHE	93	ROCHE	46	7.404	0.150	2.03	6.400	8.400	
2024-785	3	ARSEN.-III	165 VITROS	63	KODAK	162	6.586	0.152	2.30	5.600	7.600	
2024-785	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	35	6.571	0.145	2.20	5.600	7.600	
2024-785	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	32	6.877	0.250	3.63	5.900	7.900	
2024-785	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	11	6.600	0.160	2.42	5.600	7.600	
2024-785	3	ARSEN.-III	220 Medica E.	99	STAMBIO	12	6.008	0.253	4.21	5.000	7.000	
2024-785	5	CALC-NONFL	197 ARCHITECT	1	ABBOTT	10	6.550	0.254	3.88	5.600	7.600	
2024-785	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	90	6.569	0.232	3.53	5.600	7.600	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-785	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	6.600	0.171	2.59	5.600	7.600
2024-785	8	CRESOLPHT.	203	ROCHE	93	ROCHE	11	6.636	0.143	2.16	5.600	7.600
2024-785	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	17	6.453	0.212	3.28	5.500	7.500
2024-785	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	15	6.680	0.248	3.72	5.700	7.700
2024-785	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	46	6.593	0.140	2.13	5.600	7.600
011	CHLORIDE	CLIA TEST ID #: 355				EVALUATION CRITERIA: TARGET VALUE 5 %						
2024-781	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	93.414	1.543	1.65	89.000	98.000
2024-781	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	92.667	1.682	1.81	88.000	97.000
2024-781	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	96.714	1.332	1.38	92.000	102.000
2024-781	3	ISE DILUTE	203	ROCHE	93	ROCHE	59	88.333	0.943	1.07	84.000	93.000
2024-781	3	ISE DILUTE	203	ROCHE	93	ROCHE	59	89.441	2.345	2.62	85.000	94.000
2024-781	4	ISE UND-DI	165	VITROS	63	KODAK	64	95.297	1.756	1.84	91.000	100.000
2024-781	4	ISE UND-DI	165	VITROS	156	Kit 32	96	95.833	1.618	1.69	91.000	101.000
2024-781	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	31	91.774	2.310	2.52	87.000	96.000
2024-781	4	ISE UND-DI	220	Medica E.	130	MEDICA	13	90.231	1.967	2.18	86.000	95.000
2024-781	8	IMT	219	ATELLICA	143	SIEMENS	18	97.444	1.499	1.54	93.000	102.000
2024-781	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	88	89.609	1.628	1.82	85.000	94.000
2024-782	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	113.700	2.532	2.23	108.000	119.000
2024-782	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	110.719	1.231	1.11	105.000	116.000
2024-782	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	114.000	1.414	1.24	108.000	120.000
2024-782	3	ISE DILUTE	203	ROCHE	93	ROCHE	59	109.914	2.321	2.11	104.000	115.000
2024-782	3	ISE DILUTE	203	ROCHE	93	ROCHE	59	109.000	1.414	1.30	104.000	114.000
2024-782	4	ISE UND-DI	165	VITROS	63	KODAK	64	112.730	1.994	1.77	107.000	118.000
2024-782	4	ISE UND-DI	165	VITROS	156	Kit 32	96	113.274	1.552	1.37	108.000	119.000
2024-782	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	31	110.710	2.504	2.26	105.000	116.000
2024-782	4	ISE UND-DI	220	Medica E.	130	MEDICA	13	112.308	3.073	2.74	107.000	118.000
2024-782	8	IMT	219	ATELLICA	143	SIEMENS	18	114.722	1.520	1.33	109.000	120.000
2024-782	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	88	110.500	1.925	1.74	105.000	116.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
011	CHLORIDE	CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %								
2024-783	3	ISE DILUTE	184 INTEGRA	93	ROCHE	30	122.200	2.857	2.34	116.000	128.000	
2024-783	3	ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	33	116.545	1.986	1.70	111.000	122.000	
2024-783	3	ISE DILUTE	197 ARCHITECT	1	ABBOTT	14	121.071	1.791	1.48	115.000	127.000	
2024-783	3	ISE DILUTE	203 ROCHE	93	ROCHE	59	118.000	3.742	3.17	112.000	124.000	
2024-783	3	ISE DILUTE	203 ROCHE	93	ROCHE	59	117.644	2.048	1.74	112.000	124.000	
2024-783	4	ISE UND-DI	165 VITROS	63	KODAK	64	119.391	2.356	1.97	113.000	125.000	
2024-783	4	ISE UND-DI	165 VITROS	156	Kit 32	96	120.198	1.880	1.56	114.000	126.000	
2024-783	4	ISE UND-DI	191 RX-SERIES	126	RANDOX	31	118.387	3.357	2.84	112.000	124.000	
2024-783	4	ISE UND-DI	220 Medica E.	130	MEDICA	13	121.846	2.597	2.13	116.000	128.000	
2024-783	8	IMT	219 ATELLICA	143	SIEMENS	18	121.833	2.062	1.69	116.000	128.000	
2024-783	9	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	88	118.886	2.069	1.74	113.000	125.000	
2024-784	3	ISE DILUTE	184 INTEGRA	93	ROCHE	30	104.433	2.028	1.94	99.000	110.000	
2024-784	3	ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	33	102.364	1.432	1.40	97.000	107.000	
2024-784	3	ISE DILUTE	197 ARCHITECT	1	ABBOTT	14	105.571	1.400	1.33	100.000	111.000	
2024-784	3	ISE DILUTE	203 ROCHE	93	ROCHE	59	100.000	2.449	2.45	95.000	105.000	
2024-784	3	ISE DILUTE	203 ROCHE	93	ROCHE	59	99.983	2.549	2.55	95.000	105.000	
2024-784	4	ISE UND-DI	165 VITROS	63	KODAK	64	104.000	2.114	2.03	99.000	109.000	
2024-784	4	ISE UND-DI	165 VITROS	156	Kit 32	96	104.792	1.881	1.80	100.000	110.000	
2024-784	4	ISE UND-DI	191 RX-SERIES	126	RANDOX	31	101.500	2.766	2.72	96.000	107.000	
2024-784	4	ISE UND-DI	220 Medica E.	130	MEDICA	13	102.615	2.095	2.04	97.000	108.000	
2024-784	8	IMT	219 ATELLICA	143	SIEMENS	18	106.111	1.560	1.47	101.000	111.000	
2024-784	9	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	88	100.716	1.699	1.69	96.000	106.000	
2024-785	3	ISE DILUTE	184 INTEGRA	93	ROCHE	30	99.500	1.857	1.87	95.000	104.000	
2024-785	3	ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	33	98.212	1.493	1.52	93.000	103.000	
2024-785	3	ISE DILUTE	197 ARCHITECT	1	ABBOTT	14	101.786	1.612	1.58	97.000	107.000	
2024-785	3	ISE DILUTE	203 ROCHE	93	ROCHE	59	95.051	2.251	2.37	90.000	100.000	
2024-785	3	ISE DILUTE	203 ROCHE	93	ROCHE	59	95.000	1.633	1.72	90.000	100.000	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2024-785	4	ISE UND-DI	165 VITROS	63 KODAK	64	100.125	2.154	2.15	95.000	105.000		
2024-785	4	ISE UND-DI	165 VITROS	156 Kit 32	96	100.708	1.664	1.65	96.000	106.000		
2024-785	4	ISE UND-DI	191 RX-SERIES	126 RANDOX	31	96.032	2.348	2.45	91.000	101.000		
2024-785	4	ISE UND-DI	220 Medica E.	130 MEDICA	13	96.000	2.353	2.45	91.000	101.000		
2024-785	8	IMT	219 ATELLICA	143 SIEMENS	18	101.556	1.343	1.32	96.000	107.000		
2024-785	9	QUICK LYTE	38 SIEMENS DI	143 SIEMENS	88	95.437	1.337	1.40	91.000	100.000		
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365			EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-781	1	ENZYMATIC	38 SIEMENS DI	143 SIEMENS	87	110.153	3.821	3.47	99.000	121.000		
2024-781	1	ENZYMATIC	165 VITROS	63 KODAK	147	107.630	3.292	3.06	97.000	118.000		
2024-781	1	ENZYMATIC	184 INTEGRA	93 ROCHE	12	114.250	3.832	3.35	103.000	126.000		
2024-781	1	ENZYMATIC	191 RX-SERIES	126 RANDOX	36	123.306	6.658	5.40	111.000	136.000		
2024-781	1	ENZYMATIC	194 BIOLIS-24S	154 (IDG)	10	121.400	2.973	2.45	109.000	134.000		
2024-781	1	ENZYMATIC	197 ARCHITECT	1 ABBOTT	10	113.500	3.008	2.65	102.000	125.000		
2024-781	1	ENZYMATIC	203 ROCHE	93 ROCHE	21	116.050	2.837	2.44	104.000	128.000		
2024-781	1	ENZYMATIC	220 Medica E.	130 MEDICA	12	119.167	3.891	3.27	107.000	131.000		
2024-781	5	FE-SALTS-N	197 ARCHITECT	1 ABBOTT	12	114.833	3.484	3.03	103.000	126.000		
2024-781	8	ENZYMATIC	186 BECK. COUL	76 AU-BECKMAN	31	111.290	2.654	2.38	100.000	122.000		
2024-781	8	ENZYMATIC	203 ROCHE	93 ROCHE	16	115.333	3.419	2.96	104.000	127.000		
2024-781	9	ENZYMATIC	203 ROCHE	93 ROCHE	15	115.933	3.043	2.63	104.000	128.000		
2024-781	9	ENZYMATIC	219 ATELLICA	143 SIEMENS	18	115.000	3.215	2.80	104.000	127.000		
2024-782	1	ENZYMATIC	38 SIEMENS DI	143 SIEMENS	87	156.583	5.542	3.54	141.000	172.000		
2024-782	1	ENZYMATIC	165 VITROS	63 KODAK	147	171.479	5.240	3.06	154.000	189.000		
2024-782	1	ENZYMATIC	184 INTEGRA	93 ROCHE	12	167.583	6.130	3.66	151.000	184.000		
2024-782	1	ENZYMATIC	191 RX-SERIES	126 RANDOX	36	183.944	9.276	5.04	166.000	202.000		
2024-782	1	ENZYMATIC	194 BIOLIS-24S	154 (IDG)	10	178.300	3.926	2.20	160.000	196.000		
2024-782	1	ENZYMATIC	197 ARCHITECT	1 ABBOTT	10	167.800	1.939	1.16	151.000	185.000		
2024-782	1	ENZYMATIC	203 ROCHE	93 ROCHE	21	170.714	6.009	3.52	154.000	188.000		
2024-782	1	ENZYMATIC	220 Medica E.	130 MEDICA	12	172.500	4.153	2.41	155.000	190.000		
2024-782	5	FE-SALTS-N	197 ARCHITECT	1 ABBOTT	12	166.583	4.212	2.53	150.000	183.000		

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-782	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	31	164.903	2.680	1.63	148.000	181.000
2024-782	8	ENZYMATIC	203	ROCHE	93	ROCHE	16	170.733	4.597	2.69	154.000	188.000
2024-782	9	ENZYMATIC	203	ROCHE	93	ROCHE	15	172.214	3.931	2.28	155.000	189.000
2024-782	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	18	172.944	5.126	2.96	156.000	190.000
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365			EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-783	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	87	177.200	5.837	3.29	159.000	195.000
2024-783	1	ENZYMATIC	165	VITROS	63	KODAK	147	201.170	7.187	3.57	181.000	221.000
2024-783	1	ENZYMATIC	184	INTEGRA	93	ROCHE	12	188.750	5.818	3.08	170.000	208.000
2024-783	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	36	209.444	10.175	4.86	189.000	230.000
2024-783	1	ENZYMATIC	194	BIOLIS-24S	154	(IDG)	10	202.400	4.477	2.21	182.000	223.000
2024-783	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	10	192.200	2.960	1.54	173.000	211.000
2024-783	1	ENZYMATIC	203	ROCHE	93	ROCHE	21	193.857	7.517	3.88	174.000	213.000
2024-783	1	ENZYMATIC	220	Medica E.	130	MEDICA	12	196.833	6.375	3.24	177.000	217.000
2024-783	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	12	190.833	4.120	2.16	172.000	210.000
2024-783	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	31	187.548	4.398	2.35	169.000	206.000
2024-783	8	ENZYMATIC	203	ROCHE	93	ROCHE	16	194.667	4.093	2.10	175.000	214.000
2024-783	9	ENZYMATIC	203	ROCHE	93	ROCHE	15	196.133	4.031	2.06	177.000	216.000
2024-783	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	18	197.833	5.336	2.70	178.000	218.000
2024-784	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	87	135.541	4.351	3.21	122.000	149.000
2024-784	1	ENZYMATIC	165	VITROS	63	KODAK	147	144.020	4.637	3.22	130.000	158.000
2024-784	1	ENZYMATIC	184	INTEGRA	93	ROCHE	12	145.083	5.795	3.99	131.000	160.000
2024-784	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	36	157.333	7.750	4.93	142.000	173.000
2024-784	1	ENZYMATIC	194	BIOLIS-24S	154	(IDG)	10	153.300	3.900	2.54	138.000	169.000
2024-784	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	10	144.700	2.369	1.64	130.000	159.000
2024-784	1	ENZYMATIC	203	ROCHE	93	ROCHE	21	147.048	5.232	3.56	132.000	162.000
2024-784	1	ENZYMATIC	220	Medica E.	130	MEDICA	12	150.750	3.767	2.50	136.000	166.000
2024-784	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	12	143.417	3.402	2.37	129.000	158.000
2024-784	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	31	141.581	3.241	2.29	127.000	156.000
2024-784	8	ENZYMATIC	203	ROCHE	93	ROCHE	16	145.533	3.879	2.67	131.000	160.000

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-784	9	ENZYMATIC	203	ROCHE	93	ROCHE	15	146.667	3.978	2.71	132.000	161.000
2024-784	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	18	148.000	4.190	2.83	133.000	163.000
012 CHOLESTEROL, TOTAL		CLIA TEST ID #: 365				EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-785	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	87	122.744	4.003	3.26	110.000	135.000
2024-785	1	ENZYMATIC	165	VITROS	63	KODAK	147	126.138	3.827	3.03	114.000	139.000
2024-785	1	ENZYMATIC	184	INTEGRA	93	ROCHE	12	129.750	4.418	3.41	117.000	143.000
2024-785	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	36	141.194	7.852	5.56	127.000	155.000
2024-785	1	ENZYMATIC	194	BIOLIS-24S	154	(IDG)	10	136.000	4.539	3.34	122.000	150.000
2024-785	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	10	129.900	1.921	1.48	117.000	143.000
2024-785	1	ENZYMATIC	203	ROCHE	93	ROCHE	21	131.476	4.807	3.66	118.000	145.000
2024-785	1	ENZYMATIC	220	Medica E.	130	MEDICA	12	134.833	5.289	3.92	121.000	148.000
2024-785	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	12	129.083	3.174	2.46	116.000	142.000
2024-785	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	31	126.903	2.692	2.12	114.000	140.000
2024-785	8	ENZYMATIC	203	ROCHE	93	ROCHE	16	130.533	2.918	2.24	117.000	144.000
2024-785	9	ENZYMATIC	203	ROCHE	93	ROCHE	15	132.000	2.828	2.14	119.000	145.000
2024-785	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	18	131.444	3.804	2.89	118.000	145.000
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375				EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-781	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	45.882	3.612	7.87	32.100	59.600
2024-781	11	ENC.-COLO.	165	VITROS	63	KODAK	144	41.333	1.700	4.11	28.900	53.700
2024-781	11	ENC.-COLO.	165	VITROS	63	KODAK	144	43.068	1.883	4.37	30.100	56.000
2024-781	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	27	49.796	3.323	6.67	34.900	64.700
2024-781	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	32	43.209	2.158	5.00	30.200	56.200
2024-781	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	38	39.111	4.039	10.33	27.400	50.800
2024-781	11	ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	31.000	2.864	9.24	21.700	40.300
2024-781	11	ENC.-COLO.	203	ROCHE	93	ROCHE	48	49.091	2.118	4.32	34.400	63.800
2024-781	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	17	46.329	1.880	4.06	32.400	60.200
2024-781	11	ENC.-COLO.	220	Medica E.	130	MEDICA	12	38.917	1.891	4.86	27.200	50.600
2024-781	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	45.833	2.853	6.22	32.100	59.600
2024-781	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	84	53.048	2.708	5.11	37.100	69.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
013	CHOLESTEROL, (HDL)	CLIA TEST ID #: 375	EVALUATION CRITERIA: TARGET VALUE 30 %								
2024-782	5 DEX.SUL/Mg	197 ARCHITECT	1 ABBOTT		11	59.409	2.867	4.83	41.600	77.200	
2024-782	11 ENC.-COLO.	165 VITROS	63 KODAK		144	55.333	3.091	5.59	38.700	71.900	
2024-782	11 ENC.-COLO.	165 VITROS	63 KODAK		144	57.707	2.962	5.13	40.400	75.000	
2024-782	11 ENC.-COLO.	184 INTEGRA	93 ROCHE		27	62.319	4.758	7.63	43.600	81.000	
2024-782	11 ENC.-COLO.	186 BECK. COUL	76 AU-BECKMAN		32	60.103	2.137	3.56	42.100	78.100	
2024-782	11 ENC.-COLO.	191 RX-SERIES	126 RANDOX		38	53.955	4.714	8.74	37.800	70.100	
2024-782	11 ENC.-COLO.	194 BIOLIS-24S	154 (IDG)		10	43.300	3.551	8.20	30.300	56.300	
2024-782	11 ENC.-COLO.	203 ROCHE	93 ROCHE		48	61.281	2.838	4.63	42.900	79.700	
2024-782	11 ENC.-COLO.	219 ATELLICA	143 SIEMENS		17	62.435	2.986	4.78	43.700	81.200	
2024-782	11 ENC.-COLO.	220 Medica E.	130 MEDICA		12	53.417	2.691	5.04	37.400	69.400	
2024-782	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT		12	60.250	3.467	5.75	42.200	78.300	
2024-782	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS		84	58.387	2.490	4.27	40.900	75.900	
2024-783	5 DEX.SUL/Mg	197 ARCHITECT	1 ABBOTT		11	66.109	4.091	6.19	46.300	85.900	
2024-783	11 ENC.-COLO.	165 VITROS	63 KODAK		144	65.922	3.326	5.05	46.100	85.700	
2024-783	11 ENC.-COLO.	165 VITROS	63 KODAK		144	60.000	4.320	7.20	42.000	78.000	
2024-783	11 ENC.-COLO.	184 INTEGRA	93 ROCHE		27	65.270	4.759	7.29	45.700	84.900	
2024-783	11 ENC.-COLO.	186 BECK. COUL	76 AU-BECKMAN		32	66.881	2.271	3.40	46.800	86.900	
2024-783	11 ENC.-COLO.	191 RX-SERIES	126 RANDOX		38	60.684	6.928	11.42	42.500	78.900	
2024-783	11 ENC.-COLO.	194 BIOLIS-24S	154 (IDG)		10	47.800	4.377	9.16	33.500	62.100	
2024-783	11 ENC.-COLO.	203 ROCHE	93 ROCHE		48	65.004	2.472	3.80	45.500	84.500	
2024-783	11 ENC.-COLO.	219 ATELLICA	143 SIEMENS		17	69.071	3.293	4.77	48.300	89.800	
2024-783	11 ENC.-COLO.	220 Medica E.	130 MEDICA		12	60.250	2.773	4.60	42.200	78.300	
2024-783	12 HOM-LQ.S.D	197 ARCHITECT	1 ABBOTT		12	65.636	1.666	2.54	45.900	85.300	
2024-783	13 AMIN.W.E.Q	38 SIEMENS DI	143 SIEMENS		84	59.893	2.667	4.45	41.900	77.900	
2024-784	5 DEX.SUL/Mg	197 ARCHITECT	1 ABBOTT		11	53.300	2.752	5.16	37.300	69.300	
2024-784	11 ENC.-COLO.	165 VITROS	63 KODAK		144	46.000	2.449	5.32	32.200	59.800	
2024-784	11 ENC.-COLO.	165 VITROS	63 KODAK		144	49.829	2.545	5.11	34.900	64.800	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-784	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	27	56.656	3.774	6.66	39.700	73.700	
2024-784	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	32	52.178	2.553	4.89	36.500	67.800	
2024-784	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	38	47.539	5.369	11.29	33.300	61.800	
2024-784	11 ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	37.400	3.231	8.64	26.200	48.600	
2024-784	11 ENC.-COLO.	203	ROCHE	93	ROCHE	48	55.538	2.295	4.13	38.900	72.200	
2024-784	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	17	54.900	2.156	3.93	38.400	71.400	
2024-784	11 ENC.-COLO.	220	Medica E.	130	MEDICA	12	46.500	2.327	5.01	32.600	60.500	
2024-784	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	53.000	1.477	2.79	37.100	68.900	
2024-784	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	84	55.895	2.322	4.15	39.100	72.700	
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375				EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-785	5 DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	49.591	2.636	5.31	34.700	64.500	
2024-785	11 ENC.-COLO.	165	VITROS	63	KODAK	144	46.373	2.141	4.62	32.500	60.300	
2024-785	11 ENC.-COLO.	165	VITROS	63	KODAK	144	43.667	2.625	6.01	30.600	56.800	
2024-785	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	27	53.859	3.637	6.75	37.700	70.000	
2024-785	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	32	48.288	2.734	5.66	33.800	62.800	
2024-785	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	38	43.221	5.072	11.73	30.300	56.200	
2024-785	11 ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	34.200	2.891	8.45	23.900	44.500	
2024-785	11 ENC.-COLO.	203	ROCHE	93	ROCHE	48	52.645	1.969	3.74	36.900	68.400	
2024-785	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	17	50.706	2.067	4.08	35.500	65.900	
2024-785	11 ENC.-COLO.	220	Medica E.	130	MEDICA	12	42.250	1.639	3.88	29.600	54.900	
2024-785	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	50.417	3.353	6.65	35.300	65.500	
2024-785	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	84	55.059	2.537	4.61	38.500	71.600	
014 CREATINE KINASE (CK)		CLIA TEST ID #: 385										
2024-781	3 KINETIC 37	165	VITROS	63	KODAK	72	26.577	3.591	13.51	19.000	35.000	
2024-781	3 KINETIC 37	165	VITROS	63	KODAK	72	30.750	3.031	9.86	22.000	40.000	
2024-781	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	20.235	2.486	12.29	14.000	26.000	
2024-781	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	15	25.733	1.982	7.70	18.000	33.000	
2024-781	8 Hexokinase	203	ROCHE	93	ROCHE	11	23.455	1.305	5.56	16.000	30.000	
2024-781	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	26	22.440	2.844	12.67	16.000	29.000	
2024-781	10 ENZYMATIC-	203	ROCHE	93	ROCHE	14	23.429	1.678	7.16	16.000	30.000	

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
014	CREATINE KINASE (CK)	CLIA TEST ID #: 385				EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-782	3 KINETIC 37	165	VITROS	63	KODAK	72	349.250	37.466	10.73	244.000	454.000	
2024-782	3 KINETIC 37	165	VITROS	63	KODAK	72	240.014	18.491	7.70	168.000	312.000	
2024-782	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	258.529	12.857	4.97	181.000	336.000	
2024-782	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	15	295.667	8.276	2.80	207.000	384.000	
2024-782	8 Hexokinase	203	ROCHE	93	ROCHE	11	287.500	4.319	1.50	201.000	374.000	
2024-782	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	26	291.115	7.464	2.56	204.000	378.000	
2024-782	10 ENZYMATI-	203	ROCHE	93	ROCHE	14	287.000	8.485	2.96	201.000	373.000	
2024-783	3 KINETIC 37	165	VITROS	63	KODAK	72	311.444	22.245	7.14	218.000	405.000	
2024-783	3 KINETIC 37	165	VITROS	63	KODAK	72	489.750	47.746	9.75	343.000	637.000	
2024-783	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	366.500	12.068	3.29	257.000	476.000	
2024-783	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	15	419.333	13.749	3.28	294.000	545.000	
2024-783	8 Hexokinase	203	ROCHE	93	ROCHE	11	403.800	11.259	2.79	283.000	525.000	
2024-783	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	26	411.385	9.532	2.32	288.000	535.000	
2024-783	10 ENZYMATI-	203	ROCHE	93	ROCHE	14	408.714	12.931	3.16	286.000	531.000	
2024-784	3 KINETIC 37	165	VITROS	63	KODAK	72	224.500	17.414	7.76	157.000	292.000	
2024-784	3 KINETIC 37	165	VITROS	63	KODAK	72	162.958	11.485	7.05	114.000	212.000	
2024-784	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	162.500	5.362	3.30	114.000	211.000	
2024-784	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	15	187.400	4.601	2.46	131.000	244.000	
2024-784	8 Hexokinase	203	ROCHE	93	ROCHE	11	185.545	11.750	6.33	130.000	241.000	
2024-784	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	26	183.692	4.487	2.44	129.000	239.000	
2024-784	10 ENZYMATI-	203	ROCHE	93	ROCHE	14	182.071	5.298	2.91	127.000	237.000	
2024-785	3 KINETIC 37	165	VITROS	63	KODAK	72	95.352	6.818	7.15	67.000	124.000	
2024-785	3 KINETIC 37	165	VITROS	63	KODAK	72	135.500	6.265	4.62	95.000	176.000	
2024-785	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	91.000	3.102	3.41	64.000	118.000	
2024-785	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	15	106.933	4.404	4.12	75.000	139.000	
2024-785	8 Hexokinase	203	ROCHE	93	ROCHE	11	105.636	8.886	8.41	74.000	137.000	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-785	9	SIEMENS	38	SIEMENS DI	143	SIEMENS	26	103.692	3.484	3.36	73.000	135.000
2024-785	10	ENZYMATIC-	203	ROCHE	93	ROCHE	14	103.214	3.277	3.18	72.000	134.000
016 CREATININE			CLIA TEST ID #: 405			EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}						
2024-781	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	25	0.911	0.060	6.64	0.610	1.210
2024-781	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	25	1.029	0.058	5.68	0.730	1.330
2024-781	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	0.878	0.052	5.91	0.580	1.180
2024-781	4	ENZYMATIC	220	Medica E.	130	MEDICA	13	0.944	0.054	5.68	0.640	1.240
2024-781	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	0.951	0.039	4.11	0.650	1.250
2024-781	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	35	0.882	0.041	4.68	0.580	1.180
2024-781	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	15	0.802	0.028	3.47	0.500	1.100
2024-781	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	0.903	0.055	6.08	0.600	1.200
2024-781	8	IDMS-CREA	165	VITROS	63	KODAK	160	0.883	0.030	3.37	0.580	1.180
2024-781	9	MODIFIED	219	ATELLICA	143	SIEMENS	17	0.836	0.048	5.70	0.540	1.140
2024-781	10	JAFFE COMP	203	ROCHE	93	ROCHE	11	0.884	0.033	3.68	0.580	1.180
2024-781	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	83	0.874	0.052	5.99	0.570	1.170
2024-782	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	25	3.594	0.070	1.95	3.230	3.950
2024-782	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	25	3.196	0.200	6.24	2.880	3.520
2024-782	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	3.542	0.145	4.10	3.190	3.900
2024-782	4	ENZYMATIC	220	Medica E.	130	MEDICA	13	3.651	0.082	2.25	3.290	4.020
2024-782	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	3.629	0.119	3.29	3.270	3.990
2024-782	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	35	3.643	0.073	2.00	3.280	4.010
2024-782	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	15	3.813	0.076	1.98	3.430	4.190
2024-782	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	3.603	0.116	3.22	3.240	3.960
2024-782	8	IDMS-CREA	165	VITROS	63	KODAK	160	3.687	0.080	2.18	3.320	4.060
2024-782	9	MODIFIED	219	ATELLICA	143	SIEMENS	17	3.547	0.148	4.18	3.190	3.900
2024-782	10	JAFFE COMP	203	ROCHE	93	ROCHE	11	3.625	0.101	2.79	3.260	3.990
2024-782	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	83	3.717	0.107	2.89	3.340	4.090
2024-783	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	25	4.260	0.283	6.64	3.830	4.690

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-783	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	25	4.763	0.166	3.48	4.290	5.240
2024-783	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	4.738	0.150	3.17	4.260	5.210
2024-783	4	ENZYMATIC	220	Medica E.	130	MEDICA	13	5.000	0.172	3.44	4.500	5.500
2024-783	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	4.746	0.181	3.81	4.270	5.220
2024-783	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	35	4.850	0.123	2.53	4.370	5.340
2024-783	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	15	5.253	0.164	3.11	4.730	5.780
2024-783	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	4.777	0.152	3.18	4.300	5.250
2024-783	8	IDMS-CREA	165	VITROS	63	KODAK	160	4.951	0.112	2.26	4.460	5.450
2024-783	9	MODIFIED	219	ATELLICA	143	SIEMENS	17	4.817	0.207	4.31	4.340	5.300
2024-783	10	JAFFE COMP	203	ROCHE	93	ROCHE	11	4.827	0.111	2.30	4.340	5.310
2024-783	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	83	5.034	0.133	2.64	4.530	5.540
016	CREATININE	CLIA TEST ID #: 405				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}						
2024-784	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	25	2.525	0.066	2.62	2.230	2.830
2024-784	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	25	2.273	0.150	6.59	1.970	2.570
2024-784	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	2.499	0.088	3.53	2.200	2.800
2024-784	4	ENZYMATIC	220	Medica E.	130	MEDICA	13	2.531	0.100	3.97	2.230	2.830
2024-784	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	2.567	0.094	3.65	2.270	2.870
2024-784	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	35	2.521	0.062	2.47	2.220	2.820
2024-784	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	15	2.590	0.052	2.00	2.290	2.890
2024-784	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	2.530	0.085	3.35	2.230	2.830
2024-784	8	IDMS-CREA	165	VITROS	63	KODAK	160	2.521	0.073	2.89	2.220	2.820
2024-784	9	MODIFIED	219	ATELLICA	143	SIEMENS	17	2.431	0.094	3.88	2.130	2.730
2024-784	10	JAFFE COMP	203	ROCHE	93	ROCHE	11	2.537	0.069	2.72	2.240	2.840
2024-784	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	83	2.648	0.091	3.42	2.350	2.950
2024-785	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	25	1.623	0.100	6.16	1.320	1.920
2024-785	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	25	1.696	0.116	6.82	1.400	2.000
2024-785	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	1.695	0.103	6.10	1.400	2.000
2024-785	4	ENZYMATIC	220	Medica E.	130	MEDICA	13	1.745	0.068	3.90	1.440	2.040
2024-785	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	1.763	0.060	3.39	1.460	2.060

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-785	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	35	1.718	0.060	3.52	1.420	2.020
2024-785	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	15	1.675	0.053	3.14	1.370	1.970
2024-785	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	1.732	0.070	4.06	1.430	2.030
2024-785	8	IDMS-CREA	165	VITROS	63	KODAK	160	1.701	0.057	3.36	1.400	2.000
2024-785	9	MODIFIED	219	ATELLICA	143	SIEMENS	17	1.644	0.067	4.05	1.340	1.940
2024-785	10	JAFFE COMP	203	ROCHE	93	ROCHE	11	1.731	0.051	2.95	1.430	2.030
2024-785	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	83	1.775	0.073	4.09	1.470	2.070
017	GLUCOSE		CLIA TEST ID #: 415			EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2024-781	3	GL. OXI. C	165	VITROS	63	KODAK	163	36.708	0.969	2.64	31.000	43.000
2024-781	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	90	42.667	1.247	2.92	37.000	49.000
2024-781	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	90	43.472	1.716	3.95	37.000	49.000
2024-781	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	35	40.714	1.232	3.03	35.000	47.000
2024-781	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	47.333	1.886	3.98	41.000	53.000
2024-781	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	45.033	2.302	5.11	39.000	51.000
2024-781	5	HEXOKINASE	203	ROCHE	93	ROCHE	35	40.206	1.207	3.00	34.000	46.000
2024-781	5	HEXOKINASE	203	ROCHE	93	ROCHE	35	38.800	0.980	2.53	33.000	45.000
2024-781	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	42.500	1.432	3.37	37.000	49.000
2024-781	6	HEXOKI. CO	220	Medica E.	130	MEDICA	13	43.231	2.189	5.06	37.000	49.000
2024-781	12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	41.053	1.234	3.01	35.000	47.000
2024-781	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	39.071	0.703	1.80	33.000	45.000
2024-781	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	40.174	0.761	1.89	34.000	46.000
2024-781	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	18	41.235	0.876	2.13	35.000	47.000
2024-782	3	GL. OXI. C	165	VITROS	63	KODAK	163	96.601	2.280	2.36	87.000	106.000
2024-782	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	90	102.483	2.509	2.45	92.000	113.000
2024-782	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	90	105.000	3.559	3.39	95.000	116.000
2024-782	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	35	97.029	2.741	2.83	87.000	107.000
2024-782	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	102.097	4.350	4.26	92.000	112.000
2024-782	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	103.000	2.582	2.51	93.000	113.000
2024-782	5	HEXOKINASE	203	ROCHE	93	ROCHE	35	97.147	2.614	2.69	87.000	107.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-782	5	HEXOKINASE	203	ROCHE	93	ROCHE	35	94.800	2.040	2.15	85.000	104.000
2024-782	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	96.600	2.245	2.32	87.000	106.000
2024-782	6	HEXOKI. CO	220	Medica E.	130	MEDICA	13	102.231	2.939	2.88	92.000	112.000
2024-782	12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	98.700	3.226	3.27	89.000	109.000
2024-782	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	94.857	1.597	1.68	85.000	104.000
2024-782	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	96.696	1.921	1.99	87.000	106.000
2024-782	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	18	96.333	2.134	2.22	87.000	106.000
017	GLUCOSE	CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}								
2024-783	3	GL. OXI. C	165	VITROS	63	KODAK	163	123.265	2.593	2.10	111.000	136.000
2024-783	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	90	131.000	3.742	2.86	118.000	144.000
2024-783	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	90	129.719	3.647	2.81	117.000	143.000
2024-783	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	35	122.853	2.972	2.42	111.000	135.000
2024-783	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	128.500	4.717	3.67	116.000	141.000
2024-783	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	127.581	6.126	4.80	115.000	140.000
2024-783	5	HEXOKINASE	203	ROCHE	93	ROCHE	35	123.771	2.306	1.86	111.000	136.000
2024-783	5	HEXOKINASE	203	ROCHE	93	ROCHE	35	119.400	1.855	1.55	107.000	131.000
2024-783	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	121.700	3.743	3.08	110.000	134.000
2024-783	6	HEXOKI. CO	220	Medica E.	130	MEDICA	13	130.308	4.083	3.13	117.000	143.000
2024-783	12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	124.600	4.091	3.28	112.000	137.000
2024-783	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	121.071	2.219	1.83	109.000	133.000
2024-783	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	122.348	2.460	2.01	110.000	135.000
2024-783	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	18	121.389	3.039	2.50	109.000	134.000
2024-784	3	GL. OXI. C	165	VITROS	63	KODAK	163	72.448	2.076	2.87	65.000	80.000
2024-784	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	90	78.000	2.136	2.74	70.000	86.000
2024-784	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	90	78.000	2.160	2.77	70.000	86.000
2024-784	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	35	73.314	1.801	2.46	66.000	81.000
2024-784	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	78.033	2.949	3.78	70.000	86.000
2024-784	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	78.667	1.972	2.51	71.000	87.000
2024-784	5	HEXOKINASE	203	ROCHE	93	ROCHE	35	73.735	1.521	2.06	66.000	81.000

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-784	5	HEXOKINASE	203	ROCHE	93	ROCHE	35	70.600	1.625	2.30	64.000	78.000
2024-784	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	74.300	1.792	2.41	67.000	82.000
2024-784	6	HEXOKI. CO	220	Medica E.	130	MEDICA	13	78.385	2.237	2.85	71.000	86.000
2024-784	12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	74.950	2.376	3.17	67.000	82.000
2024-784	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	72.143	1.301	1.80	65.000	79.000
2024-784	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	73.261	1.259	1.72	66.000	81.000
2024-784	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	18	73.611	1.736	2.36	66.000	81.000
017	GLUCOSE	CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}								
2024-785	3	GL. OXI. C	165	VITROS	63	KODAK	163	54.393	1.652	3.04	48.000	60.000
2024-785	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	90	62.333	3.091	4.96	56.000	69.000
2024-785	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	90	60.787	1.672	2.75	55.000	67.000
2024-785	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	35	57.457	1.872	3.26	51.000	63.000
2024-785	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	62.500	1.258	2.01	56.000	69.000
2024-785	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	62.161	2.795	4.50	56.000	68.000
2024-785	5	HEXOKINASE	203	ROCHE	93	ROCHE	35	57.029	1.248	2.19	51.000	63.000
2024-785	5	HEXOKINASE	203	ROCHE	93	ROCHE	35	54.600	0.800	1.47	49.000	61.000
2024-785	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	59.500	1.565	2.63	54.000	66.000
2024-785	6	HEXOKI. CO	220	Medica E.	130	MEDICA	13	61.000	1.961	3.22	55.000	67.000
2024-785	12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	58.500	2.012	3.44	53.000	65.000
2024-785	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	55.500	0.982	1.77	50.000	62.000
2024-785	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	56.696	1.040	1.83	51.000	63.000
2024-785	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	18	57.333	1.333	2.33	51.000	63.000
018	IRON, TOTAL	CLIA TEST ID #: 425		EVALUATION CRITERIA: TARGET VALUE 20 %								
2024-781	4	COULOMETR.	165	VITROS	63	KODAK	18	50.778	4.732	9.32	41.000	61.000
2024-782	4	COULOMETR.	165	VITROS	63	KODAK	18	187.556	5.580	2.98	150.000	225.000
2024-783	4	COULOMETR.	165	VITROS	63	KODAK	18	266.176	6.573	2.47	213.000	319.000
2024-784	4	COULOMETR.	165	VITROS	63	KODAK	18	130.111	4.864	3.74	104.000	156.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
018	IRON, TOTAL	CLIA TEST ID #: 425				EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-785	4 COULOMETR.	165	VITROS	63	KODAK	18	89.333	5.088	5.70	71.000	107.000	
019	LACTASE DEHY. (LDH)	CLIA TEST ID #: 435										
2024-781	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	47.947	3.692	7.70	38.000	58.000	
2024-781	6 NADH	203	ROCHE	93	ROCHE	27	62.593	3.165	5.06	50.000	75.000	
2024-781	6 NADH	203	ROCHE	93	ROCHE	27	69.333	4.989	7.20	55.000	83.000	
2024-781	6 NADH	219	ATELLICA	143	SIEMENS	15	61.333	1.955	3.19	49.000	74.000	
2024-781	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	34	56.824	5.050	8.89	45.000	68.000	
2024-781	9 LDH1	165	VITROS	63	KODAK	71	80.986	4.502	5.56	65.000	97.000	
2024-782	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	314.421	21.095	6.71	252.000	377.000	
2024-782	6 NADH	203	ROCHE	93	ROCHE	27	437.333	31.030	7.10	350.000	525.000	
2024-782	6 NADH	203	ROCHE	93	ROCHE	27	396.154	17.869	4.51	317.000	475.000	
2024-782	6 NADH	219	ATELLICA	143	SIEMENS	15	389.333	7.096	1.82	311.000	467.000	
2024-782	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	34	374.647	14.695	3.92	300.000	450.000	
2024-782	9 LDH1	165	VITROS	63	KODAK	71	500.739	14.176	2.83	401.000	601.000	
2024-783	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	437.263	29.975	6.86	350.000	525.000	
2024-783	6 NADH	203	ROCHE	93	ROCHE	27	545.538	20.646	3.78	436.000	655.000	
2024-783	6 NADH	203	ROCHE	93	ROCHE	27	571.333	34.683	6.07	457.000	686.000	
2024-783	6 NADH	219	ATELLICA	143	SIEMENS	15	534.467	12.366	2.31	428.000	641.000	
2024-783	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	34	524.000	15.482	2.95	419.000	629.000	
2024-783	9 LDH1	165	VITROS	63	KODAK	71	695.514	31.401	4.51	556.000	835.000	
2024-784	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	205.579	14.673	7.14	164.000	247.000	
2024-784	6 NADH	203	ROCHE	93	ROCHE	27	278.667	15.326	5.50	223.000	334.000	
2024-784	6 NADH	203	ROCHE	93	ROCHE	27	259.731	10.339	3.98	208.000	312.000	
2024-784	6 NADH	219	ATELLICA	143	SIEMENS	15	259.933	4.479	1.72	208.000	312.000	
2024-784	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	34	245.206	6.902	2.81	196.000	294.000	
2024-784	9 LDH1	165	VITROS	63	KODAK	71	334.629	9.558	2.86	268.000	402.000	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
019	LACTASE DEHY. (LDH)	CLIA TEST ID #: 435		EVALUATION CRITERIA: TARGET VALUE 20 %								
2024-785	3 KINETIC-37	186 BECK. COUL	76 AU-BECKMAN	19	126.632	8.773	6.93	101.000	152.000			
2024-785	6 NADH	203 ROCHE	93 ROCHE	27	160.654	6.139	3.82	129.000	193.000			
2024-785	6 NADH	203 ROCHE	93 ROCHE	27	179.000	11.225	6.27	143.000	215.000			
2024-785	6 NADH	219 ATELLICA	143 SIEMENS	15	162.200	3.331	2.05	130.000	195.000			
2024-785	7 SIEMENS 37	38 SIEMENS DI	143 SIEMENS	34	151.000	7.260	4.81	121.000	181.000			
2024-785	9 LDH1	165 VITROS	63 KODAK	71	206.671	6.872	3.32	165.000	248.000			
021	MAGNESIUM	CLIA TEST ID #: 455		EVALUATION CRITERIA: TARGET VALUE 25 %								
2024-781	5 COLOR./K E	165 VITROS	63 KODAK	28	1.318	0.060	4.56	1.000	1.600			
2024-782	5 COLOR./K E	165 VITROS	63 KODAK	28	3.564	0.093	2.62	2.700	4.500			
2024-783	5 COLOR./K E	165 VITROS	63 KODAK	28	4.575	0.115	2.52	3.400	5.700			
2024-784	5 COLOR./K E	165 VITROS	63 KODAK	28	2.643	0.090	3.42	2.000	3.300			
2024-785	5 COLOR./K E	165 VITROS	63 KODAK	28	1.993	0.065	3.27	1.500	2.500			
022	POTASSIUM	CLIA TEST ID #: 465		EVALUATION CRITERIA: TARGET VALUE 1.00								
2024-781	3 ISE DILUT.	184 INTEGRA	93 ROCHE	28	2.022	0.057	2.80	1.000	3.000			
2024-781	3 ISE DILUT.	186 BECK. COUL	76 AU-BECKMAN	34	2.070	0.052	2.52	1.100	3.100			
2024-781	3 ISE DILUT.	197 ARCHITECT	1 ABBOTT	13	2.015	0.053	2.64	1.000	3.000			
2024-781	3 ISE DILUT.	203 ROCHE	93 ROCHE	60	2.063	0.073	3.54	1.100	3.100			
2024-781	4 ISE UNDIL.	165 VITROS	63 KODAK	65	2.000	0.000	0.00	1.000	3.000			
2024-781	4 ISE UNDIL.	165 VITROS	156 Kit 32	96	2.000	0.043	2.17	1.000	3.000			
2024-781	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX	30	2.137	0.108	5.05	1.100	3.100			
2024-781	4 ISE UNDIL.	220 Medica E.	130 MEDICA	13	1.969	0.082	4.17	1.000	3.000			
2024-781	5 IMT	197 ARCHITECT	1 ABBOTT	10	1.990	0.054	2.71	1.000	3.000			
2024-781	5 IMT	219 ATELLICA	143 SIEMENS	18	2.000	0.000	0.00	1.000	3.000			
2024-781	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	87	1.942	0.056	2.89	0.900	2.900			

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS			NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
022 POTASSIUM		CLIA TEST ID #: 465	EVALUATION CRITERIA: TARGET VALUE 1.00									
2024-782	3 ISE DILUT.	184 INTEGRA	93 ROCHE	28	3.841	0.073	1.91	2.800	4.800			
2024-782	3 ISE DILUT.	186 BECK. COUL	76 AU-BECKMAN	34	3.803	0.057	1.49	2.800	4.800			
2024-782	3 ISE DILUT.	197 ARCHITECT	1 ABBOTT	13	3.823	0.042	1.10	2.800	4.800			
2024-782	3 ISE DILUT.	203 ROCHE	93 ROCHE	60	3.890	0.080	2.05	2.900	4.900			
2024-782	4 ISE UNDIL.	165 VITROS	63 KODAK	65	3.883	0.074	1.89	2.900	4.900			
2024-782	4 ISE UNDIL.	165 VITROS	156 Kit 32	96	3.871	0.071	1.82	2.900	4.900			
2024-782	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX	30	3.823	0.080	2.10	2.800	4.800			
2024-782	4 ISE UNDIL.	220 Medica E.	130 MEDICA	13	3.738	0.100	2.68	2.700	4.700			
2024-782	5 IMT	197 ARCHITECT	1 ABBOTT	10	3.770	0.064	1.70	2.800	4.800			
2024-782	5 IMT	219 ATELLICA	143 SIEMENS	18	3.806	0.070	1.85	2.800	4.800			
2024-782	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	87	3.780	0.068	1.80	2.800	4.800			
2024-783	3 ISE DILUT.	184 INTEGRA	93 ROCHE	28	4.644	0.092	1.97	3.600	5.600			
2024-783	3 ISE DILUT.	186 BECK. COUL	76 AU-BECKMAN	34	4.591	0.082	1.78	3.600	5.600			
2024-783	3 ISE DILUT.	197 ARCHITECT	1 ABBOTT	13	4.692	0.073	1.56	3.700	5.700			
2024-783	3 ISE DILUT.	203 ROCHE	93 ROCHE	60	4.725	0.087	1.84	3.700	5.700			
2024-783	4 ISE UNDIL.	165 VITROS	63 KODAK	65	4.772	0.081	1.70	3.800	5.800			
2024-783	4 ISE UNDIL.	165 VITROS	156 Kit 32	96	4.763	0.090	1.89	3.800	5.800			
2024-783	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX	30	4.637	0.135	2.92	3.600	5.600			
2024-783	4 ISE UNDIL.	220 Medica E.	130 MEDICA	13	4.608	0.092	1.99	3.600	5.600			
2024-783	5 IMT	197 ARCHITECT	1 ABBOTT	10	4.650	0.081	1.73	3.700	5.700			
2024-783	5 IMT	219 ATELLICA	143 SIEMENS	18	4.622	0.092	1.98	3.600	5.600			
2024-783	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	87	4.638	0.091	1.97	3.600	5.600			
2024-784	3 ISE DILUT.	184 INTEGRA	93 ROCHE	28	3.052	0.057	1.86	2.100	4.100			
2024-784	3 ISE DILUT.	186 BECK. COUL	76 AU-BECKMAN	34	3.082	0.052	1.69	2.100	4.100			
2024-784	3 ISE DILUT.	197 ARCHITECT	1 ABBOTT	13	3.069	0.046	1.50	2.100	4.100			
2024-784	3 ISE DILUT.	203 ROCHE	93 ROCHE	60	3.107	0.073	2.34	2.100	4.100			
2024-784	4 ISE UNDIL.	165 VITROS	63 KODAK	65	3.085	0.064	2.07	2.100	4.100			

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-784	4	ISE UNLIL.	165	VITROS	156	Kit 32	96	3.076	0.069	2.25	2.100 4.100	
2024-784	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	30	3.123	0.080	2.57	2.100 4.100	
2024-784	4	ISE UNLIL.	220	Medica E.	130	MEDICA	13	2.992	0.107	3.58	2.000 4.000	
2024-784	5	IMT	197	ARCHITECT	1	ABBOTT	10	3.020	0.060	1.99	2.000 4.000	
2024-784	5	IMT	219	ATELLICA	143	SIEMENS	18	3.022	0.053	1.76	2.000 4.000	
2024-784	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	87	3.008	0.061	2.04	2.000 4.000	
022	POTASSIUM	CLIA TEST ID #: 465		EVALUATION CRITERIA: TARGET VALUE 1.00								
2024-785	3	ISE DILUT.	184	INTEGRA	93	ROCHE	28	2.556	0.057	2.22	1.600 3.600	
2024-785	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	34	2.579	0.053	2.06	1.600 3.600	
2024-785	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	13	2.531	0.046	1.82	1.500 3.500	
2024-785	3	ISE DILUT.	203	ROCHE	93	ROCHE	60	2.587	0.064	2.49	1.600 3.600	
2024-785	4	ISE UNLIL.	165	VITROS	63	KODAK	65	2.543	0.061	2.39	1.500 3.500	
2024-785	4	ISE UNLIL.	165	VITROS	156	Kit 32	96	2.545	0.063	2.46	1.500 3.500	
2024-785	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	30	2.607	0.073	2.79	1.600 3.600	
2024-785	4	ISE UNLIL.	220	Medica E.	130	MEDICA	13	2.467	0.047	1.91	1.500 3.500	
2024-785	5	IMT	197	ARCHITECT	1	ABBOTT	10	2.500	0.045	1.79	1.500 3.500	
2024-785	5	IMT	219	ATELLICA	143	SIEMENS	18	2.500	0.047	1.89	1.500 3.500	
2024-785	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	87	2.474	0.062	2.49	1.500 3.500	
023	SODIUM	CLIA TEST ID #: 475		EVALUATION CRITERIA: TARGET VALUE 4.00								
2024-781	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	131.037	2.472	1.89	127.000 135.000	
2024-781	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	131.143	1.959	1.49	127.000 135.000	
2024-781	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	130.471	2.003	1.54	126.000 134.000	
2024-781	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	131.143	1.959	1.49	127.000 135.000	
2024-781	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	11	131.818	1.336	1.01	128.000 136.000	
2024-781	3	ISE DILUTE	203	ROCHE	93	ROCHE	53	131.615	2.040	1.55	128.000 136.000	
2024-781	3	ISE DILUTE	203	ROCHE	93	ROCHE	53	131.143	1.959	1.49	127.000 135.000	
2024-781	4	ISE UNLIL.	165	VITROS	63	KODAK	60	129.833	1.685	1.30	126.000 134.000	
2024-781	4	ISE UNLIL.	165	VITROS	156	Kit 32	101	130.059	1.521	1.17	126.000 134.000	
2024-781	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	29	131.143	1.959	1.49	127.000 135.000	
2024-781	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	29	130.138	1.676	1.29	126.000 134.000	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-781	4 ISE UNDIL.	220 Medica E.	130 MEDICA	13	130.154	1.460	1.12	126.000	134.000		
2024-781	5 IMT	197 ARCHITECT	1 ABBOTT	12	131.000	1.291	0.99	127.000	135.000		
2024-781	5 IMT	219 ATELLICA	143 SIEMENS	18	132.944	1.545	1.16	129.000	137.000		
2024-781	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	88	133.989	2.087	1.56	130.000	138.000		
023 SODIUM		CLIA TEST ID #: 475	EVALUATION CRITERIA: TARGET VALUE 4.00								
2024-782	3 ISE DILUTE	184 INTEGRA	93 ROCHE	28	149.143	3.136	2.10	145.000	153.000		
2024-782	3 ISE DILUTE	184 INTEGRA	93 ROCHE	28	154.704	2.826	1.83	151.000	159.000		
2024-782	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	34	149.143	3.136	2.10	145.000	153.000		
2024-782	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	34	154.912	2.005	1.29	151.000	159.000		
2024-782	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	11	156.364	1.823	1.17	152.000	160.000		
2024-782	3 ISE DILUTE	203 ROCHE	93 ROCHE	53	149.143	3.136	2.10	145.000	153.000		
2024-782	3 ISE DILUTE	203 ROCHE	93 ROCHE	53	156.481	2.866	1.83	152.000	160.000		
2024-782	4 ISE UNDIL.	165 VITROS	63 KODAK	60	157.633	2.175	1.38	154.000	162.000		
2024-782	4 ISE UNDIL.	165 VITROS	156 Kit 32	101	157.697	1.678	1.06	154.000	162.000		
2024-782	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX	29	153.379	3.199	2.09	149.000	157.000		
2024-782	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX	29	149.143	3.136	2.10	145.000	153.000		
2024-782	4 ISE UNDIL.	220 Medica E.	130 MEDICA	13	153.923	2.368	1.54	150.000	158.000		
2024-782	5 IMT	197 ARCHITECT	1 ABBOTT	12	154.583	1.891	1.22	151.000	159.000		
2024-782	5 IMT	219 ATELLICA	143 SIEMENS	18	155.056	2.437	1.57	151.000	159.000		
2024-782	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	88	156.195	2.268	1.45	152.000	160.000		
2024-783	3 ISE DILUTE	184 INTEGRA	93 ROCHE	28	163.222	2.283	1.40	159.000	167.000		
2024-783	3 ISE DILUTE	184 INTEGRA	93 ROCHE	28	155.857	3.399	2.18	152.000	160.000		
2024-783	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	34	162.794	2.459	1.51	159.000	167.000		
2024-783	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	34	155.857	3.399	2.18	152.000	160.000		
2024-783	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	11	166.182	2.167	1.30	162.000	170.000		
2024-783	3 ISE DILUTE	203 ROCHE	93 ROCHE	53	165.245	2.874	1.74	161.000	169.000		
2024-783	3 ISE DILUTE	203 ROCHE	93 ROCHE	53	155.857	3.399	2.18	152.000	160.000		
2024-783	4 ISE UNDIL.	165 VITROS	63 KODAK	60	168.833	2.478	1.47	165.000	173.000		
2024-783	4 ISE UNDIL.	165 VITROS	156 Kit 32	101	168.910	2.055	1.22	165.000	173.000		

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-783	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	29	155.857	3.399	2.18	152.000	160.000
2024-783	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	29	162.241	4.352	2.68	158.000	166.000
2024-783	4	ISE UNLIL.	220	Medica E.	130	MEDICA	13	164.462	2.135	1.30	160.000	168.000
2024-783	5	IMT	197	ARCHITECT	1	ABBOTT	12	164.750	2.005	1.22	161.000	169.000
2024-783	5	IMT	219	ATELLICA	143	SIEMENS	18	163.500	2.651	1.62	160.000	168.000
2024-783	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	88	164.391	2.404	1.46	160.000	168.000
023	SODIUM		CLIA TEST ID #: 475			EVALUATION CRITERIA: TARGET VALUE 4.00						
2024-784	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	140.143	2.167	1.55	136.000	144.000
2024-784	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	142.714	2.750	1.93	139.000	147.000
2024-784	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	140.143	2.167	1.55	136.000	144.000
2024-784	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	143.588	1.912	1.33	140.000	148.000
2024-784	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	11	144.273	2.300	1.59	140.000	148.000
2024-784	3	ISE DILUTE	203	ROCHE	93	ROCHE	53	140.143	2.167	1.55	136.000	144.000
2024-784	3	ISE DILUTE	203	ROCHE	93	ROCHE	53	144.558	2.538	1.76	141.000	149.000
2024-784	4	ISE UNLIL.	165	VITROS	63	KODAK	60	143.917	2.297	1.60	140.000	148.000
2024-784	4	ISE UNLIL.	165	VITROS	156	Kit 32	101	144.416	1.936	1.34	140.000	148.000
2024-784	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	29	141.893	1.800	1.27	138.000	146.000
2024-784	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	29	140.143	2.167	1.55	136.000	144.000
2024-784	4	ISE UNLIL.	220	Medica E.	130	MEDICA	13	142.846	1.791	1.25	139.000	147.000
2024-784	5	IMT	197	ARCHITECT	1	ABBOTT	12	143.167	1.908	1.33	139.000	147.000
2024-784	5	IMT	219	ATELLICA	143	SIEMENS	18	144.278	1.820	1.26	140.000	148.000
2024-784	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	88	145.330	2.141	1.47	141.000	149.000
2024-785	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	137.429	2.731	1.99	133.000	141.000
2024-785	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	136.286	2.603	1.91	132.000	140.000
2024-785	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	138.059	2.028	1.47	134.000	142.000
2024-785	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	136.286	2.603	1.91	132.000	140.000
2024-785	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	11	138.091	1.676	1.21	134.000	142.000
2024-785	3	ISE DILUTE	203	ROCHE	93	ROCHE	53	138.712	2.169	1.56	135.000	143.000
2024-785	3	ISE DILUTE	203	ROCHE	93	ROCHE	53	136.286	2.603	1.91	132.000	140.000

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-785	4	ISE UNLIL.	165	VITROS	63	KODAK	60	137.733	1.991	1.45	134.000	142.000
2024-785	4	ISE UNLIL.	165	VITROS	156	Kit 32	101	137.822	1.749	1.27	134.000	142.000
2024-785	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	29	136.286	2.603	1.91	132.000	140.000
2024-785	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	29	136.034	2.109	1.55	132.000	140.000
2024-785	4	ISE UNLIL.	220	Medica E.	130	MEDICA	13	136.615	2.203	1.61	133.000	141.000
2024-785	5	IMT	197	ARCHITECT	1	ABBOTT	12	137.667	1.650	1.20	134.000	142.000
2024-785	5	IMT	219	ATELLICA	143	SIEMENS	18	138.611	1.603	1.16	135.000	143.000
2024-785	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	88	139.659	1.770	1.27	136.000	144.000
024 TOTAL PROTEIN		CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-781	1	BIURET	38	SIEMENS DI	143	SIEMENS	88	2.945	0.112	3.81	2.700	3.200
2024-781	1	BIURET	165	VITROS	63	KODAK	145	3.016	0.072	2.38	2.700	3.300
2024-781	1	BIURET	184	INTEGRA	93	ROCHE	16	2.794	0.130	4.64	2.500	3.100
2024-781	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	33	2.869	0.081	2.82	2.600	3.200
2024-781	1	BIURET	191	RX-SERIES	126	RANLIX	30	2.887	0.150	5.20	2.600	3.200
2024-781	1	BIURET	197	ARCHITECT	1	ABBOTT	18	2.761	0.083	2.99	2.500	3.000
2024-781	1	BIURET	203	ROCHE	93	ROCHE	47	2.904	0.066	2.27	2.600	3.200
2024-781	1	BIURET	219	ATELLICA	143	SIEMENS	18	2.850	0.069	2.41	2.600	3.100
2024-781	1	BIURET	220	Medica E.	130	MEDICA	10	2.740	0.102	3.72	2.500	3.000
2024-781	3	BIURET COL	203	ROCHE	93	ROCHE	15	2.857	0.098	3.43	2.600	3.100
2024-782	1	BIURET	38	SIEMENS DI	143	SIEMENS	88	5.494	0.131	2.38	4.900	6.000
2024-782	1	BIURET	165	VITROS	63	KODAK	145	5.339	0.109	2.05	4.800	5.900
2024-782	1	BIURET	184	INTEGRA	93	ROCHE	16	5.150	0.158	3.07	4.600	5.700
2024-782	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	33	5.267	0.103	1.96	4.700	5.800
2024-782	1	BIURET	191	RX-SERIES	126	RANLIX	30	5.360	0.215	4.02	4.800	5.900
2024-782	1	BIURET	197	ARCHITECT	1	ABBOTT	18	5.233	0.111	2.11	4.700	5.800
2024-782	1	BIURET	203	ROCHE	93	ROCHE	47	5.341	0.121	2.26	4.800	5.900
2024-782	1	BIURET	219	ATELLICA	143	SIEMENS	18	5.322	0.181	3.40	4.800	5.900
2024-782	1	BIURET	220	Medica E.	130	MEDICA	10	5.030	0.149	2.96	4.500	5.500
2024-782	3	BIURET COL	203	ROCHE	93	ROCHE	15	5.286	0.130	2.46	4.800	5.800

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
024 TOTAL PROTEIN		CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 10 %					
2024-783	1 BIURET	38 SIEMENS DI	143 SIEMENS		88	6.634	0.179	2.70	6.000	7.300	
2024-783	1 BIURET	165 VITROS	63 KODAK		145	6.345	0.130	2.05	5.700	7.000	
2024-783	1 BIURET	184 INTEGRA	93 ROCHE		16	6.169	0.165	2.67	5.600	6.800	
2024-783	1 BIURET	186 BECK. COUL	76 AU-BECKMAN		33	6.330	0.136	2.15	5.700	7.000	
2024-783	1 BIURET	191 RX-SERIES	126 RANDOX		30	6.423	0.292	4.54	5.800	7.100	
2024-783	1 BIURET	197 ARCHITECT	1 ABBOTT		18	6.433	0.120	1.87	5.800	7.100	
2024-783	1 BIURET	203 ROCHE	93 ROCHE		47	6.376	0.151	2.36	5.700	7.000	
2024-783	1 BIURET	219 ATELLICA	143 SIEMENS		18	6.422	0.202	3.14	5.800	7.100	
2024-783	1 BIURET	220 Medica E.	130 MEDICA		10	6.110	0.176	2.88	5.500	6.700	
2024-783	3 BIURET COL	203 ROCHE	93 ROCHE		15	6.440	0.120	1.86	5.800	7.100	
2024-784	1 BIURET	38 SIEMENS DI	143 SIEMENS		88	4.435	0.129	2.90	4.000	4.900	
2024-784	1 BIURET	165 VITROS	63 KODAK		145	4.386	0.102	2.33	3.900	4.800	
2024-784	1 BIURET	184 INTEGRA	93 ROCHE		16	4.163	0.162	3.88	3.700	4.600	
2024-784	1 BIURET	186 BECK. COUL	76 AU-BECKMAN		33	4.252	0.086	2.02	3.800	4.700	
2024-784	1 BIURET	191 RX-SERIES	126 RANDOX		30	4.303	0.192	4.47	3.900	4.700	
2024-784	1 BIURET	197 ARCHITECT	1 ABBOTT		18	4.183	0.107	2.55	3.800	4.600	
2024-784	1 BIURET	203 ROCHE	93 ROCHE		47	4.293	0.105	2.45	3.900	4.700	
2024-784	1 BIURET	219 ATELLICA	143 SIEMENS		18	4.278	0.108	2.53	3.900	4.700	
2024-784	1 BIURET	220 Medica E.	130 MEDICA		10	4.080	0.140	3.43	3.700	4.500	
2024-784	3 BIURET COL	203 ROCHE	93 ROCHE		15	4.321	0.086	1.99	3.900	4.800	
2024-785	1 BIURET	38 SIEMENS DI	143 SIEMENS		88	3.713	0.103	2.78	3.300	4.100	
2024-785	1 BIURET	165 VITROS	63 KODAK		145	3.721	0.088	2.36	3.300	4.100	
2024-785	1 BIURET	184 INTEGRA	93 ROCHE		16	3.513	0.141	4.01	3.200	3.900	
2024-785	1 BIURET	186 BECK. COUL	76 AU-BECKMAN		33	3.558	0.074	2.08	3.200	3.900	
2024-785	1 BIURET	191 RX-SERIES	126 RANDOX		30	3.587	0.167	4.65	3.200	3.900	
2024-785	1 BIURET	197 ARCHITECT	1 ABBOTT		18	3.478	0.108	3.11	3.100	3.800	
2024-785	1 BIURET	203 ROCHE	93 ROCHE		47	3.613	0.082	2.28	3.300	4.000	

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-785	1	BIURET	219	APELLICA	143	SIEMENS	18	3.583	0.121	3.39	3.200	3.900
2024-785	1	BIURET	220	Medica E.	130	MEDICA	10	3.430	0.127	3.70	3.100	3.800
2024-785	3	BIURET COL	203	ROCHE	93	ROCHE	15	3.607	0.059	1.64	3.200	4.000
025 TRIGLYCERIDES			CLIA TEST ID #: 495				EVALUATION CRITERIA: TARGET VALUE 25 %					
2024-781	2	ENZ. COLO.	165	VITROS	63	KODAK	147	89.637	3.769	4.20	67.000	112.000
2024-781	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	83.833	1.772	2.11	63.000	105.000
2024-781	2	ENZ. COLO.	203	ROCHE	93	ROCHE	31	81.613	3.210	3.93	61.000	102.000
2024-781	2	ENZ. COLO.	220	Medica E.	130	MEDICA	12	82.250	3.467	4.22	62.000	103.000
2024-781	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	87	71.570	3.388	4.73	54.000	89.000
2024-781	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	76.000	1.958	2.58	57.000	95.000
2024-781	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	32	82.065	2.154	2.63	62.000	103.000
2024-781	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	31	80.400	2.678	3.33	60.000	101.000
2024-781	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	82.538	2.561	3.10	62.000	103.000
2024-781	10	ENZYM. GPO	203	ROCHE	93	ROCHE	26	82.038	1.931	2.35	62.000	103.000
2024-781	10	ENZYM. GPO	219	APELLICA	143	SIEMENS	18	83.389	4.071	4.88	63.000	104.000
2024-781	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	10	73.900	3.145	4.26	55.000	92.000
2024-782	2	ENZ. COLO.	165	VITROS	63	KODAK	147	173.497	6.504	3.75	130.000	217.000
2024-782	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	150.583	4.271	2.84	113.000	188.000
2024-782	2	ENZ. COLO.	203	ROCHE	93	ROCHE	31	145.700	5.041	3.46	109.000	182.000
2024-782	2	ENZ. COLO.	220	Medica E.	130	MEDICA	12	139.833	4.758	3.40	105.000	175.000
2024-782	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	87	141.140	3.632	2.57	106.000	176.000
2024-782	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	142.909	3.260	2.28	107.000	179.000
2024-782	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	32	151.000	4.228	2.80	113.000	189.000
2024-782	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	31	145.903	4.895	3.35	109.000	182.000
2024-782	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	146.000	4.915	3.37	110.000	183.000
2024-782	10	ENZYM. GPO	203	ROCHE	93	ROCHE	26	146.808	2.949	2.01	110.000	184.000
2024-782	10	ENZYM. GPO	219	APELLICA	143	SIEMENS	18	150.722	3.649	2.42	113.000	188.000
2024-782	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	10	139.000	5.158	3.71	104.000	174.000

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
025 TRIGLYCERIDES		CLIA TEST ID #: 495				EVALUATION CRITERIA: TARGET VALUE 25 %						
2024-783	2	ENZ. COLO.	165	VITROS	63	KODAK	147	211.558	7.531	3.56	159.000 264.000	
2024-783	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	176.833	3.131	1.77	133.000 221.000	
2024-783	2	ENZ. COLO.	203	ROCHE	93	ROCHE	31	172.129	5.863	3.41	129.000 215.000	
2024-783	2	ENZ. COLO.	220	Medica E.	130	MEDICA	12	165.083	4.349	2.63	124.000 206.000	
2024-783	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	87	172.279	5.144	2.99	129.000 215.000	
2024-783	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	174.583	4.349	2.49	131.000 218.000	
2024-783	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	32	181.906	5.282	2.90	136.000 227.000	
2024-783	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	31	174.452	6.329	3.63	131.000 218.000	
2024-783	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	172.077	5.413	3.15	129.000 215.000	
2024-783	10	ENZYM. GPO	203	ROCHE	93	ROCHE	26	173.808	3.397	1.95	130.000 217.000	
2024-783	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	18	180.889	3.071	1.70	136.000 226.000	
2024-783	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	10	168.200	5.016	2.98	126.000 210.000	
2024-784	2	ENZ. COLO.	165	VITROS	63	KODAK	147	137.639	5.336	3.88	103.000 172.000	
2024-784	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	122.667	2.392	1.95	92.000 153.000	
2024-784	2	ENZ. COLO.	203	ROCHE	93	ROCHE	31	120.267	4.305	3.58	90.000 150.000	
2024-784	2	ENZ. COLO.	220	Medica E.	130	MEDICA	12	115.167	3.955	3.43	86.000 144.000	
2024-784	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	87	111.988	2.957	2.64	84.000 140.000	
2024-784	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	116.083	5.171	4.45	87.000 145.000	
2024-784	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	32	122.000	3.571	2.93	92.000 153.000	
2024-784	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	31	119.290	3.803	3.19	89.000 149.000	
2024-784	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	119.846	4.222	3.52	90.000 150.000	
2024-784	10	ENZYM. GPO	203	ROCHE	93	ROCHE	26	120.654	2.674	2.22	90.000 151.000	
2024-784	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	18	122.778	3.690	3.01	92.000 153.000	
2024-784	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	10	112.000	3.715	3.32	84.000 140.000	
2024-785	2	ENZ. COLO.	165	VITROS	63	KODAK	147	114.301	4.711	4.12	86.000 143.000	
2024-785	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	104.667	2.392	2.29	79.000 131.000	
2024-785	2	ENZ. COLO.	203	ROCHE	93	ROCHE	31	101.467	3.232	3.19	76.000 127.000	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024-785	2	ENZ. COLO.	220 Medica E.	130	MEDICA	12	97.833	2.882	2.95	73.000	122.000
2024-785	4	ENZ. (GPD)	38 SIEMENS DI	143	SIEMENS	87	92.244	3.073	3.33	69.000	115.000
2024-785	5	HANTZCH-C)	197 ARCHITECT	1	ABBOTT	12	96.167	1.724	1.79	72.000	120.000
2024-785	9	GPO TRIND.	186 BECK. COUL	76	AU-BECKMAN	32	102.094	3.311	3.24	77.000	128.000
2024-785	9	GPO TRIND.	191 RX-SERIES	126	RANDOX	31	100.710	3.862	3.83	76.000	126.000
2024-785	10	ENZYM. GPO	184 INTEGRA	93	ROCHE	13	101.923	3.125	3.07	76.000	127.000
2024-785	10	ENZYM. GPO	203 ROCHE	93	ROCHE	26	102.385	2.203	2.15	77.000	128.000
2024-785	10	ENZYM. GPO	219 ATELLICA	143	SIEMENS	18	102.588	3.743	3.65	77.000	128.000
2024-785	11	GLY PO4 OX	197 ARCHITECT	1	ABBOTT	10	93.000	2.933	3.15	70.000	116.000
026 UREA NITROGEN (BUN)			CLIA TEST ID #: 505	EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}							
2024-781	2	UREAS.GLDH	38 SIEMENS DI	143	SIEMENS	90	10.756	0.821	7.63	9.000	13.000
2024-781	2	UREAS.GLDH	184 INTEGRA	93	ROCHE	30	10.931	0.521	4.76	9.000	13.000
2024-781	2	UREAS.GLDH	186 BECK. COUL	76	AU-BECKMAN	34	11.294	0.456	4.03	9.000	13.000
2024-781	2	UREAS.GLDH	191 RX-SERIES	126	RANDOX	31	11.323	0.894	7.90	9.000	13.000
2024-781	2	UREAS.GLDH	191 RX-SERIES	126	RANDOX	31	10.667	0.471	4.42	9.000	13.000
2024-781	2	UREAS.GLDH	203 ROCHE	93	ROCHE	60	11.067	0.544	4.91	9.000	13.000
2024-781	2	UREAS.GLDH	219 ATELLICA	143	SIEMENS	18	11.556	0.598	5.18	10.000	14.000
2024-781	5	CHROMATOG.	197 ARCHITECT	1	ABBOTT	13	10.923	0.474	4.34	9.000	13.000
2024-781	8	UREASE QUI	165 VITROS	63	KODAK	162	9.074	0.479	5.27	7.000	11.000
2024-781	10	UREASE 37	220 Medica E.	130	MEDICA	13	11.154	0.662	5.93	9.000	13.000
2024-782	2	UREAS.GLDH	38 SIEMENS DI	143	SIEMENS	90	24.789	1.110	4.48	23.000	27.000
2024-782	2	UREAS.GLDH	184 INTEGRA	93	ROCHE	30	25.103	0.923	3.68	23.000	27.000
2024-782	2	UREAS.GLDH	186 BECK. COUL	76	AU-BECKMAN	34	25.294	0.787	3.11	23.000	28.000
2024-782	2	UREAS.GLDH	191 RX-SERIES	126	RANDOX	31	26.000	0.816	3.14	24.000	28.000
2024-782	2	UREAS.GLDH	191 RX-SERIES	126	RANDOX	31	24.129	1.314	5.44	22.000	26.000
2024-782	2	UREAS.GLDH	203 ROCHE	93	ROCHE	60	24.831	0.977	3.93	23.000	27.000
2024-782	2	UREAS.GLDH	219 ATELLICA	143	SIEMENS	18	25.167	0.898	3.57	23.000	27.000
2024-782	5	CHROMATOG.	197 ARCHITECT	1	ABBOTT	13	24.846	0.948	3.82	23.000	27.000
2024-782	8	UREASE QUI	165 VITROS	63	KODAK	162	21.549	0.658	3.05	20.000	24.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-782	10 UREASE 37	220	Medica E.	130	MEDICA	13	24.462	0.843	3.44	22.000	27.000	
026	UREA NITROGEN (BUN)	CLIA TEST ID #: 505		EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}								
2024-783	2 UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	90	31.556	1.514	4.80	29.000	34.000	
2024-783	2 UREAS.GLDH	184	INTEGRA	93	ROCHE	30	31.448	1.003	3.19	29.000	34.000	
2024-783	2 UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	34	31.471	0.947	3.01	29.000	34.000	
2024-783	2 UREAS.GLDH	191	RX-SERIES	126	RANDOX	31	29.903	1.907	6.38	27.000	33.000	
2024-783	2 UREAS.GLDH	191	RX-SERIES	126	RANDOX	31	31.667	1.247	3.94	29.000	35.000	
2024-783	2 UREAS.GLDH	203	ROCHE	93	ROCHE	60	31.339	1.083	3.46	29.000	34.000	
2024-783	2 UREAS.GLDH	219	APELLICA	143	SIEMENS	18	31.389	1.061	3.38	29.000	34.000	
2024-783	5 CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	31.615	1.146	3.63	29.000	34.000	
2024-783	8 UREASE QUI	165	VITROS	63	KODAK	162	27.681	0.710	2.57	25.000	30.000	
2024-783	10 UREASE 37	220	Medica E.	130	MEDICA	13	30.692	1.202	3.91	28.000	33.000	
2024-784	2 UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	90	19.033	1.038	5.45	17.000	21.000	
2024-784	2 UREAS.GLDH	184	INTEGRA	93	ROCHE	30	19.103	0.661	3.46	17.000	21.000	
2024-784	2 UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	34	19.412	0.600	3.09	17.000	21.000	
2024-784	2 UREAS.GLDH	191	RX-SERIES	126	RANDOX	31	19.667	1.247	6.34	18.000	22.000	
2024-784	2 UREAS.GLDH	191	RX-SERIES	126	RANDOX	31	18.967	1.197	6.31	17.000	21.000	
2024-784	2 UREAS.GLDH	203	ROCHE	93	ROCHE	60	19.121	0.745	3.89	17.000	21.000	
2024-784	2 UREAS.GLDH	219	APELLICA	143	SIEMENS	18	19.722	0.650	3.30	18.000	22.000	
2024-784	5 CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	18.846	0.662	3.51	17.000	21.000	
2024-784	8 UREASE QUI	165	VITROS	63	KODAK	162	16.298	0.648	3.98	14.000	18.000	
2024-784	10 UREASE 37	220	Medica E.	130	MEDICA	13	18.692	0.606	3.24	17.000	21.000	
2024-785	2 UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	90	14.910	0.944	6.33	13.000	17.000	
2024-785	2 UREAS.GLDH	184	INTEGRA	93	ROCHE	30	15.033	0.752	5.00	13.000	17.000	
2024-785	2 UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	34	15.441	0.553	3.58	13.000	17.000	
2024-785	2 UREAS.GLDH	191	RX-SERIES	126	RANDOX	31	14.968	1.121	7.49	13.000	17.000	
2024-785	2 UREAS.GLDH	191	RX-SERIES	126	RANDOX	31	15.667	1.247	7.96	14.000	18.000	
2024-785	2 UREAS.GLDH	203	ROCHE	93	ROCHE	60	15.000	0.577	3.85	13.000	17.000	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-785	2	UREAS.GLDH	219	APELLICA	143	SIEMENS	18	15.611	0.591	3.78	14.000	18.000
2024-785	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	14.923	0.615	4.12	13.000	17.000
2024-785	8	UREASE QUI	165	VITROS	63	KODAK	162	12.716	0.593	4.66	11.000	15.000
2024-785	10	UREASE 37	220	Medica E.	130	MEDICA	13	14.846	0.533	3.59	13.000	17.000
027	URIC ACID		CLIA TEST ID #: 515				EVALUATION CRITERIA: TARGET VALUE 17 %					
2024-781	2	URICASE	38	SIEMENS DI	143	SIEMENS	47	1.698	0.109	6.44	1.400	2.000
2024-781	2	URICASE	165	VITROS	63	KODAK	98	1.679	0.056	3.32	1.400	2.000
2024-781	2	URICASE	184	INTEGRA	93	ROCHE	10	1.640	0.066	4.04	1.400	1.900
2024-781	2	URICASE	203	ROCHE	93	ROCHE	34	1.576	0.055	3.50	1.300	1.800
2024-781	2	URICASE	219	APELLICA	143	SIEMENS	16	1.750	0.050	2.86	1.500	2.000
2024-781	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	1.726	0.055	3.17	1.400	2.000
2024-781	6	ENZY. COL	203	ROCHE	93	ROCHE	17	1.576	0.042	2.69	1.300	1.800
2024-782	2	URICASE	38	SIEMENS DI	143	SIEMENS	47	5.904	0.189	3.20	4.900	6.900
2024-782	2	URICASE	165	VITROS	63	KODAK	98	5.858	0.154	2.63	4.900	6.900
2024-782	2	URICASE	184	INTEGRA	93	ROCHE	10	5.980	0.299	5.01	5.000	7.000
2024-782	2	URICASE	203	ROCHE	93	ROCHE	34	5.770	0.226	3.92	4.800	6.800
2024-782	2	URICASE	219	APELLICA	143	SIEMENS	16	6.106	0.160	2.62	5.100	7.100
2024-782	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	5.879	0.128	2.18	4.900	6.900
2024-782	6	ENZY. COL	203	ROCHE	93	ROCHE	17	5.750	0.117	2.04	4.800	6.700
2024-783	2	URICASE	38	SIEMENS DI	143	SIEMENS	47	7.900	0.300	3.80	6.600	9.200
2024-783	2	URICASE	165	VITROS	63	KODAK	98	7.851	0.183	2.33	6.500	9.200
2024-783	2	URICASE	184	INTEGRA	93	ROCHE	10	7.950	0.406	5.10	6.600	9.300
2024-783	2	URICASE	203	ROCHE	93	ROCHE	34	7.697	0.263	3.42	6.400	9.000
2024-783	2	URICASE	219	APELLICA	143	SIEMENS	16	8.131	0.196	2.41	6.700	9.500
2024-783	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	7.832	0.213	2.72	6.500	9.200
2024-783	6	ENZY. COL	203	ROCHE	93	ROCHE	17	7.759	0.161	2.08	6.400	9.100
2024-784	2	URICASE	38	SIEMENS DI	143	SIEMENS	47	4.113	0.139	3.39	3.400	4.800

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS			NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-784	2	URICASE	165	VITROS	63	KODAK	98	4.091	0.103	2.52	3.400	4.800
2024-784	2	URICASE	184	INTEGRA	93	ROCHE	10	4.210	0.158	3.75	3.500	4.900
2024-784	2	URICASE	203	ROCHE	93	ROCHE	34	4.050	0.120	2.96	3.400	4.700
2024-784	2	URICASE	219	ATELLICA	143	SIEMENS	16	4.338	0.117	2.69	3.600	5.100
2024-784	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	4.205	0.105	2.50	3.500	4.900
2024-784	6	ENZY. COL	203	ROCHE	93	ROCHE	17	4.035	0.084	2.07	3.300	4.700
027	URIC ACID		CLIA TEST ID #: 515			EVALUATION CRITERIA: TARGET VALUE 17 %						
2024-785	2	URICASE	38	SIEMENS DI	143	SIEMENS	47	2.911	0.120	4.13	2.400	3.400
2024-785	2	URICASE	165	VITROS	63	KODAK	98	2.863	0.084	2.93	2.400	3.400
2024-785	2	URICASE	184	INTEGRA	93	ROCHE	10	2.900	0.134	4.63	2.400	3.400
2024-785	2	URICASE	203	ROCHE	93	ROCHE	34	2.819	0.081	2.87	2.300	3.300
2024-785	2	URICASE	219	ATELLICA	143	SIEMENS	16	3.044	0.061	2.00	2.500	3.600
2024-785	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	2.989	0.066	2.20	2.500	3.500
2024-785	6	ENZY. COL	203	ROCHE	93	ROCHE	17	2.824	0.055	1.93	2.300	3.300
135	GGT (GAMMA GLU. TRA)		CLIA TEST ID #: 0			EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-781	5	KINETIC 37	165	VITROS	63	KODAK	27	21.741	1.235	5.68	17.000	26.000
2024-781	5	KINETIC 37	219	ATELLICA	143	SIEMENS	10	16.600	3.169	19.09	13.000	20.000
2024-782	5	KINETIC 37	165	VITROS	63	KODAK	27	351.889	8.582	2.44	282.000	422.000
2024-782	5	KINETIC 37	219	ATELLICA	143	SIEMENS	10	243.000	7.183	2.96	194.000	292.000
2024-783	5	KINETIC 37	165	VITROS	63	KODAK	27	474.259	14.165	2.99	379.000	569.000
2024-783	5	KINETIC 37	219	ATELLICA	143	SIEMENS	10	348.700	9.487	2.72	279.000	418.000
2024-784	5	KINETIC 37	165	VITROS	63	KODAK	27	229.778	6.112	2.66	184.000	276.000
2024-784	5	KINETIC 37	219	ATELLICA	143	SIEMENS	10	150.800	4.490	2.98	121.000	181.000
2024-785	5	KINETIC 37	165	VITROS	63	KODAK	27	128.741	3.797	2.95	103.000	154.000
2024-785	5	KINETIC 37	219	ATELLICA	143	SIEMENS	10	82.800	2.750	3.32	66.000	99.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
136	LACTIC ACID	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-781	1 LACTATE-P.	165	VITROS	63	KODAK	25	0.564	0.056	9.88	0.500	0.700	
2024-782	1 LACTATE-P.	165	VITROS	63	KODAK	25	3.538	0.075	2.13	2.800	4.200	
2024-783	1 LACTATE-P.	165	VITROS	63	KODAK	25	4.912	0.107	2.18	3.900	5.900	
2024-784	1 LACTATE-P.	165	VITROS	63	KODAK	25	2.283	0.099	4.32	1.800	2.700	
2024-785	1 LACTATE-P.	165	VITROS	63	KODAK	25	1.376	0.071	5.15	1.100	1.700	
137	LIPASE											
2024-781	1 COLORIMET.	203	ROCHE	93	ROCHE	18	15.111	0.809	5.35	12.000	18.000	
2024-781	1 COLORIMET.	219	ATELLICA	143	SIEMENS	11	17.182	1.192	6.94	14.000	21.000	
2024-781	2 ENZIMATIC	165	VITROS	63	KODAK	86	74.349	4.250	5.72	59.000	89.000	
2024-781	4 ENZ/COLOR	184	INTEGRA	93	ROCHE	10	15.700	0.781	4.97	13.000	19.000	
2024-781	4 ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	15.333	1.738	11.34	12.000	18.000	
2024-781	4 ENZ/COLOR	203	ROCHE	93	ROCHE	14	15.071	0.799	5.30	12.000	18.000	
2024-781	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	15	17.600	0.952	5.41	14.000	21.000	
2024-782	1 COLORIMET.	203	ROCHE	93	ROCHE	18	51.444	3.578	6.96	41.000	62.000	
2024-782	1 COLORIMET.	219	ATELLICA	143	SIEMENS	11	59.273	2.136	3.60	47.000	71.000	
2024-782	2 ENZIMATIC	165	VITROS	63	KODAK	86	444.247	14.689	3.31	355.000	533.000	
2024-782	4 ENZ/COLOR	184	INTEGRA	93	ROCHE	10	49.600	4.386	8.84	40.000	60.000	
2024-782	4 ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	55.400	1.993	3.60	44.000	66.000	
2024-782	4 ENZ/COLOR	203	ROCHE	93	ROCHE	14	51.857	3.399	6.55	41.000	62.000	
2024-782	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	15	54.533	2.849	5.22	44.000	65.000	
2024-783	1 COLORIMET.	203	ROCHE	93	ROCHE	18	68.444	4.462	6.52	55.000	82.000	
2024-783	1 COLORIMET.	219	ATELLICA	143	SIEMENS	11	77.091	2.937	3.81	62.000	93.000	
2024-783	2 ENZIMATIC	165	VITROS	63	KODAK	86	590.553	20.406	3.46	472.000	709.000	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-783	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	63.800	3.763	5.90	51.000	77.000
2024-783	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	74.867	3.612	4.83	60.000	90.000
2024-783	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	67.000	3.317	4.95	54.000	80.000
2024-783	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	15	71.867	3.201	4.45	57.000	86.000
137	LIPASE		CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %					
2024-784	1	COLORIMET.	203	ROCHE	93	ROCHE	18	36.889	2.105	5.71	30.000	44.000
2024-784	1	COLORIMET.	219	ATELLICA	143	SIEMENS	11	42.000	1.706	4.06	34.000	50.000
2024-784	2	ENZIMATIC	165	VITROS	63	KODAK	86	302.753	12.623	4.17	242.000	363.000
2024-784	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	35.300	1.952	5.53	28.000	42.000
2024-784	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	38.867	1.543	3.97	31.000	47.000
2024-784	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	36.429	2.095	5.75	29.000	44.000
2024-784	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	15	40.200	2.007	4.99	32.000	48.000
2024-785	1	COLORIMET.	203	ROCHE	93	ROCHE	18	26.278	1.483	5.65	21.000	32.000
2024-785	1	COLORIMET.	219	ATELLICA	143	SIEMENS	11	29.909	1.564	5.23	24.000	36.000
2024-785	2	ENZIMATIC	165	VITROS	63	KODAK	86	191.349	8.135	4.25	153.000	230.000
2024-785	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	26.000	1.789	6.88	21.000	31.000
2024-785	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	26.933	1.731	6.43	22.000	32.000
2024-785	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	26.000	1.069	4.11	21.000	31.000
2024-785	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	15	29.133	1.454	4.99	23.000	35.000
138	PHOSPHORUS											
2024-781	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	47	1.674	0.130	7.74	1.300	2.000
2024-781	1	PHOSPHOMO.	165	VITROS	63	KODAK	95	1.817	0.106	5.85	1.500	2.200
2024-781	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	1.592	0.107	6.73	1.300	1.900
2024-781	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	1.600	0.077	4.84	1.300	1.900
2024-781	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	48	1.536	0.063	4.12	1.200	1.800
2024-781	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	16	1.613	0.099	6.15	1.300	1.900
2024-782	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	47	3.928	0.162	4.13	3.100	4.700
2024-782	1	PHOSPHOMO.	165	VITROS	63	KODAK	95	3.891	0.128	3.28	3.100	4.700

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-782	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	3.762	0.139	3.69	3.000	4.500
2024-782	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	3.830	0.138	3.61	3.100	4.600
2024-782	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	48	3.755	0.127	3.38	3.000	4.500
2024-782	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	16	3.900	0.137	3.51	3.100	4.700
138	PHOSPHORUS	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-783	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	47	4.937	0.137	2.78	3.900	5.900
2024-783	1	PHOSPHOMO.	165	VITROS	63	KODAK	95	4.784	0.148	3.10	3.800	5.700
2024-783	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	4.715	0.135	2.86	3.800	5.700
2024-783	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	4.825	0.167	3.46	3.900	5.800
2024-783	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	48	4.738	0.104	2.20	3.800	5.700
2024-783	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	16	4.881	0.181	3.71	3.900	5.900
2024-784	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	47	3.009	0.101	3.35	2.400	3.600
2024-784	1	PHOSPHOMO.	165	VITROS	63	KODAK	95	3.101	0.128	4.11	2.500	3.700
2024-784	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	2.900	0.118	4.06	2.300	3.500
2024-784	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	2.905	0.080	2.77	2.300	3.500
2024-784	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	48	2.857	0.074	2.60	2.300	3.400
2024-784	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	16	2.969	0.092	3.09	2.400	3.600
2024-785	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	47	2.357	0.117	4.98	1.900	2.800
2024-785	1	PHOSPHOMO.	165	VITROS	63	KODAK	95	2.521	0.118	4.67	2.000	3.000
2024-785	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	2.262	0.115	5.07	1.800	2.700
2024-785	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	2.295	0.107	4.67	1.800	2.800
2024-785	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	48	2.228	0.071	3.20	1.800	2.700
2024-785	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	16	2.331	0.098	4.21	1.900	2.800
169	CO2					EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-781	1	Generic Me	184	INTEGRA	93	ROCHE	10	10.500	3.442	32.78	0.000	21.000
2024-781	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	8.222	0.786	9.56	6.000	11.000
2024-781	1	Generic Me	203	ROCHE	93	ROCHE	24	7.875	1.201	15.25	4.000	11.000
2024-781	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	72	10.486	1.787	17.04	5.000	16.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-781	2	ENZYMATIC	165	VITROS	63	KODAK	59	6.345	1.092	17.20	3.000	10.000
2024-781	2	ENZYMATIC	165	VITROS	156	Kit 32	85	6.345	1.018	16.04	3.000	9.000
2024-781	2	ENZYMATIC	203	ROCHE	93	ROCHE	12	7.583	1.605	21.17	3.000	12.000
2024-781	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	16	10.200	0.748	7.34	8.000	12.000
169	CO2	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD								
2024-782	1	Generic Me	184	INTEGRA	93	ROCHE	10	15.800	3.187	20.17	6.000	25.000
2024-782	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	14.071	2.069	14.70	8.000	20.000
2024-782	1	Generic Me	203	ROCHE	93	ROCHE	24	13.500	1.893	14.02	8.000	19.000
2024-782	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	72	16.569	2.067	12.48	10.000	23.000
2024-782	2	ENZYMATIC	165	VITROS	63	KODAK	59	11.707	1.543	13.18	7.000	16.000
2024-782	2	ENZYMATIC	165	VITROS	156	Kit 32	85	11.929	1.731	14.51	7.000	17.000
2024-782	2	ENZYMATIC	203	ROCHE	93	ROCHE	12	13.417	1.498	11.16	9.000	18.000
2024-782	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	16	16.313	2.171	13.31	10.000	23.000
2024-783	1	Generic Me	184	INTEGRA	93	ROCHE	10	18.400	3.323	18.06	8.000	28.000
2024-783	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	17.714	2.218	12.52	11.000	24.000
2024-783	1	Generic Me	203	ROCHE	93	ROCHE	24	16.667	1.772	10.63	11.000	22.000
2024-783	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	72	20.500	2.154	10.51	14.000	27.000
2024-783	2	ENZYMATIC	165	VITROS	63	KODAK	59	14.814	1.926	13.00	9.000	21.000
2024-783	2	ENZYMATIC	165	VITROS	156	Kit 32	85	14.821	1.705	11.51	10.000	20.000
2024-783	2	ENZYMATIC	203	ROCHE	93	ROCHE	12	17.083	1.706	9.99	12.000	22.000
2024-783	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	16	19.688	2.567	13.04	12.000	27.000
2024-784	1	Generic Me	184	INTEGRA	93	ROCHE	10	12.800	3.458	27.02	2.000	23.000
2024-784	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	11.750	1.703	14.50	7.000	17.000
2024-784	1	Generic Me	203	ROCHE	93	ROCHE	24	11.000	1.658	15.08	6.000	16.000
2024-784	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	72	14.181	2.110	14.88	8.000	21.000
2024-784	2	ENZYMATIC	165	VITROS	63	KODAK	59	8.797	1.876	21.32	3.000	14.000
2024-784	2	ENZYMATIC	165	VITROS	156	Kit 32	85	9.188	1.576	17.15	4.000	14.000
2024-784	2	ENZYMATIC	203	ROCHE	93	ROCHE	12	11.083	1.656	14.94	6.000	16.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-784	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	16	13.500	2.062	15.27	7.000	20.000
169	CO2	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-785	1	Generic Me	184	INTEGRA	93	ROCHE	10	10.700	2.648	24.74	3.000	19.000
2024-785	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	9.667	1.054	10.90	7.000	13.000
2024-785	1	Generic Me	203	ROCHE	93	ROCHE	24	9.083	1.801	19.83	4.000	14.000
2024-785	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	72	12.139	1.797	14.81	7.000	18.000
2024-785	2	ENZYMATIC	165	VITROS	63	KODAK	59	7.119	1.263	17.75	3.000	11.000
2024-785	2	ENZYMATIC	165	VITROS	156	Kit 32	85	7.524	1.314	17.46	4.000	11.000
2024-785	2	ENZYMATIC	203	ROCHE	93	ROCHE	12	9.583	1.320	13.78	6.000	14.000
2024-785	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	16	11.438	1.968	17.20	6.000	17.000
170	DIRECT BILIRUBIN	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}										
2024-781	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	45	0.078	0.042	53.45	0.000	0.200
2024-781	5	JEND.-GROG	197	ARCHITECT	1	ABBOTT	13	0.100	0.000	0.00	0.100	0.100
2024-781	11	SPECT. WIT	165	VITROS	63	KODAK	70	0.007	0.026	352.14	0	0.100
2024-781	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	20	0.200	0.000	0.00	0.200	0.200
2024-781	14	VANADATE O	219	ATELLICA	143	SIEMENS	16	0.100	0.000	0.00	0.100	0.100
2024-782	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	45	0.644	0.054	8.38	0.500	0.800
2024-782	5	JEND.-GROG	197	ARCHITECT	1	ABBOTT	13	1.062	0.092	8.70	0.800	1.300
2024-782	11	SPECT. WIT	165	VITROS	63	KODAK	70	0.251	0.264	105.17	0	1.000
2024-782	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	20	0.568	0.073	12.83	0.300	0.800
2024-782	14	VANADATE O	219	ATELLICA	143	SIEMENS	16	1.338	0.086	6.41	1.100	1.600
2024-783	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	45	0.923	0.052	5.64	0.700	1.100
2024-783	5	JEND.-GROG	197	ARCHITECT	1	ABBOTT	13	1.462	0.108	7.37	1.100	1.800
2024-783	11	SPECT. WIT	165	VITROS	63	KODAK	70	0.461	0.281	60.95	0	1.300
2024-783	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	20	0.795	0.100	12.57	0.500	1.100
2024-783	14	VANADATE O	219	ATELLICA	143	SIEMENS	16	1.844	0.122	6.63	1.500	2.200
2024-784	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	45	0.389	0.032	8.17	0.300	0.500

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-784	5	JEND.-GROG	197 ARCHITECT	1	ABBOTT	13	0.662	0.062	9.45	0.500	0.800
2024-784	11	SPECT. WIT	165 VITROS	63	KODAK	70	0.110	0.210	190.79	0	0.700
2024-784	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	20	0.370	0.078	21.11	0.100	0.600
2024-784	14	VANADATE O	219 ATELLICA	143	SIEMENS	16	0.844	0.061	7.22	0.700	1.000
170 DIRECT BILIRUBIN						CLIA TEST ID #: 0 EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}					
2024-785	4	JEND.-GROG	38 SIEMENS DI	143	SIEMENS	45	0.200	0.000	0.00	0.200	0.200
2024-785	5	JEND.-GROG	197 ARCHITECT	1	ABBOTT	13	0.354	0.063	17.93	0.200	0.500
2024-785	11	SPECT. WIT	165 VITROS	63	KODAK	70	0.074	0.148	199.26	0	0.500
2024-785	13	AZOBIL.W/D	203 ROCHE	93	ROCHE	20	0.200	0.000	0.00	0.200	0.200
2024-785	14	VANADATE O	219 ATELLICA	143	SIEMENS	16	0.463	0.048	10.47	0.300	0.600

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 15 WHOLE BLOOD GLUCOSE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
157 WHOLE BLOOD GLUCOSE						EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}					
2024-881	23	ABBOTT PRE		23	178.522	11.197	6.27	161.000	196.000		
2024-881	23	ABBOTT PRE		23	167.000	10.424	6.24	150.000	184.000		
2024-881	27	STAT SRIP.		83	167.000	10.424	6.24	150.000	184.000		
2024-881	27	STAT SRIP.		83	164.458	6.720	4.09	148.000	181.000		
2024-881	33	AC.CHEK II		37	181.405	5.796	3.19	163.000	200.000		
2024-881	34	FREE STYL		46	190.848	15.293	8.01	172.000	210.000		
2024-882	23	ABBOTT PRE		23	356.000	17.795	5.00	320.000	392.000		
2024-882	23	ABBOTT PRE		23	353.870	32.752	9.26	318.000	389.000		
2024-882	27	STAT SRIP.		83	336.585	15.691	4.66	303.000	370.000		
2024-882	27	STAT SRIP.		83	356.000	17.795	5.00	320.000	392.000		
2024-882	33	AC.CHEK II		37	380.778	9.942	2.61	343.000	419.000		
2024-882	34	FREE STYL		46	389.783	29.600	7.59	351.000	429.000		

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE		GRP: 15 WHOLE BLOOD GLUCOSE					
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
157 WHOLE BLOOD GLUCOSE					CLIA TEST ID #: 0 EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}					
2024-883	23	ABBOTT PRE		23	78.391	4.679	5.97	71.000	86.000	
2024-883	23	ABBOTT PRE		23	75.667	1.247	1.65	68.000	83.000	
2024-883	27	STAT SRIP.		83	75.667	1.247	1.65	68.000	83.000	
2024-883	27	STAT SRIP.		83	75.048	3.304	4.40	68.000	83.000	
2024-883	33	AC.CHEK II		37	81.806	1.898	2.32	74.000	90.000	
2024-883	34	FREE STYL		46	83.087	6.111	7.35	75.000	91.000	
2024-884	23	ABBOTT PRE		23	171.000	15.513	9.07	154.000	188.000	
2024-884	23	ABBOTT PRE		23	174.957	8.770	5.01	157.000	192.000	
2024-884	27	STAT SRIP.		83	164.110	7.158	4.36	148.000	181.000	
2024-884	27	STAT SRIP.		83	171.000	15.513	9.07	154.000	188.000	
2024-884	33	AC.CHEK II		37	180.486	5.401	2.99	162.000	199.000	
2024-884	34	FREE STYL		46	190.413	13.821	7.26	171.000	209.000	
2024-885	23	ABBOTT PRE		23	71.333	2.867	4.02	64.000	78.000	
2024-885	23	ABBOTT PRE		23	78.609	4.431	5.64	71.000	86.000	
2024-885	27	STAT SRIP.		83	71.333	2.867	4.02	64.000	78.000	
2024-885	27	STAT SRIP.		83	74.573	4.491	6.02	67.000	82.000	
2024-885	33	AC.CHEK II		37	81.730	2.250	2.75	74.000	90.000	
2024-885	34	FREE STYL		46	83.435	5.788	6.94	75.000	92.000	

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES		GRP: 30 BLOOD GASES					
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
007 BLOOD GASES-pCO2					CLIA TEST ID #: 335 EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}					
2024-831	256	GEM PREMI.		10	67.000	1.673	2.50	61.600	72.400	
2024-831	265	ROCHE COBA		33	66.276	1.282	1.93	61.000	71.600	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES				
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
007	BLOOD GASES-pCO2		CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE	8	% OR 5.00	{GREATER}			
2024-832	256	GEM PREMI.			10	41.200	0.872	2.12	36.200	46.200
2024-832	265	ROCHE COBA			33	43.228	0.651	1.51	38.200	48.200
2024-833	256	GEM PREMI.			10	21.400	0.663	3.10	16.400	26.400
2024-833	265	ROCHE COBA			33	22.878	0.508	2.22	17.900	27.900
2024-834	256	GEM PREMI.			10	54.300	2.052	3.78	49.300	59.300
2024-834	265	ROCHE COBA			33	55.200	1.575	2.85	50.200	60.200
2024-835	256	GEM PREMI.			10	53.100	1.375	2.59	48.100	58.100
2024-835	265	ROCHE COBA			33	55.225	1.706	3.09	50.200	60.200
008	BLOOD GASES-pH		CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE	0.04					
2024-831	256	GEM PREMI.			10	7.159	0.009	0.13	7.119	7.199
2024-831	265	ROCHE COBA			33	7.179	0.007	0.09	7.139	7.219
2024-832	256	GEM PREMI.			10	7.436	0.005	0.07	7.396	7.476
2024-832	265	ROCHE COBA			33	7.409	0.005	0.07	7.370	7.450
2024-833	256	GEM PREMI.			10	7.637	0.009	0.12	7.597	7.677
2024-833	265	ROCHE COBA			33	7.575	0.006	0.08	7.535	7.615
2024-834	256	GEM PREMI.			10	7.231	0.009	0.13	7.191	7.271
2024-834	265	ROCHE COBA			33	7.229	0.007	0.10	7.189	7.269
2024-835	256	GEM PREMI.			10	7.233	0.009	0.12	7.193	7.273
2024-835	265	ROCHE COBA			33	7.229	0.005	0.08	7.189	7.269
009	BLOOD GASES-pO2		CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE	3	SD				
2024-831	256	GEM PREMI.			10	67.800	2.713	4.00	59.700	75.900

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-831	265	ROCHE COBA		33	49.252	4.459	9.05	35.900	62.600	
009	BLOOD GASES-pO2		CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-832	256	GEM PREMI.		10	115.200	4.142	3.60	102.800	127.600	
2024-832	265	ROCHE COBA		33	112.866	6.012	5.33	94.800	130.900	
2024-833	256	GEM PREMI.		10	178.700	6.694	3.75	158.600	198.800	
2024-833	265	ROCHE COBA		33	183.448	5.524	3.01	166.900	200.000	
2024-834	256	GEM PREMI.		10	260.600	30.306	11.63	169.700	351.500	
2024-834	265	ROCHE COBA		33	288.736	32.335	11.20	191.700	385.700	
2024-835	256	GEM PREMI.		10	260.200	25.431	9.77	183.900	336.500	
2024-835	265	ROCHE COBA		33	285.845	28.483	9.96	200.400	371.300	

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
029	FOLL. STIM. HOR.-FSH		CLIA TEST ID #: 0							
2024-811	116	ROCHE COBA		15	7.060	0.342	4.85	6.000	8.100	
2024-811	125	B.C.ACCESS		10	7.610	0.441	5.80	6.300	8.900	
2024-811	149	ARC i2000s		11	6.709	0.419	6.24	5.500	8.000	
2024-811	169	ATELLICA		10	7.260	0.420	5.79	6.000	8.500	
2024-812	116	ROCHE COBA		15	21.820	1.013	4.64	18.800	24.900	
2024-812	125	B.C.ACCESS		10	24.000	1.581	6.59	19.300	28.700	
2024-812	149	ARC i2000s		11	21.218	0.846	3.99	18.700	23.800	
2024-812	169	ATELLICA		10	24.280	1.349	5.56	20.200	28.300	
2024-813	116	ROCHE COBA		15	28.627	1.524	5.32	24.100	33.200	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024-813	125	B.C.ACCESS		10	31.520	1.712	5.43	26.400	36.700
2024-813	149	ARC i2000s		11	28.373	1.975	6.96	22.400	34.300
2024-813	169	APELLICA		10	31.600	2.861	9.05	23.000	40.200
029 FOLL. STIM. HOR.-FSH			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-814	116	ROCHE COBA		15	15.980	0.928	5.80	13.200	18.800
2024-814	125	B.C.ACCESS		10	17.280	0.836	4.84	14.800	19.800
2024-814	149	ARC i2000s		11	15.227	0.810	5.32	12.800	17.700
2024-814	169	APELLICA		10	17.560	1.296	7.38	13.700	21.400
2024-815	116	ROCHE COBA		15	11.513	0.564	4.90	9.800	13.200
2024-815	125	B.C.ACCESS		10	12.200	1.046	8.57	9.100	15.300
2024-815	149	ARC i2000s		11	10.818	0.690	6.38	8.700	12.900
2024-815	169	APELLICA		10	12.280	0.901	7.34	9.600	15.000
030 FREE THYROXINE			CLIA TEST ID #: 545						
2024-811	115	VITROS ECI		46	1.000	0.000	0.00	1.000	1.000
2024-811	115	VITROS ECI		46	1.717	0.087	5.05	1.500	2.000
2024-811	116	ROCHE COBA		47	0.960	0.053	5.55	0.800	1.100
2024-811	125	B.C.ACCESS		46	0.960	0.065	6.73	0.800	1.200
2024-811	149	ARC i2000s		22	0.864	0.048	5.57	0.700	1.000
2024-811	160	SIEMENS EX		50	0.984	0.073	7.43	0.800	1.200
2024-811	169	APELLICA		14	0.829	0.059	7.11	0.700	1.000
2024-812	115	VITROS ECI		46	5.240	0.195	3.72	4.700	5.800
2024-812	115	VITROS ECI		46	2.233	0.094	4.22	2.000	2.500
2024-812	116	ROCHE COBA		47	2.260	0.087	3.84	2.000	2.500
2024-812	125	B.C.ACCESS		46	2.037	0.105	5.15	1.700	2.400
2024-812	149	ARC i2000s		22	1.943	0.079	4.07	1.700	2.200
2024-812	160	SIEMENS EX		50	2.262	0.121	5.37	1.900	2.600
2024-812	169	APELLICA		14	1.821	0.067	3.70	1.600	2.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
030	FREE THYROXINE	CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-813	115 VITROS ECI			46	6.264	0.247	3.94	5.500	7.000
2024-813	115 VITROS ECI			46	2.833	0.125	4.40	2.500	3.200
2024-813	116 ROCHE COBA			47	2.751	0.120	4.36	2.400	3.100
2024-813	125 B.C.ACCESS			46	2.385	0.118	4.94	2.000	2.700
2024-813	149 ARC i2000s			22	2.336	0.201	8.61	1.700	2.900
2024-813	160 SIEMENS EX			50	2.796	0.131	4.69	2.400	3.200
2024-813	169 ATELLICA			14	2.207	0.070	3.19	2.000	2.400
2024-814	115 VITROS ECI			46	4.039	0.194	4.82	3.500	4.600
2024-814	115 VITROS ECI			46	1.800	0.082	4.54	1.600	2.000
2024-814	116 ROCHE COBA			47	1.817	0.069	3.82	1.600	2.000
2024-814	125 B.C.ACCESS			46	1.667	0.093	5.60	1.400	1.900
2024-814	149 ARC i2000s			22	1.564	0.077	4.93	1.300	1.800
2024-814	160 SIEMENS EX			50	1.780	0.083	4.68	1.500	2.000
2024-814	169 ATELLICA			14	1.471	0.080	5.41	1.200	1.700
2024-815	115 VITROS ECI			46	2.922	0.166	5.68	2.400	3.400
2024-815	115 VITROS ECI			46	1.400	0.082	5.83	1.200	1.600
2024-815	116 ROCHE COBA			47	1.423	0.059	4.15	1.200	1.600
2024-815	125 B.C.ACCESS			46	1.333	0.084	6.32	1.100	1.600
2024-815	149 ARC i2000s			22	1.232	0.055	4.50	1.100	1.400
2024-815	160 SIEMENS EX			50	1.382	0.080	5.79	1.100	1.600
2024-815	169 ATELLICA			14	1.171	0.059	5.03	1.000	1.300
032	hCG-QUANTITATIVE	CLIA TEST ID #: 555							
2024-811	115 VITROS ECI			22	3.409	0.307	9.02	2.500	4.300
2024-811	116 ROCHE COBA			18	2.950	0.050	1.69	2.800	3.100
2024-811	116 ROCHE COBA			18	2.372	0.185	7.80	1.800	2.900
2024-811	125 B.C.ACCESS			10	3.440	0.246	7.14	2.700	4.200

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
032 hCG-QUANTITATIVE		CLIA TEST ID #: 555		EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-812	115	VITROS ECI		22	591.323	20.841	3.52	528.800	653.800	
2024-812	116	ROCHE COBA		18	438.653	24.906	5.68	363.900	513.400	
2024-812	116	ROCHE COBA		18	561.625	6.204	1.10	543.000	580.200	
2024-812	125	B.C.ACCESS		10	389.640	20.984	5.39	326.700	452.600	
2024-813	115	VITROS ECI		22	876.105	28.486	3.25	790.600	961.600	
2024-813	116	ROCHE COBA		18	818.725	4.614	0.56	804.900	832.600	
2024-813	116	ROCHE COBA		18	645.400	30.521	4.73	553.800	737.000	
2024-813	125	B.C.ACCESS		10	560.450	23.978	4.28	488.500	632.400	
2024-814	115	VITROS ECI		22	355.523	12.707	3.57	317.400	393.600	
2024-814	116	ROCHE COBA		18	266.044	20.852	7.84	203.500	328.600	
2024-814	116	ROCHE COBA		18	335.775	4.890	1.46	321.100	350.400	
2024-814	125	B.C.ACCESS		10	245.720	10.463	4.26	214.300	277.100	
2024-815	115	VITROS ECI		22	178.695	6.729	3.77	158.500	198.900	
2024-815	116	ROCHE COBA		18	168.750	1.417	0.84	164.500	173.000	
2024-815	116	ROCHE COBA		18	129.347	5.577	4.31	112.600	146.100	
2024-815	125	B.C.ACCESS		10	122.880	5.770	4.70	105.600	140.200	
035 PROLACTIN		CLIA TEST ID #: 0								
2024-811	116	ROCHE COBA		16	1.806	0.075	4.14	1.600	2.000	
2024-811	125	B.C.ACCESS		11	1.691	0.116	6.89	1.300	2.000	
2024-811	169	APELLICA		10	1.540	0.102	6.62	1.200	1.800	
2024-812	116	ROCHE COBA		16	15.407	0.409	2.65	14.200	16.600	
2024-812	125	B.C.ACCESS		11	16.727	0.677	4.05	14.700	18.800	
2024-812	169	APELLICA		10	13.050	0.815	6.25	10.600	15.500	
2024-813	116	ROCHE COBA		16	22.350	0.707	3.16	20.200	24.500	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-813	125	B.C.ACCESS		11	23.091	1.145	4.96	19.700	26.500	
2024-813	169	ATELLICA		10	18.480	0.848	4.59	15.900	21.000	
035	PROLACTIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-814	116	ROCHE COBA		16	9.844	0.408	4.14	8.600	11.100	
2024-814	125	B.C.ACCESS		11	10.809	0.504	4.66	9.300	12.300	
2024-814	169	ATELLICA		10	8.380	0.435	5.20	7.100	9.700	
2024-815	116	ROCHE COBA		16	5.656	0.209	3.70	5.000	6.300	
2024-815	125	B.C.ACCESS		11	6.336	0.201	3.18	5.700	6.900	
2024-815	169	ATELLICA		10	4.920	0.236	4.79	4.200	5.600	
037	TESTOSTERONE									
2024-811	149	ARC i2000s		10	0.700	0.089	12.78	0.400	1.000	
2024-812	149	ARC i2000s		10	6.630	0.699	10.54	4.500	8.700	
2024-813	149	ARC i2000s		10	9.750	0.875	8.98	7.100	12.400	
2024-814	149	ARC i2000s		10	4.060	0.367	9.03	3.000	5.200	
2024-815	149	ARC i2000s		10	2.330	0.205	8.81	1.700	2.900	
039	THYRO. STI. HOR.-TSH		CLIA TEST ID #: 585							
2024-811	106	TOSOH AIA		11	0.673	0.062	9.17	0.500	0.900	
2024-811	115	VITROS ECI		54	0.508	0.026	5.20	0.400	0.600	
2024-811	116	ROCHE COBA		54	0.706	0.030	4.28	0.600	0.800	
2024-811	125	B.C.ACCESS		54	0.546	0.050	9.13	0.400	0.700	
2024-811	149	ARC i2000s		24	0.488	0.033	6.78	0.400	0.600	
2024-811	160	SIEMENS EX		76	0.533	0.047	8.84	0.400	0.700	
2024-811	169	ATELLICA		16	0.588	0.048	8.24	0.400	0.700	

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
039	THYRO. STI. HOR.-TSH	CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-812	106 TOSOH AIA			11	5.245	0.535	10.20	3.600	6.900
2024-812	115 VITROS ECI			54	5.128	0.202	3.94	4.500	5.700
2024-812	116 ROCHE COBA			54	4.343	0.183	4.21	3.800	4.900
2024-812	125 B.C.ACCESS			54	3.783	0.202	5.33	3.200	4.400
2024-812	149 ARC i2000s			24	3.813	0.251	6.57	3.100	4.600
2024-812	160 SIEMENS EX			76	3.541	0.228	6.43	2.900	4.200
2024-812	169 ATELLICA			16	4.400	0.289	6.58	3.500	5.300
2024-813	106 TOSOH AIA			11	7.791	1.011	12.98	4.800	10.800
2024-813	115 VITROS ECI			54	7.198	0.279	3.88	6.400	8.000
2024-813	116 ROCHE COBA			54	5.879	0.192	3.26	5.300	6.500
2024-813	125 B.C.ACCESS			54	5.337	0.349	6.54	4.300	6.400
2024-813	149 ARC i2000s			24	5.392	0.358	6.64	4.300	6.500
2024-813	160 SIEMENS EX			76	4.912	0.315	6.42	4.000	5.900
2024-813	169 ATELLICA			16	6.106	0.356	5.83	5.000	7.200
2024-814	106 TOSOH AIA			11	3.509	0.414	11.81	2.300	4.800
2024-814	115 VITROS ECI			54	3.383	0.138	4.09	3.000	3.800
2024-814	116 ROCHE COBA			54	2.942	0.131	4.45	2.500	3.300
2024-814	125 B.C.ACCESS			54	2.476	0.132	5.33	2.100	2.900
2024-814	149 ARC i2000s			24	2.463	0.132	5.35	2.100	2.900
2024-814	160 SIEMENS EX			76	2.355	0.159	6.73	1.900	2.800
2024-814	169 ATELLICA			16	2.938	0.154	5.23	2.500	3.400
2024-815	106 TOSOH AIA			11	2.109	0.235	11.16	1.400	2.800
2024-815	115 VITROS ECI			54	1.992	0.076	3.79	1.800	2.200
2024-815	116 ROCHE COBA			54	1.838	0.087	4.75	1.600	2.100
2024-815	125 B.C.ACCESS			54	1.498	0.083	5.52	1.200	1.700
2024-815	149 ARC i2000s			24	1.471	0.084	5.72	1.200	1.700

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-815	160	SIEMENS EX		76	1.437	0.104	7.25	1.100	1.800	
2024-815	169	ATELLICA		16	1.750	0.106	6.06	1.400	2.100	
040	THYROXINE (T4)		CLIA TEST ID #: 595		EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}					
2024-811	32	SIEM DIME.		46	3.680	0.499	13.56	2.700	4.700	
2024-811	115	VITROS ECI		42	3.015	0.152	5.05	2.000	4.000	
2024-811	115	VITROS ECI		42	3.238	0.223	6.90	2.200	4.200	
2024-811	116	ROCHE COBA		47	3.585	0.224	6.25	2.600	4.600	
2024-811	125	B.C.ACCESS		43	3.207	0.317	9.87	2.200	4.200	
2024-811	149	ARC i2000s		23	3.052	0.239	7.84	2.100	4.100	
2024-811	169	ATELLICA		15	3.700	0.234	6.32	2.700	4.700	
2024-812	32	SIEM DIME.		46	9.596	0.458	4.77	7.700	11.500	
2024-812	115	VITROS ECI		42	7.588	0.912	12.02	6.100	9.100	
2024-812	115	VITROS ECI		42	7.522	0.450	5.99	6.000	9.000	
2024-812	116	ROCHE COBA		47	8.711	0.430	4.94	7.000	10.500	
2024-812	125	B.C.ACCESS		43	8.986	0.592	6.58	7.200	10.800	
2024-812	149	ARC i2000s		23	9.235	0.484	5.24	7.400	11.100	
2024-812	169	ATELLICA		15	9.180	0.546	5.94	7.300	11.000	
2024-813	32	SIEM DIME.		46	12.643	0.649	5.14	10.100	15.200	
2024-813	115	VITROS ECI		42	9.629	0.440	4.57	7.700	11.600	
2024-813	115	VITROS ECI		42	10.200	0.939	9.21	8.200	12.200	
2024-813	116	ROCHE COBA		47	11.140	0.632	5.67	8.900	13.400	
2024-813	125	B.C.ACCESS		43	11.150	0.789	7.08	8.900	13.400	
2024-813	149	ARC i2000s		23	11.809	0.726	6.15	9.400	14.200	
2024-813	169	ATELLICA		15	11.207	0.642	5.73	9.000	13.400	
2024-814	32	SIEM DIME.		46	7.076	0.533	7.54	5.700	8.500	
2024-814	115	VITROS ECI		42	6.088	0.509	8.35	4.900	7.300	
2024-814	115	VITROS ECI		42	5.793	0.347	6.00	4.600	7.000	

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-814	116	ROCHE COBA		47	6.645	0.376	5.66	5.300	8.000
2024-814	125	B.C.ACCESS		43	6.919	0.547	7.91	5.500	8.300
2024-814	149	ARC i2000s		23	6.664	0.352	5.29	5.300	8.000
2024-814	169	ATELLICA		15	7.186	0.472	6.57	5.700	8.600
040	THYROXINE (T4)		CLIA TEST ID #: 595		EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}				
2024-815	32	SIEM DIME.		46	5.322	0.483	9.07	4.300	6.400
2024-815	115	VITROS ECI		42	4.433	0.248	5.60	3.400	5.400
2024-815	115	VITROS ECI		42	4.638	0.485	10.45	3.600	5.600
2024-815	116	ROCHE COBA		47	5.130	0.291	5.67	4.100	6.200
2024-815	125	B.C.ACCESS		43	5.251	0.492	9.37	4.200	6.300
2024-815	149	ARC i2000s		23	4.870	0.282	5.79	3.900	5.900
2024-815	169	ATELLICA		15	5.513	0.379	6.88	4.400	6.600
141	FOLATE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %				
2024-811	115	VITROS ECI		16	0.813	0.159	19.50	0.600	1.000
2024-811	116	ROCHE COBA		22	2.000	0.000	0.00	1.500	2.500
2024-811	125	B.C.ACCESS		12	0.633	0.232	36.65	0.500	0.800
2024-811	149	ARC i2000s		13	1.085	0.819	75.50	0.800	1.400
2024-812	115	VITROS ECI		16	5.833	0.719	12.32	4.400	7.300
2024-812	116	ROCHE COBA		22	4.291	0.757	17.64	3.200	5.400
2024-812	125	B.C.ACCESS		12	6.442	0.431	6.69	4.800	8.100
2024-812	149	ARC i2000s		13	6.646	0.467	7.02	5.000	8.300
2024-813	115	VITROS ECI		16	9.180	1.094	11.91	6.900	11.500
2024-813	116	ROCHE COBA		22	6.652	0.875	13.15	5.000	8.300
2024-813	125	B.C.ACCESS		12	9.292	0.844	9.08	7.000	11.600
2024-813	149	ARC i2000s		13	9.867	0.809	8.20	7.400	12.300
2024-814	115	VITROS ECI		16	3.387	0.449	13.24	2.500	4.200
2024-814	116	ROCHE COBA		22	2.462	0.411	16.70	1.800	3.100

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024-814	125	B.C.ACCESS		12	4.008	0.312	7.79	3.000	5.000
2024-814	149	ARC i2000s		13	3.962	0.389	9.83	3.000	5.000
141	FOLATE		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 %					
2024-815	115	VITROS ECI		16	1.869	0.676	36.18	1.400	2.300
2024-815	116	ROCHE COBA		22	2.000	0.000	0.00	1.500	2.500
2024-815	125	B.C.ACCESS		12	2.333	0.189	8.08	1.800	2.900
2024-815	149	ARC i2000s		13	2.323	0.272	11.72	1.700	2.900
142	hLH (HUMAN LUT. HOR)								
2024-811	116	ROCHE COBA		13	4.615	0.248	5.36	3.500	5.800
2024-811	125	B.C.ACCESS		10	3.180	0.209	6.57	2.400	4.000
2024-811	149	ARC i2000s		10	2.480	0.140	5.65	1.900	3.100
2024-811	169	APELLICA		10	3.270	0.173	5.31	2.500	4.100
2024-812	116	ROCHE COBA		13	18.600	0.787	4.23	14.000	23.300
2024-812	125	B.C.ACCESS		10	16.020	0.576	3.59	12.000	20.000
2024-812	149	ARC i2000s		10	11.650	0.480	4.12	8.700	14.600
2024-812	169	APELLICA		10	14.770	0.310	2.10	11.100	18.500
2024-813	116	ROCHE COBA		13	24.823	0.815	3.28	18.600	31.000
2024-813	125	B.C.ACCESS		10	21.820	1.042	4.78	16.400	27.300
2024-813	149	ARC i2000s		10	15.770	0.405	2.57	11.800	19.700
2024-813	169	APELLICA		10	19.610	0.823	4.20	14.700	24.500
2024-814	116	ROCHE COBA		13	13.169	0.516	3.92	9.900	16.500
2024-814	125	B.C.ACCESS		10	11.120	0.371	3.34	8.300	13.900
2024-814	149	ARC i2000s		10	7.880	0.399	5.07	5.900	9.900
2024-814	169	APELLICA		10	10.230	0.400	3.91	7.700	12.800
2024-815	116	ROCHE COBA		13	8.946	0.414	4.63	6.700	11.200
2024-815	125	B.C.ACCESS		10	7.150	0.294	4.11	5.400	8.900

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-815	149	ARC i2000s		10	5.160	0.196	3.80	3.900	6.500	
2024-815	169	APELLICA		10	6.790	0.230	3.39	5.100	8.500	

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)						
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART	# LABS	# "SF"	Score	
SAMPLE	RESULT CODE	RESULT CODE	RESULT CODE	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS		
031 hCG-QUALITATIVE												
2024-811	113	BIO-SIGN		001	001	001	001	001 - NEGATIVE	23	23	23	100
2024-811	142	INSTANT VI		001	001	001	001	001 - NEGATIVE	28	28	28	100
2024-811	150	AIM STEP		001	001	001	001	001 - NEGATIVE	109	99	99	100
2024-811	150	AIM STEP		001	001	001	001	002 - POSITIVE	109	10	99	0
2024-811	164	HCG Alere		001	001	001	001	001 - NEGATIVE	73	69	69	100
2024-811	164	HCG Alere		001	001	001	001	002 - POSITIVE	73	4	69	0
2024-811	165	Osom HCG C		001	001	001	001	001 - NEGATIVE	16	16	16	100
2024-811	166	FaStep		001	001	001	001	001 - NEGATIVE	16	16	16	100
2024-811	167	Tanner Sci		001	001	001	001	001 - NEGATIVE	10	10	10	100
2024-811	168	STANBIO 20		001	001	001	001	001 - NEGATIVE	15	13	13	100
2024-811	168	STANBIO 20		001	001	001	001	002 - POSITIVE	15	2	13	0
2024-812	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	23	23	23	100
2024-812	142	INSTANT VI		002	002	002	002	002 - POSITIVE	28	28	28	100
2024-812	150	AIM STEP		002	002	002	002	001 - NEGATIVE	109	1	108	0
2024-812	150	AIM STEP		002	002	002	002	002 - POSITIVE	109	108	108	100
2024-812	164	HCG Alere		002	002	002	002	002 - POSITIVE	73	73	73	100
2024-812	165	Osom HCG C		002	002	002	002	002 - POSITIVE	16	16	16	100
2024-812	166	FaStep		002	002	002	002	002 - POSITIVE	16	16	16	100
2024-812	167	Tanner Sci		002	002	002	002	002 - POSITIVE	10	10	10	100
2024-812	168	STANBIO 20		002	002	002	002	002 - POSITIVE	15	15	15	100

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
031 hCG-QUALITATIVE											
2024-813	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	23	23	23	100
2024-813	142	INSTANT VI		002 002	002 002		002 - POSITIVE	28	28	28	100
2024-813	150	AIM STEP		002 002	002 002		002 - POSITIVE	109	109	109	100
2024-813	164	HCG Alere		002 002	002 002		002 - POSITIVE	73	73	73	100
2024-813	165	Osom HCG C		002 002	002 002		002 - POSITIVE	16	16	16	100
2024-813	166	FaStep		002 002	002 002		002 - POSITIVE	16	16	16	100
2024-813	167	Tanner Sci		002 002	002 002		002 - POSITIVE	10	10	10	100
2024-813	168	STANBIO 20		002 002	002 002		002 - POSITIVE	15	15	15	100
2024-814	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	23	23	23	100
2024-814	142	INSTANT VI		002 002	002 002		002 - POSITIVE	28	28	28	100
2024-814	150	AIM STEP		002 002	002 002		002 - POSITIVE	109	109	109	100
2024-814	164	HCG Alere		002 002	002 002		002 - POSITIVE	73	73	73	100
2024-814	165	Osom HCG C		002 002	002 002		002 - POSITIVE	16	16	16	100
2024-814	166	FaStep		002 002	002 002		002 - POSITIVE	16	16	16	100
2024-814	167	Tanner Sci		002 002	002 002		002 - POSITIVE	10	10	10	100
2024-814	168	STANBIO 20		002 002	002 002		002 - POSITIVE	15	15	15	100
2024-815	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	23	23	23	100
2024-815	142	INSTANT VI		002 002	002 002		002 - POSITIVE	28	28	28	100
2024-815	150	AIM STEP		002 002	002 002		001 - NEGATIVE	109	1	108	0
2024-815	150	AIM STEP		002 002	002 002		002 - POSITIVE	109	108	108	100
2024-815	164	HCG Alere		002 002	002 002		002 - POSITIVE	73	73	73	100
2024-815	165	Osom HCG C		002 002	002 002		002 - POSITIVE	16	16	16	100
2024-815	166	FaStep		002 002	002 002		002 - POSITIVE	16	16	16	100
2024-815	167	Tanner Sci		002 002	002 002		001 - NEGATIVE	10	1	9	0
2024-815	167	Tanner Sci		002 002	002 002		002 - POSITIVE	10	9	9	100
2024-815	168	STANBIO 20		002 002	002 002		002 - POSITIVE	15	15	15	100

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
151 hCG ONLY QUALITATIVE												
2024-801	018	BIO SIGN		002	002	002	002	002 - POSITIVE	24	24	24	100
2024-801	114	INSTANT VI		002	002	002	002	002 - POSITIVE	59	59	59	100
2024-801	118	AIM STEP		002	002	002	002	002 - POSITIVE	216	216	216	100
2024-801	130	ALERE HCG		002	002	002	002	002 - POSITIVE	100	100	100	100
2024-801	131	OSOM HCG		002	002	002	002	002 - POSITIVE	27	27	27	100
2024-801	133	FaStep		002	002	002	002	002 - POSITIVE	37	37	37	100
2024-801	134	Tanner Sc.		002	002	002	002	001 - NEGATIVE	59	1	58	0
2024-801	134	Tanner Sc.		002	002	002	002	002 - POSITIVE	59	58	58	100
2024-801	136	CLARITY		002	002	002	002	002 - POSITIVE	19	19	19	100
2024-802	018	BIO SIGN		001	001	001	001	001 - NEGATIVE	24	24	24	100
2024-802	114	INSTANT VI		001	001	001	001	001 - NEGATIVE	59	59	59	100
2024-802	118	AIM STEP		001	001	001	001	001 - NEGATIVE	216	216	216	100
2024-802	130	ALERE HCG		001	001	001	001	001 - NEGATIVE	100	100	100	100
2024-802	131	OSOM HCG		001	001	001	001	001 - NEGATIVE	27	27	27	100
2024-802	133	FaStep		001	001	001	001	001 - NEGATIVE	37	37	37	100
2024-802	134	Tanner Sc.		001	001	001	001	001 - NEGATIVE	59	58	58	100
2024-802	134	Tanner Sc.		001	001	001	001	002 - POSITIVE	59	1	58	0
2024-802	136	CLARITY		001	001	001	001	001 - NEGATIVE	19	19	19	100
2024-803	018	BIO SIGN		002	002	002	002	002 - POSITIVE	24	24	24	100
2024-803	114	INSTANT VI		002	002	002	002	002 - POSITIVE	59	59	59	100
2024-803	118	AIM STEP		002	002	002	002	002 - POSITIVE	216	216	216	100
2024-803	130	ALERE HCG		002	002	002	002	002 - POSITIVE	100	100	100	100

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-803	131	OSOM HCG		002 002	002 002		002 - POSITIVE	27	27	27	100	
2024-803	133	FaStep		002 002	002 002		002 - POSITIVE	37	37	37	100	
2024-803	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	59	59	59	100	
2024-803	136	CLARITY		002 002	002 002		002 - POSITIVE	19	19	19	100	
151 hCG ONLY QUALITATIVE												
2024-804	018	BIO SIGN		002 002	002 002		002 - POSITIVE	24	24	24	100	
2024-804	114	INSTANT VI		002 002	002 002		002 - POSITIVE	59	59	59	100	
2024-804	118	AIM STEP		002 002	002 002		002 - POSITIVE	216	216	216	100	
2024-804	130	ALERE HCG		002 002	002 002		002 - POSITIVE	100	100	100	100	
2024-804	131	OSOM HCG		002 002	002 002		002 - POSITIVE	27	27	27	100	
2024-804	133	FaStep		002 002	002 002		002 - POSITIVE	37	37	37	100	
2024-804	134	Tanner Sc.		002 002	002 002		001 - NEGATIVE	59	1	58	0	
2024-804	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	59	58	58	100	
2024-804	136	CLARITY		002 002	002 002		002 - POSITIVE	19	19	19	100	
2024-805	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	24	24	24	100	
2024-805	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	59	59	59	100	
2024-805	118	AIM STEP		001 001	001 001		001 - NEGATIVE	216	216	216	100	
2024-805	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	100	99	99	100	
2024-805	130	ALERE HCG		001 001	001 001		002 - POSITIVE	100	1	99	0	
2024-805	131	OSOM HCG		001 001	001 001		001 - NEGATIVE	27	27	27	100	
2024-805	133	FaStep		001 001	001 001		001 - NEGATIVE	37	37	37	100	
2024-805	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	59	58	58	100	
2024-805	134	Tanner Sc.		001 001	001 001		002 - POSITIVE	59	1	58	0	
2024-805	136	CLARITY		001 001	001 001		001 - NEGATIVE	19	19	19	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 55 ENDO.(T3 UPTAKE)

ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
173 T3 UPTAKE		CLIA TEST ID #: 565	EVALUATION CRITERIA: TARGET VALUE	3	SD								
2024-811	1 %U	84 VITROS ECI	1 25-35	34	59.842	2.527	4.22	52.260	67.420				
2024-811	1 %U	91 B.C.ACCESS	2 35-45	24	53.850	2.856	5.30	45.280	62.420				
2024-811	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	0.634	0.065	10.30	0.440	0.830				
2024-811	4 %	32 DIMENSION	2 35-45	47	38.496	1.418	3.68	34.240	42.750				
2024-811	4 %	91 B.C.ACCESS	2 35-45	13	52.192	3.548	6.80	41.550	62.840				
2024-811	4 %	106 ATELLICA	1 25-35	13	52.593	2.195	4.17	46.010	59.180				
2024-811	5 TBI	98 ROCHE COBA	4 0.8-1.3	43	0.821	0.055	6.64	0.660	0.990				
2024-812	1 %U	84 VITROS ECI	1 25-35	34	53.123	3.208	6.04	43.500	62.750				
2024-812	1 %U	91 B.C.ACCESS	2 35-45	24	50.563	3.534	6.99	39.960	61.170				
2024-812	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	0.893	0.079	8.89	0.650	1.130				
2024-812	4 %	32 DIMENSION	2 35-45	47	39.004	1.450	3.72	34.650	43.350				
2024-812	4 %	91 B.C.ACCESS	2 35-45	13	48.867	3.578	7.32	38.130	59.600				
2024-812	4 %	106 ATELLICA	1 25-35	13	41.993	1.733	4.13	36.790	47.190				
2024-812	5 TBI	98 ROCHE COBA	4 0.8-1.3	43	0.674	0.055	8.20	0.510	0.840				
2024-813	1 %U	84 VITROS ECI	1 25-35	34	50.303	3.756	7.47	39.040	61.570				
2024-813	1 %U	91 B.C.ACCESS	2 35-45	24	49.200	2.750	5.59	40.950	57.450				
2024-813	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	0.998	0.081	8.13	0.750	1.240				
2024-813	4 %	32 DIMENSION	2 35-45	47	39.522	1.180	2.98	35.980	43.060				
2024-813	4 %	91 B.C.ACCESS	2 35-45	13	48.404	3.344	6.91	38.370	58.440				
2024-813	4 %	106 ATELLICA	1 25-35	13	38.660	1.426	3.69	34.380	42.940				
2024-813	5 TBI	98 ROCHE COBA	4 0.8-1.3	43	0.617	0.051	8.31	0.460	0.770				
2024-814	1 %U	84 VITROS ECI	1 25-35	34	55.990	2.758	4.93	47.720	64.260				
2024-814	1 %U	91 B.C.ACCESS	2 35-45	24	51.442	2.728	5.30	43.260	59.630				
2024-814	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	0.793	0.076	9.56	0.570	1.020				
2024-814	4 %	32 DIMENSION	2 35-45	47	38.932	1.183	3.04	35.380	42.480				
2024-814	4 %	91 B.C.ACCESS	2 35-45	13	51.217	3.117	6.09	41.870	60.570				

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024-814	4 %	106	ATELLICA	1	25-35	13	45.780	1.632	3.56	40.880	50.680		
2024-814	5 TBI	98	ROCHE COBA	4	0.8-1.3	43	0.724	0.048	6.64	0.580	0.870		
173	T3 UPTAKE	CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 3 SD							
2024-815	1 %U	84	VITROS ECI	1	25-35	34	58.113	2.443	4.20	50.780	65.440		
2024-815	1 %U	91	B.C.ACCESS	2	35-45	24	53.129	2.847	5.36	44.590	61.670		
2024-815	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	0.715	0.074	10.29	0.490	0.940		
2024-815	4 %	32	DIMENSION	2	35-45	47	38.535	1.047	2.72	35.390	41.680		
2024-815	4 %	91	B.C.ACCESS	2	35-45	13	52.642	3.196	6.07	43.050	62.230		
2024-815	4 %	106	ATELLICA	1	25-35	13	49.106	1.908	3.89	43.380	54.830		
2024-815	5 TBI	98	ROCHE COBA	4	0.8-1.3	43	0.763	0.064	8.43	0.570	0.960		

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY				GRP: 60 TOXICOLOGY							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
043	DIGOXIN	CLIA TEST ID #: 645				EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}							
2024-811	50 VITROS					17	0.559	0.114	20.41	0.400	0.800		
2024-812	50 VITROS					17	1.000	0.077	7.67	0.800	1.200		
2024-813	50 VITROS					17	1.306	0.094	7.18	1.000	1.600		
2024-814	50 VITROS					17	0.782	0.086	10.95	0.600	1.000		
2024-815	50 VITROS					17	0.641	0.097	15.19	0.400	0.800		
045	FERRITIN	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-811	50 VITROS					21	16.590	0.883	5.32	12.400	20.700		

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024-811	90	ROCHE COBA		15	28.173	1.848	6.56	21.100	35.200
2024-811	105	APELLICA		11	17.064	1.123	6.58	12.800	21.300
045 FERRITIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 %						
2024-812	50	VITROS		21	76.490	3.432	4.49	57.400	95.600
2024-812	90	ROCHE COBA		15	136.847	8.641	6.31	102.600	171.100
2024-812	105	APELLICA		11	93.400	4.074	4.36	70.100	116.800
2024-813	50	VITROS		21	109.967	5.650	5.14	82.500	137.500
2024-813	90	ROCHE COBA		15	192.593	10.553	5.48	144.400	240.700
2024-813	105	APELLICA		11	130.991	5.187	3.96	98.200	163.700
2024-814	50	VITROS		21	51.371	2.454	4.78	38.500	64.200
2024-814	90	ROCHE COBA		15	93.100	5.661	6.08	69.800	116.400
2024-814	105	APELLICA		11	60.927	1.756	2.88	45.700	76.200
2024-815	50	VITROS		21	34.243	1.390	4.06	25.700	42.800
2024-815	90	ROCHE COBA		15	60.320	4.063	6.74	45.200	75.400
2024-815	105	APELLICA		11	38.191	1.566	4.10	28.600	47.700
046 GENTAMICIN		CLIA TEST ID #: 665							
2024-811	50	VITROS		18	0.600	0.000	0.00	0.500	0.800
2024-812	50	VITROS		18	6.622	0.282	4.26	5.000	8.300
2024-813	50	VITROS		18	9.994	0.542	5.42	7.500	12.500
2024-814	50	VITROS		18	3.983	0.209	5.24	3.000	5.000
2024-815	50	VITROS		18	2.006	0.078	3.89	1.500	2.500

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
050 PHENYTOIN		CLIA TEST ID #: 695	EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-811	50 VITROS			17	3.000	0.000	0.00	2.300	3.800	
2024-812	50 VITROS			17	13.306	0.266	2.00	10.000	16.600	
2024-813	50 VITROS			17	19.469	0.630	3.24	14.600	24.300	
2024-814	50 VITROS			17	7.819	0.251	3.20	5.900	9.800	
2024-815	50 VITROS			17	3.418	0.182	5.33	2.600	4.300	
054 THEOPHYLLINE		CLIA TEST ID #: 735								
2024-811	50 VITROS			13	3.285	0.353	10.74	2.500	4.100	
2024-812	50 VITROS			13	37.846	1.139	3.01	28.400	47.300	
2024-813	50 VITROS			13	49.300	2.787	5.65	37.000	61.600	
2024-814	50 VITROS			13	24.085	0.788	3.27	18.100	30.100	
2024-815	50 VITROS			13	13.500	0.576	4.27	10.100	16.900	
127 VANCOMYCIN		CLIA TEST ID #: 0								
2024-811	50 VITROS			22	5.000	0.000	0.00	3.800	6.300	
2024-811	50 VITROS			22	3.000	0.000	0.00	2.300	3.800	
2024-811	92 ROCHE COBA			10	4.000	0.000	0.00	3.000	5.000	
2024-812	50 VITROS			22	26.700	0.660	2.47	20.000	33.400	
2024-812	50 VITROS			22	23.657	0.797	3.37	17.700	29.600	
2024-812	92 ROCHE COBA			10	23.910	1.593	6.66	17.900	29.900	

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
127	VANCOMYCIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %					
2024-813	50	VITROS		22	36.127	1.223	3.39	27.100	45.200	
2024-813	50	VITROS		22	38.975	0.776	1.99	29.200	48.700	
2024-813	92	ROCHE COBA		10	35.650	1.569	4.40	26.700	44.600	
2024-814	50	VITROS		22	16.075	0.327	2.03	12.100	20.100	
2024-814	50	VITROS		22	14.219	0.438	3.08	10.700	17.800	
2024-814	92	ROCHE COBA		10	14.070	0.746	5.30	10.600	17.600	
2024-815	50	VITROS		22	7.450	0.278	3.73	5.600	9.300	
2024-815	50	VITROS		22	8.000	0.212	2.65	6.000	10.000	
2024-815	92	ROCHE COBA		10	6.810	0.584	8.57	5.100	8.500	

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
065	URINA-PROTEIN QUANT.				EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2024-841	58	VITROS		40	139.625	13.794	9.88	104.700	174.500	
2024-841	62	SIEM DIM.		49	110.064	2.480	2.25	82.500	137.600	
2024-841	79	BECK. COUL		20	100.295	3.683	3.67	75.200	125.400	
2024-841	93	ARCHITECT		17	97.112	5.431	5.59	72.800	121.400	
2024-841	113	ROCHE COBA		41	90.932	2.203	2.42	68.200	113.700	
2024-841	146	ATELLICA		12	109.983	3.456	3.14	82.500	137.500	
2024-842	58	VITROS		40	5.000	0.000	0.00	0.000	10.000	
2024-842	62	SIEM DIM.		49	15.355	1.406	9.16	10.400	20.400	
2024-842	79	BECK. COUL		20	4.930	0.545	11.06	0	9.900	
2024-842	93	ARCHITECT		17	6.838	0.105	1.54	1.800	11.800	
2024-842	113	ROCHE COBA		41	4.385	0.830	18.93	0	9.400	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-842	146	APELLICA	12	16.383	4.269	26.06	11.400	21.400
065 URINA-PROTEIN QUANT.			CLIA TEST ID #: 0 EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2024-843	58	VITROS	40	149.974	12.573	8.38	112.500	187.500
2024-843	62	SIEM DIM.	49	112.990	1.541	1.36	84.700	141.200
2024-843	79	BECK. COUL	20	99.260	3.574	3.60	74.400	124.100
2024-843	93	ARCHITECT	17	94.535	5.210	5.51	70.900	118.200
2024-843	113	ROCHE COBA	41	88.649	1.863	2.10	66.500	110.800
2024-843	146	APELLICA	12	112.275	3.941	3.51	84.200	140.300
2024-844	58	VITROS	40	5.282	0.597	11.30	0.300	10.300
2024-844	62	SIEM DIM.	49	22.754	1.560	6.86	17.100	28.400
2024-844	79	BECK. COUL	20	4.868	0.547	11.23	0	9.900
2024-844	93	ARCHITECT	17	6.813	0.048	0.71	1.800	11.800
2024-844	113	ROCHE COBA	41	4.080	1.025	25.12	0	9.100
2024-844	146	APELLICA	12	25.667	4.397	17.13	19.300	32.100
2024-845	58	VITROS	40	150.282	13.204	8.79	112.700	187.900
2024-845	62	SIEM DIM.	49	113.988	1.850	1.62	85.500	142.500
2024-845	79	BECK. COUL	20	96.385	3.487	3.62	72.300	120.500
2024-845	93	ARCHITECT	17	95.147	5.296	5.57	71.400	118.900
2024-845	113	ROCHE COBA	41	90.539	2.151	2.38	67.900	113.200
2024-845	146	APELLICA	12	113.617	3.587	3.16	85.200	142.000
067 URI-SPECIFIC GRAVITY			EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-841	11	AMES NM10S	34	1.024	0.003	0.33	1.014	1.035
2024-841	13	BAYER CLI	20	1.022	0.003	0.29	1.013	1.031
2024-841	67	URISCAN	54	1.020	0.004	0.39	1.008	1.032
2024-841	72	URS-9-TECO	57	1.021	0.004	0.42	1.008	1.034
2024-841	80	ROCHE (CHE	37	1.015	0.000	0.00	1.015	1.015
2024-841	89	AIMSTRIP	147	1.020	0.002	0.17	1.015	1.026
2024-841	94	CLINITEK	106	1.024	0.003	0.31	1.015	1.034

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024-841	102	ACON LAB		127	1.020	0.002	0.20	1.014	1.026
2024-841	131	iCHEM VELO		33	1.024	0.001	0.08	1.022	1.027
2024-841	140	MISSION A		44	1.020	0.003	0.32	1.010	1.030
2024-841	145	CLINITEK		41	1.030	0.001	0.06	1.028	1.031
2024-841	147	Mission120		39	1.022	0.003	0.28	1.013	1.030
2024-841	148	Mission500		133	1.020	0.002	0.15	1.016	1.025
2024-841	151	Clari. Uro		21	1.021	0.003	0.26	1.013	1.029
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-842	11	AMES NM10S		34	1.023	0.003	0.32	1.013	1.032
2024-842	13	BAYER CLI		20	1.021	0.004	0.44	1.007	1.034
2024-842	67	URISCAN		54	1.021	0.003	0.32	1.011	1.031
2024-842	72	URS-9-TECO		57	1.020	0.006	0.55	1.003	1.037
2024-842	80	ROCHE (CHE		37	1.017	0.002	0.24	1.010	1.024
2024-842	89	AIMSTRIP		147	1.021	0.003	0.28	1.013	1.030
2024-842	94	CLINITEK		106	1.022	0.003	0.34	1.012	1.033
2024-842	102	ACON LAB		127	1.021	0.003	0.30	1.011	1.030
2024-842	131	iCHEM VELO		33	1.027	0.001	0.08	1.024	1.029
2024-842	140	MISSION A		44	1.021	0.003	0.25	1.013	1.028
2024-842	145	CLINITEK		41	1.033	0.001	0.07	1.031	1.035
2024-842	147	Mission120		39	1.020	0.002	0.22	1.014	1.027
2024-842	148	Mission500		133	1.021	0.002	0.19	1.015	1.027
2024-842	151	Clari. Uro		21	1.024	0.006	0.55	1.007	1.041
2024-843	11	AMES NM10S		34	1.023	0.003	0.32	1.013	1.032
2024-843	13	BAYER CLI		20	1.022	0.003	0.29	1.013	1.031
2024-843	67	URISCAN		54	1.018	0.003	0.32	1.008	1.027
2024-843	72	URS-9-TECO		57	1.020	0.004	0.39	1.008	1.032
2024-843	80	ROCHE (CHE		37	1.013	0.002	0.25	1.005	1.020
2024-843	89	AIMSTRIP		147	1.019	0.002	0.24	1.011	1.026
2024-843	94	CLINITEK		106	1.023	0.003	0.30	1.014	1.032

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024-843	102	ACON LAB		127	1.018	0.003	0.26	1.011	1.026
2024-843	131	iCHEM VELO		33	1.025	0.001	0.07	1.023	1.028
2024-843	140	MISSION A		44	1.017	0.003	0.32	1.007	1.027
2024-843	145	CLINITEK		41	1.027	0.001	0.06	1.025	1.029
2024-843	147	Mission120		39	1.020	0.000	0.00	1.020	1.020
2024-843	148	Mission500		133	1.019	0.002	0.21	1.013	1.025
2024-843	151	Clari. Uro		21	1.018	0.003	0.28	1.010	1.027
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-844	11	AMES NM10S		34	1.014	0.004	0.38	1.002	1.025
2024-844	13	BAYER CLI		20	1.013	0.003	0.32	1.003	1.023
2024-844	67	URISCAN		54	1.010	0.003	0.31	1.000	1.019
2024-844	72	URS-9-TECO		57	1.013	0.004	0.40	1.001	1.026
2024-844	80	ROCHE (CHE		37	1.011	0.002	0.21	1.005	1.018
2024-844	89	AIMSTRIP		147	1.013	0.003	0.33	1.003	1.023
2024-844	94	CLINITEK		106	1.014	0.003	0.29	1.005	1.023
2024-844	102	ACON LAB		127	1.012	0.003	0.32	1.003	1.022
2024-844	131	iCHEM VELO		33	1.025	0.001	0.08	1.023	1.028
2024-844	140	MISSION A		44	1.013	0.004	0.37	1.001	1.024
2024-844	145	CLINITEK		41	1.031	0.001	0.06	1.029	1.033
2024-844	147	Mission120		39	1.015	0.003	0.25	1.007	1.023
2024-844	148	Mission500		133	1.012	0.003	0.33	1.002	1.022
2024-844	151	Clari. Uro		21	1.013	0.002	0.25	1.005	1.020
2024-845	11	AMES NM10S		34	1.018	0.003	0.32	1.008	1.027
2024-845	13	BAYER CLI		20	1.017	0.003	0.33	1.007	1.027
2024-845	67	URISCAN		54	1.011	0.003	0.32	1.002	1.021
2024-845	72	URS-9-TECO		57	1.016	0.004	0.40	1.004	1.028
2024-845	80	ROCHE (CHE		37	1.011	0.002	0.19	1.005	1.016
2024-845	89	AIMSTRIP		147	1.015	0.004	0.38	1.004	1.027
2024-845	94	CLINITEK		106	1.018	0.003	0.29	1.009	1.027

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024-845	102	ACON LAB		127	1.015	0.003	0.33	1.005	1.025
2024-845	131	iCHEM VELO		33	1.028	0.001	0.10	1.025	1.031
2024-845	140	MISSION A		44	1.014	0.004	0.42	1.002	1.027
2024-845	145	CLINITEK		41	1.031	0.001	0.06	1.029	1.032
2024-845	147	Mission120		39	1.017	0.003	0.29	1.008	1.026
2024-845	148	Mission500		133	1.017	0.003	0.29	1.008	1.025
2024-845	151	Clari. Uro		21	1.013	0.003	0.32	1.004	1.023
166 MICROALBUMIN			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2024-841	58	VITROS		52	878.102	42.048	4.79	658.600	1097.600
2024-841	62	SIEM DIM.		76	863.659	52.659	6.10	647.700	1079.600
2024-841	79	BECK. COUL		21	916.833	92.880	10.13	687.600	1146.000
2024-841	79	BECK. COUL		21	786.938	121.798	15.48	590.200	983.700
2024-841	85	Rx DAYTONA		11	798.100	79.732	9.99	598.600	997.600
2024-841	93	ARCHITECT		21	848.010	40.316	4.75	636.000	1060.000
2024-841	93	ARCHITECT		21	916.833	92.880	10.13	687.600	1146.000
2024-841	95	INTEGRA		18	836.322	47.136	5.64	627.200	1045.400
2024-841	113	ROCHE COBA		47	808.804	47.181	5.83	606.600	1011.000
2024-841	146	APELLICA		15	712.547	17.703	2.48	534.400	890.700
2024-842	58	VITROS		52	6.000	0.000	0.00	1.000	11.000
2024-842	62	SIEM DIM.		76	3.955	1.600	40.45	0	9.000
2024-842	79	BECK. COUL		21	3.400	2.404	70.71	0	8.400
2024-842	79	BECK. COUL		21	2.571	2.999	116.64	0	7.600
2024-842	85	Rx DAYTONA		11	1.882	2.116	112.45	0	6.900
2024-842	93	ARCHITECT		21	5.000	0.000	0.00	0.000	10.000
2024-842	93	ARCHITECT		21	3.400	2.404	70.71	0	8.400
2024-842	95	INTEGRA		18	2.939	1.165	39.63	0	7.900
2024-842	113	ROCHE COBA		47	12.000	0.000	0.00	7.000	17.000
2024-842	146	APELLICA		15	3.000	0.000	0.00	0	8.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
166	MICROALBUMIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	25	%	OR 5.00	{GREATER}			
2024-843	58	VITROS		52	853.092	44.813	5.25	639.800	1066.400	
2024-843	62	SIEM DIM.		76	853.811	58.298	6.83	640.400	1067.300	
2024-843	79	BECK. COUL		21	857.433	70.316	8.20	643.100	1071.800	
2024-843	79	BECK. COUL		21	772.643	109.964	14.23	579.500	965.800	
2024-843	85	Rx DAYTONA		11	794.336	48.827	6.15	595.800	992.900	
2024-843	93	ARCHITECT		21	827.170	33.115	4.00	620.400	1034.000	
2024-843	93	ARCHITECT		21	857.433	70.316	8.20	643.100	1071.800	
2024-843	95	INTEGRA		18	814.233	34.892	4.29	610.700	1017.800	
2024-843	113	ROCHE COBA		47	793.865	46.369	5.84	595.400	992.300	
2024-843	146	ATELLICA		15	697.300	18.265	2.62	523.000	871.600	
2024-844	58	VITROS		52	6.000	0.000	0.00	1.000	11.000	
2024-844	62	SIEM DIM.		76	2.440	1.387	56.83	0	7.400	
2024-844	79	BECK. COUL		21	3.400	2.404	70.71	0	8.400	
2024-844	79	BECK. COUL		21	2.571	2.997	116.56	0	7.600	
2024-844	85	Rx DAYTONA		11	1.300	1.864	143.39	0	6.300	
2024-844	93	ARCHITECT		21	5.150	0.654	12.70	0.200	10.200	
2024-844	93	ARCHITECT		21	3.400	2.404	70.71	0	8.400	
2024-844	95	INTEGRA		18	2.928	1.177	40.19	0	7.900	
2024-844	113	ROCHE COBA		47	12.066	0.432	3.58	7.100	17.100	
2024-844	146	ATELLICA		15	3.000	0.000	0.00	0	8.000	
2024-845	58	VITROS		52	821.725	43.043	5.24	616.300	1027.200	
2024-845	62	SIEM DIM.		76	825.560	59.679	7.23	619.200	1032.000	
2024-845	79	BECK. COUL		21	728.500	138.620	19.03	546.400	910.600	
2024-845	79	BECK. COUL		21	757.552	108.949	14.38	568.200	946.900	
2024-845	85	Rx DAYTONA		11	774.909	65.043	8.39	581.200	968.600	
2024-845	93	ARCHITECT		21	797.195	32.636	4.09	597.900	996.500	
2024-845	93	ARCHITECT		21	728.500	138.620	19.03	546.400	910.600	

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-845	95	INTEGRA		18	792.194	36.669	4.63	594.100	990.200
2024-845	113	ROCHE COBA		47	772.726	43.032	5.57	579.500	965.900
2024-845	146	ATELLICA		15	676.840	19.929	2.94	507.600	846.100
167	CREATININE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}				
2024-841	58	VITROS		55	3.265	0.405	12.41	0	8.300
2024-841	62	SIEM DIM.		76	9.059	5.569	61.48	4.100	14.100
2024-841	79	BECK. COUL		22	0.480	0.383	79.77	0	5.500
2024-841	93	ARCHITECT		19	5.000	0.000	0.00	0.000	10.000
2024-841	95	INTEGRA		18	0.312	0.295	94.57	0	5.300
2024-841	113	ROCHE COBA		47	3.617	1.298	35.88	0	8.600
2024-841	146	ATELLICA		15	3.000	0.000	0.00	0	8.000
2024-842	58	VITROS		55	3.265	0.405	12.41	0	8.300
2024-842	62	SIEM DIM.		76	9.111	5.551	60.93	4.100	14.100
2024-842	79	BECK. COUL		22	0.380	0.457	120.19	0	5.400
2024-842	93	ARCHITECT		19	5.000	0.000	0.00	0.000	10.000
2024-842	95	INTEGRA		18	0.271	0.361	133.41	0	5.300
2024-842	113	ROCHE COBA		47	3.647	1.157	31.73	0	8.600
2024-842	146	ATELLICA		15	3.000	0.000	0.00	0	8.000
2024-843	58	VITROS		55	238.471	7.036	2.95	178.900	298.100
2024-843	62	SIEM DIM.		76	240.650	8.695	3.61	180.500	300.800
2024-843	79	BECK. COUL		22	213.876	7.500	3.51	160.400	267.300
2024-843	93	ARCHITECT		19	235.295	7.109	3.02	176.500	294.100
2024-843	95	INTEGRA		18	244.822	10.248	4.19	183.600	306.000
2024-843	113	ROCHE COBA		47	246.198	8.828	3.59	184.600	307.700
2024-843	146	ATELLICA		15	224.760	6.510	2.90	168.600	281.000
2024-844	58	VITROS		55	250.070	10.153	4.06	187.600	312.600
2024-844	62	SIEM DIM.		76	239.795	8.020	3.34	179.800	299.700

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-844	79	BECK. COUL		22	214.676	8.349	3.89	161.000	268.300
2024-844	93	ARCHITECT		19	235.747	5.575	2.36	176.800	294.700
2024-844	95	INTEGRA		18	244.500	10.267	4.20	183.400	305.600
2024-844	113	ROCHE COBA		47	245.870	8.448	3.44	184.400	307.300
2024-844	146	APELLICA		15	223.333	5.312	2.38	167.500	279.200
167 CREATININE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2024-845	58	VITROS		55	240.957	7.067	2.93	180.700	301.200
2024-845	62	SIEM DIM.		76	234.364	8.294	3.54	175.800	293.000
2024-845	79	BECK. COUL		22	199.224	8.339	4.19	149.400	249.000
2024-845	93	ARCHITECT		19	230.074	5.265	2.29	172.600	287.600
2024-845	95	INTEGRA		18	237.528	9.980	4.20	178.100	296.900
2024-845	113	ROCHE COBA		47	240.117	9.208	3.83	180.100	300.100
2024-845	146	APELLICA		15	220.753	5.985	2.71	165.600	275.900

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS								
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART	# LABS	# "SF"	Score	
SAMPLE	RESULT CODE	RESULT CODE	RESULT CODE	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS		
057 URINALYSIS-BILIRUBIN												
2024-841	011	AMES NM10S		057	057	057	057	057 - NEGATIVE	34	34	34	100
2024-841	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	20	20	20	100
2024-841	067	URISCAN		057	057	057	057	057 - NEGATIVE	54	54	54	100
2024-841	072	URS-9-TECO		057	057	057	057	057 - NEGATIVE	57	57	57	100
2024-841	080	ROCHE (CHE		057	057	057	057	057 - NEGATIVE	36	36	36	100
2024-841	089	AIMSTRIP		057	057	057	057	057 - NEGATIVE	148	148	148	100
2024-841	094	CLINITEK		057	057	057	057	057 - NEGATIVE	106	106	106	100
2024-841	102	ACON LAB		057	057	057	057	057 - NEGATIVE	121	121	121	100
2024-841	131	ICHEM VELO		057	057	057	057	057 - NEGATIVE	33	33	33	100
2024-841	140	MISSION A		057	057	057	057	057 - NEGATIVE	39	39	39	100
2024-841	145	CLINITEK		057	057	057	057	057 - NEGATIVE	41	41	41	100

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-841	147	Mission120		057 057	057 057		057 - NEGATIVE	41	41	41	100	
2024-841	148	Mission500		057 057	057 057		057 - NEGATIVE	137	137	137	100	
2024-841	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	23	23	23	100	
057 URINALYSIS-BILIRUBIN												
2024-842	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	34	34	34	100	
2024-842	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	20	20	20	100	
2024-842	067	URISCAN		057 057	057 057		057 - NEGATIVE	54	54	54	100	
2024-842	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	57	57	57	100	
2024-842	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2024-842	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	148	148	148	100	
2024-842	094	CLINITEK		057 057	057 057		057 - NEGATIVE	106	106	106	100	
2024-842	102	ACON LAB		057 057	057 057		057 - NEGATIVE	121	121	121	100	
2024-842	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	33	33	33	100	
2024-842	140	MISSION A		057 057	057 057		057 - NEGATIVE	39	39	39	100	
2024-842	145	CLINITEK		057 057	057 057		057 - NEGATIVE	41	41	41	100	
2024-842	147	Mission120		057 057	057 057		057 - NEGATIVE	41	41	41	100	
2024-842	148	Mission500		057 057	057 057		057 - NEGATIVE	137	137	137	100	
2024-842	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	23	23	23	100	
2024-843	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	34	34	34	100	
2024-843	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	20	20	20	100	
2024-843	067	URISCAN		057 057	057 057		057 - NEGATIVE	54	54	54	100	
2024-843	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	57	57	57	100	
2024-843	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2024-843	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	148	148	148	100	
2024-843	094	CLINITEK		057 057	057 057		057 - NEGATIVE	106	106	106	100	
2024-843	102	ACON LAB		057 057	057 057		057 - NEGATIVE	121	121	121	100	
2024-843	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	33	33	33	100	
2024-843	140	MISSION A		057 057	057 057		057 - NEGATIVE	39	39	39	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-843	145	CLINITEK		057 057	057 057		057 - NEGATIVE	41	41	41	100	
2024-843	147	Mission120		057 057	057 057		057 - NEGATIVE	41	41	41	100	
2024-843	148	Mission500		057 057	057 057		057 - NEGATIVE	137	137	137	100	
2024-843	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	23	23	23	100	
057 URINALYSIS-BILIRUBIN												
2024-844	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	34	34	34	100	
2024-844	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	20	20	20	100	
2024-844	067	URISCAN		057 057	057 057		057 - NEGATIVE	54	54	54	100	
2024-844	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	57	57	57	100	
2024-844	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2024-844	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	148	148	148	100	
2024-844	094	CLINITEK		057 057	057 057		057 - NEGATIVE	106	106	106	100	
2024-844	102	ACON LAB		057 057	057 057		057 - NEGATIVE	121	121	121	100	
2024-844	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	33	33	33	100	
2024-844	140	MISSION A		057 057	057 057		057 - NEGATIVE	39	39	39	100	
2024-844	145	CLINITEK		057 057	057 057		057 - NEGATIVE	41	41	41	100	
2024-844	147	Mission120		057 057	057 057		057 - NEGATIVE	41	41	41	100	
2024-844	148	Mission500		057 057	057 057		057 - NEGATIVE	137	137	137	100	
2024-844	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	23	23	23	100	
2024-845	011	AMES NM10S		058 060	057 059		058 - TRACES, 1+	34	5	34	100	
2024-845	011	AMES NM10S		058 060	057 059		059 - 2+	34	28	34	100	
2024-845	011	AMES NM10S		058 060	057 059		060 - 3+	34	1	34	100	
2024-845	013	BAYER CLI		058 060	057 059		057 - NEGATIVE	20	1	20	100	
2024-845	013	BAYER CLI		058 060	057 059		058 - TRACES, 1+	20	4	20	100	
2024-845	013	BAYER CLI		058 060	057 059		059 - 2+	20	14	20	100	
2024-845	013	BAYER CLI		058 060	057 059		060 - 3+	20	1	20	100	
2024-845	067	URISCAN		057 059	057 059		057 - NEGATIVE	54	8	53	100	
2024-845	067	URISCAN		057 059	057 059		058 - TRACES, 1+	54	40	53	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-845	067	URISCAN		057 059	057 059		059 - 2+	54	5	53	100	
2024-845	067	URISCAN		057 059	057 059		060 - 3+	54	1	53	0	
2024-845	072	URS-9-TECO		058 060	057 059		057 - NEGATIVE	57	2	57	100	
2024-845	072	URS-9-TECO		058 060	057 059		058 - TRACES, 1+	57	18	57	100	
2024-845	072	URS-9-TECO		058 060	057 059		059 - 2+	57	21	57	100	
2024-845	072	URS-9-TECO		058 060	057 059		060 - 3+	57	16	57	100	
2024-845	080	ROCHE (CHE		057 059	057 059		058 - TRACES, 1+	36	32	33	100	
2024-845	080	ROCHE (CHE		057 059	057 059		059 - 2+	36	1	33	100	
2024-845	080	ROCHE (CHE		057 059	057 059		060 - 3+	36	3	33	0	
2024-845	089	AIMSTRIP		057 059	057 059		057 - NEGATIVE	148	5	144	100	
2024-845	089	AIMSTRIP		057 059	057 059		058 - TRACES, 1+	148	98	144	100	
2024-845	089	AIMSTRIP		057 059	057 059		059 - 2+	148	41	144	100	
2024-845	089	AIMSTRIP		057 059	057 059		060 - 3+	148	4	144	0	
2024-845	094	CLINITEK		058 060	057 059		058 - TRACES, 1+	106	22	106	100	
2024-845	094	CLINITEK		058 060	057 059		059 - 2+	106	82	106	100	
2024-845	094	CLINITEK		058 060	057 059		060 - 3+	106	2	106	100	
2024-845	102	ACON LAB		057 059	057 059		057 - NEGATIVE	121	1	114	100	
2024-845	102	ACON LAB		057 059	057 059		058 - TRACES, 1+	121	85	114	100	
2024-845	102	ACON LAB		057 059	057 059		059 - 2+	121	28	114	100	
2024-845	102	ACON LAB		057 059	057 059		060 - 3+	121	7	114	0	
2024-845	131	iCHEM VELO		057 057	057 059		057 - NEGATIVE	33	33	33	100	
2024-845	140	MISSION A		057 059	057 059		058 - TRACES, 1+	39	30	37	100	
2024-845	140	MISSION A		057 059	057 059		059 - 2+	39	7	37	100	
2024-845	140	MISSION A		057 059	057 059		060 - 3+	39	2	37	0	
2024-845	145	CLINITEK		057 057	057 059		057 - NEGATIVE	41	41	41	100	
2024-845	147	Mission120		057 059	057 059		057 - NEGATIVE	41	1	41	100	
2024-845	147	Mission120		057 059	057 059		058 - TRACES, 1+	41	36	41	100	
2024-845	147	Mission120		057 059	057 059		059 - 2+	41	4	41	100	
2024-845	148	Mission500		057 059	057 059		057 - NEGATIVE	137	1	136	100	
2024-845	148	Mission500		057 059	057 059		058 - TRACES, 1+	137	122	136	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-845	148	Mission500		057 059	057 059		059 - 2+	137	13	136	100		
2024-845	148	Mission500		057 059	057 059		060 - 3+	137	1	136	0		
2024-845	151	Clari. Uro		057 059	057 059		057 - NEGATIVE	23	1	22	100		
2024-845	151	Clari. Uro		057 059	057 059		058 - TRACES, 1+	23	16	22	100		
2024-845	151	Clari. Uro		057 059	057 059		059 - 2+	23	5	22	100		
2024-845	151	Clari. Uro		057 059	057 059		060 - 3+	23	1	22	0		
058 URINALYSIS-GLUCOSE													
2024-841	011	AMES NM10S		076 078	075 077		075 - 250mg/dl-+	34	1	34	100		
2024-841	011	AMES NM10S		076 078	075 077		076 - 500mg/dl2+	34	6	34	100		
2024-841	011	AMES NM10S		076 078	075 077		077 - 1000mg/dl	34	26	34	100		
2024-841	011	AMES NM10S		076 078	075 077		078 - 2000mg/dl	34	1	34	100		
2024-841	013	BAYER CLI		076 078	075 077		075 - 250mg/dl-+	20	1	20	100		
2024-841	013	BAYER CLI		076 078	075 077		076 - 500mg/dl2+	20	8	20	100		
2024-841	013	BAYER CLI		076 078	075 077		077 - 1000mg/dl	20	11	20	100		
2024-841	067	URISCAN		077 078	075 077		076 - 500mg/dl2+	54	1	54	100		
2024-841	067	URISCAN		077 078	075 077		077 - 1000mg/dl	54	16	54	100		
2024-841	067	URISCAN		077 078	075 077		078 - 2000mg/dl	54	37	54	100		
2024-841	072	URS-9-TECO		076 078	075 077	076 078	076 - 500mg/dl2+	57	19	57	100		
2024-841	072	URS-9-TECO		076 078	075 077	076 078	077 - 1000mg/dl	57	34	57	100		
2024-841	072	URS-9-TECO		076 078	075 077	076 078	078 - 2000mg/dl	57	4	57	100		
2024-841	080	ROCHE (CHE		076 078	075 077		077 - 1000mg/dl	37	34	37	100		
2024-841	080	ROCHE (CHE		076 078	075 077		078 - 2000mg/dl	37	3	37	100		
2024-841	089	AIMSTRIP		076 078	075 077		074 - TRACES	147	1	146	0		
2024-841	089	AIMSTRIP		076 078	075 077		075 - 250mg/dl-+	147	3	146	100		
2024-841	089	AIMSTRIP		076 078	075 077		076 - 500mg/dl2+	147	41	146	100		
2024-841	089	AIMSTRIP		076 078	075 077		077 - 1000mg/dl	147	101	146	100		
2024-841	089	AIMSTRIP		076 078	075 077		078 - 2000mg/dl	147	1	146	100		
2024-841	094	CLINITEK		076 078	075 077		074 - TRACES	106	1	105	0		
2024-841	094	CLINITEK		076 078	075 077		075 - 250mg/dl-+	106	2	105	100		
2024-841	094	CLINITEK		076 078	075 077		076 - 500mg/dl2+	106	29	105	100		

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-841	094	CLINITEK		076 078	075 077		077 - 1000mg/dl	106	71	105	100		
2024-841	094	CLINITEK		076 078	075 077		078 - 2000mg/dl	106	3	105	100		
2024-841	102	ACON LAB		075 077	075 077	076 078	075 - 250mg/dl-+	125	6	125	100		
2024-841	102	ACON LAB		075 077	075 077	076 078	076 - 500mg/dl2+	125	66	125	100		
2024-841	102	ACON LAB		075 077	075 077	076 078	077 - 1000mg/dl	125	48	125	100		
2024-841	102	ACON LAB		075 077	075 077	076 078	078 - 2000mg/dl	125	5	125	100		
2024-841	131	iCHEM VELO		075 077	075 077		076 - 500mg/dl2+	33	30	33	100		
2024-841	131	iCHEM VELO		075 077	075 077		077 - 1000mg/dl	33	3	33	100		
2024-841	140	MISSION A		076 078	075 077		075 - 250mg/dl-+	42	1	42	100		
2024-841	140	MISSION A		076 078	075 077		076 - 500mg/dl2+	42	11	42	100		
2024-841	140	MISSION A		076 078	075 077		077 - 1000mg/dl	42	24	42	100		
2024-841	140	MISSION A		076 078	075 077		078 - 2000mg/dl	42	6	42	100		
2024-841	145	CLINITEK		076 078	075 077		076 - 500mg/dl2+	41	3	41	100		
2024-841	145	CLINITEK		076 078	075 077		077 - 1000mg/dl	41	37	41	100		
2024-841	145	CLINITEK		076 078	075 077		078 - 2000mg/dl	41	1	41	100		
2024-841	147	Mission120		076 078	075 077		076 - 500mg/dl2+	39	5	39	100		
2024-841	147	Mission120		076 078	075 077		077 - 1000mg/dl	39	23	39	100		
2024-841	147	Mission120		076 078	075 077		078 - 2000mg/dl	39	11	39	100		
2024-841	148	Mission500		075 077	075 077	076 078	073 - NEGATIVE	136	1	135	0		
2024-841	148	Mission500		075 077	075 077	076 078	075 - 250mg/dl-+	136	3	135	100		
2024-841	148	Mission500		075 077	075 077	076 078	076 - 500mg/dl2+	136	58	135	100		
2024-841	148	Mission500		075 077	075 077	076 078	077 - 1000mg/dl	136	51	135	100		
2024-841	148	Mission500		075 077	075 077	076 078	078 - 2000mg/dl	136	23	135	100		
2024-841	151	Clari. Uro		076 078	075 077		076 - 500mg/dl2+	23	6	23	100		
2024-841	151	Clari. Uro		076 078	075 077		077 - 1000mg/dl	23	17	23	100		
058 URINALYSIS-GLUCOSE													
2024-842	011	AMES NM10S		073 075	074 076		074 - TRACES	34	21	34	100		
2024-842	011	AMES NM10S		073 075	074 076		075 - 250mg/dl-+	34	11	34	100		
2024-842	011	AMES NM10S		073 075	074 076		076 - 500mg/dl2+	34	2	34	100		
2024-842	013	BAYER CLI		074 076	074 076		074 - TRACES	20	5	20	100		

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score			
2024-842	013	BAYER CLI		074 076	074 076		075 - 250mg/dl-+	20	15	20	100			
2024-842	067	URISCAN		075 077	074 076		073 - NEGATIVE	54	3	50	0			
2024-842	067	URISCAN		075 077	074 076		074 - TRACES	54	1	50	100			
2024-842	067	URISCAN		075 077	074 076		075 - 250mg/dl-+	54	16	50	100			
2024-842	067	URISCAN		075 077	074 076		076 - 500mg/dl2+	54	23	50	100			
2024-842	067	URISCAN		075 077	074 076		077 - 1000mg/dl	54	10	50	100			
2024-842	067	URISCAN		075 077	074 076		078 - 2000mg/dl	54	1	50	0			
2024-842	072	URS-9-TECO			074 076	073 075	073 - NEGATIVE	57	15	55	100			
2024-842	072	URS-9-TECO			074 076	073 075	074 - TRACES	57	17	55	100			
2024-842	072	URS-9-TECO			074 076	073 075	075 - 250mg/dl-+	57	22	55	100			
2024-842	072	URS-9-TECO			074 076	073 075	076 - 500mg/dl2+	57	1	55	100			
2024-842	072	URS-9-TECO			074 076	073 075	077 - 1000mg/dl	57	2	55	0			
2024-842	080	ROCHE (CHE		076 078	074 076		075 - 250mg/dl-+	37	2	37	100			
2024-842	080	ROCHE (CHE		076 078	074 076		077 - 1000mg/dl	37	33	37	100			
2024-842	080	ROCHE (CHE		076 078	074 076		078 - 2000mg/dl	37	2	37	100			
2024-842	089	AIMSTRIP		074 076	074 076		073 - NEGATIVE	147	3	144	0			
2024-842	089	AIMSTRIP		074 076	074 076		074 - TRACES	147	22	144	100			
2024-842	089	AIMSTRIP		074 076	074 076		075 - 250mg/dl-+	147	117	144	100			
2024-842	089	AIMSTRIP		074 076	074 076		076 - 500mg/dl2+	147	5	144	100			
2024-842	094	CLINITEK		074 076	074 076		073 - NEGATIVE	106	1	105	0			
2024-842	094	CLINITEK		074 076	074 076		074 - TRACES	106	46	105	100			
2024-842	094	CLINITEK		074 076	074 076		075 - 250mg/dl-+	106	59	105	100			
2024-842	102	ACON LAB		074 076	074 076	076 078	073 - NEGATIVE	125	4	121	0			
2024-842	102	ACON LAB		074 076	074 076	076 078	074 - TRACES	125	33	121	100			
2024-842	102	ACON LAB		074 076	074 076	076 078	075 - 250mg/dl-+	125	88	121	100			
2024-842	131	iCHEM VELO		075 077	074 076		074 - TRACES	33	1	33	100			
2024-842	131	iCHEM VELO		075 077	074 076		076 - 500mg/dl2+	33	29	33	100			
2024-842	131	iCHEM VELO		075 077	074 076		077 - 1000mg/dl	33	3	33	100			
2024-842	140	MISSION A		074 076	074 076		074 - TRACES	42	9	42	100			
2024-842	140	MISSION A		074 076	074 076		075 - 250mg/dl-+	42	33	42	100			

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-842	145	CLINITEK		076 078	074 076		076 - 500mg/dl2+	41	3	41	100		
2024-842	145	CLINITEK		076 078	074 076		077 - 1000mg/dl	41	37	41	100		
2024-842	145	CLINITEK		076 078	074 076		078 - 2000mg/dl	41	1	41	100		
2024-842	147	Mission120		074 076	074 076		073 - NEGATIVE	39	1	38	0		
2024-842	147	Mission120		074 076	074 076		074 - TRACES	39	10	38	100		
2024-842	147	Mission120		074 076	074 076		075 - 250mg/dl-+	39	27	38	100		
2024-842	147	Mission120		074 076	074 076		076 - 500mg/dl2+	39	1	38	100		
2024-842	148	Mission500		074 076	074 076	074 076	073 - NEGATIVE	136	1	134	0		
2024-842	148	Mission500		074 076	074 076	074 076	074 - TRACES	136	9	134	100		
2024-842	148	Mission500		074 076	074 076	074 076	075 - 250mg/dl-+	136	125	134	100		
2024-842	148	Mission500		074 076	074 076	074 076	077 - 1000mg/dl	136	1	134	0		
2024-842	151	Clari. Uro		074 076	074 076		073 - NEGATIVE	23	1	22	0		
2024-842	151	Clari. Uro		074 076	074 076		074 - TRACES	23	3	22	100		
2024-842	151	Clari. Uro		074 076	074 076		075 - 250mg/dl-+	23	19	22	100		
058 URINALYSIS-GLUCOSE													
2024-843	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	34	34	34	100		
2024-843	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	20	20	20	100		
2024-843	067	URISCAN		073 073	073 073		073 - NEGATIVE	54	54	54	100		
2024-843	072	URS-9-TECO		073 073	073 073	073 073	073 - NEGATIVE	57	57	57	100		
2024-843	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	37	37	37	100		
2024-843	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	147	147	147	100		
2024-843	094	CLINITEK		073 073	073 073		073 - NEGATIVE	106	106	106	100		
2024-843	102	ACON LAB		073 073	073 073	073 073	073 - NEGATIVE	125	125	125	100		
2024-843	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	33	33	33	100		
2024-843	140	MISSION A		073 073	073 073		073 - NEGATIVE	42	42	42	100		
2024-843	145	CLINITEK		073 073	073 073		073 - NEGATIVE	41	41	41	100		
2024-843	147	Mission120		073 073	073 073		073 - NEGATIVE	39	39	39	100		
2024-843	148	Mission500		073 073	073 073	073 073	073 - NEGATIVE	136	136	136	100		
2024-843	151	Clari. Uro		073 073	073 073		073 - NEGATIVE	23	23	23	100		

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
058 URINALYSIS-GLUCOSE													
2024-844	011 AMES NM10S			076 078	075 077		076 - 500mg/dl2+	34	8	34	100		
2024-844	011 AMES NM10S			076 078	075 077		077 - 1000mg/dl	34	25	34	100		
2024-844	011 AMES NM10S			076 078	075 077		078 - 2000mg/dl	34	1	34	100		
2024-844	013 BAYER CLI			076 078	075 077		075 - 250mg/dl-+	20	1	20	100		
2024-844	013 BAYER CLI			076 078	075 077		076 - 500mg/dl2+	20	8	20	100		
2024-844	013 BAYER CLI			076 078	075 077		077 - 1000mg/dl	20	11	20	100		
2024-844	067 URISCAN			077 078	075 077		076 - 500mg/dl2+	54	2	54	100		
2024-844	067 URISCAN			077 078	075 077		077 - 1000mg/dl	54	14	54	100		
2024-844	067 URISCAN			077 078	075 077		078 - 2000mg/dl	54	38	54	100		
2024-844	072 URS-9-TECO			076 078	075 077	076 078	074 - TRACES	57	1	56	0		
2024-844	072 URS-9-TECO			076 078	075 077	076 078	075 - 250mg/dl-+	57	4	56	100		
2024-844	072 URS-9-TECO			076 078	075 077	076 078	076 - 500mg/dl2+	57	19	56	100		
2024-844	072 URS-9-TECO			076 078	075 077	076 078	077 - 1000mg/dl	57	31	56	100		
2024-844	072 URS-9-TECO			076 078	075 077	076 078	078 - 2000mg/dl	57	2	56	100		
2024-844	080 ROCHE (CHE			076 078	075 077		075 - 250mg/dl-+	37	1	37	100		
2024-844	080 ROCHE (CHE			076 078	075 077		076 - 500mg/dl2+	37	1	37	100		
2024-844	080 ROCHE (CHE			076 078	075 077		077 - 1000mg/dl	37	32	37	100		
2024-844	080 ROCHE (CHE			076 078	075 077		078 - 2000mg/dl	37	3	37	100		
2024-844	089 AIMSTRIP			076 078	075 077		073 - NEGATIVE	147	1	146	0		
2024-844	089 AIMSTRIP			076 078	075 077		075 - 250mg/dl-+	147	7	146	100		
2024-844	089 AIMSTRIP			076 078	075 077		076 - 500mg/dl2+	147	30	146	100		
2024-844	089 AIMSTRIP			076 078	075 077		077 - 1000mg/dl	147	106	146	100		
2024-844	089 AIMSTRIP			076 078	075 077		078 - 2000mg/dl	147	3	146	100		
2024-844	094 CLINITEK			076 078	075 077		074 - TRACES	106	1	105	0		
2024-844	094 CLINITEK			076 078	075 077		076 - 500mg/dl2+	106	30	105	100		
2024-844	094 CLINITEK			076 078	075 077		077 - 1000mg/dl	106	73	105	100		
2024-844	094 CLINITEK			076 078	075 077		078 - 2000mg/dl	106	2	105	100		
2024-844	102 ACON LAB			075 077	075 077	075 077	075 - 250mg/dl-+	125	4	120	100		
2024-844	102 ACON LAB			075 077	075 077	075 077	076 - 500mg/dl2+	125	62	120	100		

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-844	102	ACON LAB		075 077	075 077	075 077	077 - 1000mg/dl	125	54	120	100		
2024-844	102	ACON LAB		075 077	075 077	075 077	078 - 2000mg/dl	125	5	120	0		
2024-844	131	iCHEM VELO		075 077	075 077		076 - 500mg/dl2+	33	30	33	100		
2024-844	131	iCHEM VELO		075 077	075 077		077 - 1000mg/dl	33	3	33	100		
2024-844	140	MISSION A		076 078	075 077		075 - 250mg/dl-+	42	1	42	100		
2024-844	140	MISSION A		076 078	075 077		076 - 500mg/dl2+	42	11	42	100		
2024-844	140	MISSION A		076 078	075 077		077 - 1000mg/dl	42	25	42	100		
2024-844	140	MISSION A		076 078	075 077		078 - 2000mg/dl	42	5	42	100		
2024-844	145	CLINITEK		075 077	075 077		075 - 250mg/dl-+	41	1	40	100		
2024-844	145	CLINITEK		075 077	075 077		076 - 500mg/dl2+	41	26	40	100		
2024-844	145	CLINITEK		075 077	075 077		077 - 1000mg/dl	41	13	40	100		
2024-844	145	CLINITEK		075 077	075 077		078 - 2000mg/dl	41	1	40	0		
2024-844	147	Mission120		076 078	075 077		076 - 500mg/dl2+	39	5	39	100		
2024-844	147	Mission120		076 078	075 077		077 - 1000mg/dl	39	18	39	100		
2024-844	147	Mission120		076 078	075 077		078 - 2000mg/dl	39	16	39	100		
2024-844	148	Mission500		076 078	075 077	076 078	073 - NEGATIVE	136	1	133	0		
2024-844	148	Mission500		076 078	075 077	076 078	074 - TRACES	136	2	133	0		
2024-844	148	Mission500		076 078	075 077	076 078	075 - 250mg/dl-+	136	5	133	100		
2024-844	148	Mission500		076 078	075 077	076 078	076 - 500mg/dl2+	136	46	133	100		
2024-844	148	Mission500		076 078	075 077	076 078	077 - 1000mg/dl	136	62	133	100		
2024-844	148	Mission500		076 078	075 077	076 078	078 - 2000mg/dl	136	20	133	100		
2024-844	151	Clari. Uro		076 078	075 077		075 - 250mg/dl-+	23	1	23	100		
2024-844	151	Clari. Uro		076 078	075 077		076 - 500mg/dl2+	23	3	23	100		
2024-844	151	Clari. Uro		076 078	075 077		077 - 1000mg/dl	23	19	23	100		
058 URINALYSIS-GLUCOSE													
2024-845	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	34	34	34	100		
2024-845	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	20	20	20	100		
2024-845	067	URISCAN		073 073	073 073		073 - NEGATIVE	54	54	54	100		
2024-845	072	URS-9-TECO		073 073	073 073	073 073	073 - NEGATIVE	57	57	57	100		
2024-845	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	37	37	37	100		

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-845	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	147	147	147	100		
2024-845	094	CLINITEK		073 073	073 073		073 - NEGATIVE	106	106	106	100		
2024-845	102	ACON LAB		073 073	073 073	073 073	073 - NEGATIVE	125	125	125	100		
2024-845	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	33	33	33	100		
2024-845	140	MISSION A		073 073	073 073		073 - NEGATIVE	42	42	42	100		
2024-845	145	CLINITEK		073 073	073 073		073 - NEGATIVE	41	41	41	100		
2024-845	147	Mission120		073 073	073 073		073 - NEGATIVE	39	39	39	100		
2024-845	148	Mission500		073 073	073 073	073 073	073 - NEGATIVE	136	136	136	100		
2024-845	151	Clari. Uro		073 073	073 073		073 - NEGATIVE	23	23	23	100		
059 URINALYS.HG.OR BLOOD													
2024-841	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	34	1	34	100		
2024-841	011	AMES NM10S		068 069	068 069		069 - POS.(3+)	34	33	34	100		
2024-841	013	BAYER CLI		068 069	068 069		069 - POS.(3+)	20	20	20	100		
2024-841	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	54	5	54	100		
2024-841	067	URISCAN		068 069	068 069		069 - POS.(3+)	54	49	54	100		
2024-841	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	57	9	57	100		
2024-841	072	URS-9-TECO		068 069	068 069		069 - POS.(3+)	57	48	57	100		
2024-841	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	37	1	37	100		
2024-841	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+)	37	36	37	100		
2024-841	089	AIMSTRIP		068 069	068 069		069 - POS.(3+)	146	146	146	100		
2024-841	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	106	4	106	100		
2024-841	094	CLINITEK		068 069	068 069		069 - POS.(3+)	106	102	106	100		
2024-841	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	127	2	127	100		
2024-841	102	ACON LAB		068 069	068 069		069 - POS.(3+)	127	125	127	100		
2024-841	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	33	2	33	100		
2024-841	131	iCHEM VELO		068 069	068 069		069 - POS.(3+)	33	31	33	100		
2024-841	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	40	1	40	100		
2024-841	140	MISSION A		068 069	068 069		069 - POS.(3+)	40	39	40	100		
2024-841	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	41	4	41	100		
2024-841	145	CLINITEK		068 069	068 069		069 - POS.(3+)	41	37	41	100		

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-841	147	Mission120		068 069	068 069		069 - POS.(3+)	40	40	40	100	
2024-841	148	Mission500		068 069	068 069		068 - POS.(1-2+)	135	1	135	100	
2024-841	148	Mission500		068 069	068 069		069 - POS.(3+)	135	134	135	100	
2024-841	151	Clari. Uro		068 069	068 069		069 - POS.(3+)	23	23	23	100	
059 URINALYS.HG.OR BLOOD												
2024-842	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	34	34	34	100	
2024-842	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	20	20	20	100	
2024-842	067	URISCAN		066 066	066 066		066 - NEGATIVE	54	54	54	100	
2024-842	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	57	57	57	100	
2024-842	080	ROCHE (CHE		066 066	066 066		066 - NEGATIVE	37	37	37	100	
2024-842	089	AIMSTRIP		066 066	066 066		066 - NEGATIVE	146	145	145	100	
2024-842	089	AIMSTRIP		066 066	066 066		067 - TRACES	146	1	145	0	
2024-842	094	CLINITEK		066 066	066 066		066 - NEGATIVE	106	106	106	100	
2024-842	102	ACON LAB		066 066	066 066		066 - NEGATIVE	127	127	127	100	
2024-842	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	33	33	33	100	
2024-842	140	MISSION A		066 066	066 066		066 - NEGATIVE	40	40	40	100	
2024-842	145	CLINITEK		066 066	066 066		066 - NEGATIVE	41	41	41	100	
2024-842	147	Mission120		066 066	066 066		066 - NEGATIVE	40	40	40	100	
2024-842	148	Mission500		066 066	066 066		066 - NEGATIVE	135	135	135	100	
2024-842	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	23	23	23	100	
2024-843	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	34	3	34	100	
2024-843	011	AMES NM10S		068 069	068 069		069 - POS.(3+)	34	31	34	100	
2024-843	013	BAYER CLI		068 069	068 069		069 - POS.(3+)	20	20	20	100	
2024-843	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	54	5	54	100	
2024-843	067	URISCAN		068 069	068 069		069 - POS.(3+)	54	49	54	100	
2024-843	072	URS-9-TECO		068 069	068 069		066 - NEGATIVE	57	1	56	0	
2024-843	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	57	4	56	100	
2024-843	072	URS-9-TECO		068 069	068 069		069 - POS.(3+)	57	52	56	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-843	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	37	1	37	100	
2024-843	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+)	37	36	37	100	
2024-843	089	AIMSTRIP		068 069	068 069		069 - POS.(3+)	146	146	146	100	
2024-843	094	CLINITEK		068 069	068 069		066 - NEGATIVE	106	1	105	0	
2024-843	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	106	4	105	100	
2024-843	094	CLINITEK		068 069	068 069		069 - POS.(3+)	106	101	105	100	
2024-843	102	ACON LAB		068 069	068 069		066 - NEGATIVE	127	1	126	0	
2024-843	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	127	2	126	100	
2024-843	102	ACON LAB		068 069	068 069		069 - POS.(3+)	127	124	126	100	
2024-843	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	33	2	33	100	
2024-843	131	iCHEM VELO		068 069	068 069		069 - POS.(3+)	33	31	33	100	
2024-843	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	40	2	40	100	
2024-843	140	MISSION A		068 069	068 069		069 - POS.(3+)	40	38	40	100	
2024-843	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	41	2	41	100	
2024-843	145	CLINITEK		068 069	068 069		069 - POS.(3+)	41	39	41	100	
2024-843	147	Mission120		068 069	068 069		069 - POS.(3+)	40	40	40	100	
2024-843	148	Mission500		068 069	068 069		067 - TRACES	135	1	134	0	
2024-843	148	Mission500		068 069	068 069		069 - POS.(3+)	135	134	134	100	
2024-843	151	Clari. Uro		068 069	068 069		069 - POS.(3+)	23	23	23	100	
059 URINALYS.HG.OR BLOOD												
2024-844	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	34	34	34	100	
2024-844	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	20	20	20	100	
2024-844	067	URISCAN		066 066	066 066		066 - NEGATIVE	54	54	54	100	
2024-844	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	57	56	56	100	
2024-844	072	URS-9-TECO		066 066	066 066		067 - TRACES	57	1	56	0	
2024-844	080	ROCHE (CHE		066 066	066 066		066 - NEGATIVE	37	36	36	100	
2024-844	080	ROCHE (CHE		066 066	066 066		067 - TRACES	37	1	36	0	
2024-844	089	AIMSTRIP		066 066	066 066		066 - NEGATIVE	146	144	144	100	
2024-844	089	AIMSTRIP		066 066	066 066		067 - TRACES	146	1	144	0	
2024-844	089	AIMSTRIP		066 066	066 066		068 - POS.(1-2+)	146	1	144	0	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-844	094	CLINITEK		066 066	066 066		066 - NEGATIVE	106	106	106	100	
2024-844	102	ACON LAB		066 066	066 066		066 - NEGATIVE	127	126	126	100	
2024-844	102	ACON LAB		066 066	066 066		067 - TRACES	127	1	126	0	
2024-844	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	33	33	33	100	
2024-844	140	MISSION A		066 066	066 066		066 - NEGATIVE	40	40	40	100	
2024-844	145	CLINITEK		066 066	066 066		066 - NEGATIVE	41	41	41	100	
2024-844	147	Mission120		066 066	066 066		066 - NEGATIVE	40	40	40	100	
2024-844	148	Mission500		066 066	066 066		066 - NEGATIVE	135	135	135	100	
2024-844	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	23	23	23	100	
059 URINALYS.HG.OR BLOOD												
2024-845	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	34	4	34	100	
2024-845	011	AMES NM10S		068 069	068 069		069 - POS.(3+)	34	30	34	100	
2024-845	013	BAYER CLI		068 069	068 069		068 - POS.(1-2+)	20	2	20	100	
2024-845	013	BAYER CLI		068 069	068 069		069 - POS.(3+)	20	18	20	100	
2024-845	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	54	5	54	100	
2024-845	067	URISCAN		068 069	068 069		069 - POS.(3+)	54	49	54	100	
2024-845	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	57	10	57	100	
2024-845	072	URS-9-TECO		068 069	068 069		069 - POS.(3+)	57	47	57	100	
2024-845	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	37	2	37	100	
2024-845	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+)	37	35	37	100	
2024-845	089	AIMSTRIP		068 069	068 069		066 - NEGATIVE	146	1	145	0	
2024-845	089	AIMSTRIP		068 069	068 069		068 - POS.(1-2+)	146	1	145	100	
2024-845	089	AIMSTRIP		068 069	068 069		069 - POS.(3+)	146	144	145	100	
2024-845	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	106	9	106	100	
2024-845	094	CLINITEK		068 069	068 069		069 - POS.(3+)	106	97	106	100	
2024-845	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	127	3	127	100	
2024-845	102	ACON LAB		068 069	068 069		069 - POS.(3+)	127	124	127	100	
2024-845	131	iCHEM VELO		067 069	068 069		068 - POS.(1-2+)	33	25	32	100	
2024-845	131	iCHEM VELO		067 069	068 069		069 - POS.(3+)	33	5	32	100	
2024-845	131	iCHEM VELO		067 069	068 069		066 - NEGATIVE	33	1	32	0	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-845	131	iCHEM VELO		067 069	068 069		067 - TRACES	33	2	32	100	
2024-845	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	40	1	40	100	
2024-845	140	MISSION A		068 069	068 069		069 - POS.(3+)	40	39	40	100	
2024-845	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	41	7	41	100	
2024-845	145	CLINITEK		068 069	068 069		069 - POS.(3+)	41	34	41	100	
2024-845	147	Mission120		068 069	068 069		069 - POS.(3+)	40	40	40	100	
2024-845	148	Mission500		068 069	068 069		068 - POS.(1-2+)	135	1	135	100	
2024-845	148	Mission500		068 069	068 069		069 - POS.(3+)	135	134	135	100	
2024-845	151	Clari. Uro		068 069	068 069		069 - POS.(3+)	23	23	23	100	
060 URINALYSIS-KETONES												
2024-841	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	34	34	34	100	
2024-841	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	20	20	20	100	
2024-841	067	URISCAN		090 090	090 090		090 - NEGATIVE	54	54	54	100	
2024-841	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	56	56	56	100	
2024-841	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-841	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	147	147	147	100	
2024-841	094	CLINITEK		090 090	090 090		090 - NEGATIVE	106	106	106	100	
2024-841	102	ACON LAB		090 090	090 090		090 - NEGATIVE	125	125	125	100	
2024-841	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	33	33	33	100	
2024-841	140	MISSION A		090 090	090 090		090 - NEGATIVE	43	43	43	100	
2024-841	145	CLINITEK		090 090	090 090		090 - NEGATIVE	41	41	41	100	
2024-841	147	Mission120		090 090	090 090		090 - NEGATIVE	39	39	39	100	
2024-841	148	Mission500		090 090	090 090		090 - NEGATIVE	135	135	135	100	
2024-841	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	23	23	23	100	
2024-842	011	AMES NM10S		092 094	092 094		092 - SMALL (1+)	34	2	34	100	
2024-842	011	AMES NM10S		092 094	092 094		093 - MOD. (2+)	34	26	34	100	
2024-842	011	AMES NM10S		092 094	092 094		094 - LARGE-3-4+	34	6	34	100	
2024-842	013	BAYER CLI		092 094	092 094		092 - SMALL (1+)	20	2	20	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-842	013	BAYER CLI		092 094	092 094		093 - MOD. (2+)	20	18	20	100
2024-842	067	URISCAN		092 094	092 094		090 - NEGATIVE	54	1	53	0
2024-842	067	URISCAN		092 094	092 094		092 - SMALL (1+)	54	1	53	100
2024-842	067	URISCAN		092 094	092 094		093 - MOD. (2+)	54	35	53	100
2024-842	067	URISCAN		092 094	092 094		094 - LARGE-3-4+	54	17	53	100
2024-842	072	URS-9-TECO		092 094	092 094		092 - SMALL (1+)	56	6	56	100
2024-842	072	URS-9-TECO		092 094	092 094		093 - MOD. (2+)	56	28	56	100
2024-842	072	URS-9-TECO		092 094	092 094		094 - LARGE-3-4+	56	22	56	100
2024-842	080	ROCHE (CHE		092 094	092 094		092 - SMALL (1+)	37	6	37	100
2024-842	080	ROCHE (CHE		092 094	092 094		093 - MOD. (2+)	37	23	37	100
2024-842	080	ROCHE (CHE		092 094	092 094		094 - LARGE-3-4+	37	8	37	100
2024-842	089	AIMSTRIP		093 094	092 094		092 - SMALL (1+)	147	10	147	100
2024-842	089	AIMSTRIP		093 094	092 094		093 - MOD. (2+)	147	60	147	100
2024-842	089	AIMSTRIP		093 094	092 094		094 - LARGE-3-4+	147	77	147	100
2024-842	094	CLINITEK		092 094	092 094		091 - TRACE	106	1	105	0
2024-842	094	CLINITEK		092 094	092 094		092 - SMALL (1+)	106	10	105	100
2024-842	094	CLINITEK		092 094	092 094		093 - MOD. (2+)	106	90	105	100
2024-842	094	CLINITEK		092 094	092 094		094 - LARGE-3-4+	106	5	105	100
2024-842	102	ACON LAB		092 094	092 094		092 - SMALL (1+)	125	15	125	100
2024-842	102	ACON LAB		092 094	092 094		093 - MOD. (2+)	125	67	125	100
2024-842	102	ACON LAB		092 094	092 094		094 - LARGE-3-4+	125	43	125	100
2024-842	131	iCHEM VELO		092 094	092 094		092 - SMALL (1+)	33	6	33	100
2024-842	131	iCHEM VELO		092 094	092 094		093 - MOD. (2+)	33	19	33	100
2024-842	131	iCHEM VELO		092 094	092 094		094 - LARGE-3-4+	33	8	33	100
2024-842	140	MISSION A		093 094	092 094		092 - SMALL (1+)	43	1	43	100
2024-842	140	MISSION A		093 094	092 094		093 - MOD. (2+)	43	14	43	100
2024-842	140	MISSION A		093 094	092 094		094 - LARGE-3-4+	43	28	43	100
2024-842	145	CLINITEK		092 094	092 094		092 - SMALL (1+)	41	3	41	100
2024-842	145	CLINITEK		092 094	092 094		093 - MOD. (2+)	41	26	41	100
2024-842	145	CLINITEK		092 094	092 094		094 - LARGE-3-4+	41	12	41	100

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-842	147	Mission120		093 094	092 094		093 - MOD. (2+)	39	9	39	100	
2024-842	147	Mission120		093 094	092 094		094 - LARGE-3-4+	39	30	39	100	
2024-842	148	Mission500		092 094	092 094		092 - SMALL (1+)	135	1	135	100	
2024-842	148	Mission500		092 094	092 094		093 - MOD. (2+)	135	89	135	100	
2024-842	148	Mission500		092 094	092 094		094 - LARGE-3-4+	135	45	135	100	
2024-842	151	Clari. Uro		093 094	092 094		093 - MOD. (2+)	23	7	23	100	
2024-842	151	Clari. Uro		093 094	092 094		094 - LARGE-3-4+	23	16	23	100	
060 URINALYSIS-KETONES												
2024-843	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	34	34	34	100	
2024-843	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	20	20	20	100	
2024-843	067	URISCAN		090 090	090 090		090 - NEGATIVE	54	54	54	100	
2024-843	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	56	56	56	100	
2024-843	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-843	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	147	147	147	100	
2024-843	094	CLINITEK		090 090	090 090		090 - NEGATIVE	106	106	106	100	
2024-843	102	ACON LAB		090 090	090 090		090 - NEGATIVE	125	125	125	100	
2024-843	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	33	32	32	100	
2024-843	131	iCHEM VELO		090 090	090 090		094 - LARGE-3-4+	33	1	32	0	
2024-843	140	MISSION A		090 090	090 090		090 - NEGATIVE	43	43	43	100	
2024-843	145	CLINITEK		090 090	090 090		090 - NEGATIVE	41	41	41	100	
2024-843	147	Mission120		090 090	090 090		090 - NEGATIVE	39	39	39	100	
2024-843	148	Mission500		090 090	090 090		090 - NEGATIVE	135	134	134	100	
2024-843	148	Mission500		090 090	090 090		094 - LARGE-3-4+	135	1	134	0	
2024-843	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	23	23	23	100	
2024-844	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	34	34	34	100	
2024-844	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	20	20	20	100	
2024-844	067	URISCAN		090 090	090 090		090 - NEGATIVE	54	54	54	100	
2024-844	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	56	56	56	100	

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-844	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-844	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	147	147	147	100	
2024-844	094	CLINITEK		090 090	090 090		090 - NEGATIVE	106	106	106	100	
2024-844	102	ACON LAB		090 090	090 090		090 - NEGATIVE	125	125	125	100	
2024-844	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	33	33	33	100	
2024-844	140	MISSION A		090 090	090 090		090 - NEGATIVE	43	43	43	100	
2024-844	145	CLINITEK		090 090	090 090		090 - NEGATIVE	41	41	41	100	
2024-844	147	Mission120		090 090	090 090		090 - NEGATIVE	39	39	39	100	
2024-844	148	Mission500		090 090	090 090		090 - NEGATIVE	135	135	135	100	
2024-844	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	23	23	23	100	
060 URINALYSIS-KETONES												
2024-845	011	AMES NM10S		093 094	093 094		094 - LARGE-3-4+	34	34	34	100	
2024-845	013	BAYER CLI		093 094	093 094		093 - MOD. (2+)	20	2	20	100	
2024-845	013	BAYER CLI		093 094	093 094		094 - LARGE-3-4+	20	18	20	100	
2024-845	067	URISCAN		093 094	093 094		091 - TRACE	54	1	53	0	
2024-845	067	URISCAN		093 094	093 094		093 - MOD. (2+)	54	14	53	100	
2024-845	067	URISCAN		093 094	093 094		094 - LARGE-3-4+	54	39	53	100	
2024-845	072	URS-9-TECO		093 094	093 094		090 - NEGATIVE	56	1	55	0	
2024-845	072	URS-9-TECO		093 094	093 094		093 - MOD. (2+)	56	1	55	100	
2024-845	072	URS-9-TECO		093 094	093 094		094 - LARGE-3-4+	56	54	55	100	
2024-845	080	ROCHE (CHE		093 094	093 094		093 - MOD. (2+)	37	5	37	100	
2024-845	080	ROCHE (CHE		093 094	093 094		094 - LARGE-3-4+	37	32	37	100	
2024-845	089	AIMSTRIP		093 094	093 094		093 - MOD. (2+)	147	2	147	100	
2024-845	089	AIMSTRIP		093 094	093 094		094 - LARGE-3-4+	147	145	147	100	
2024-845	094	CLINITEK		093 094	093 094		092 - SMALL (1+)	106	1	105	0	
2024-845	094	CLINITEK		093 094	093 094		093 - MOD. (2+)	106	4	105	100	
2024-845	094	CLINITEK		093 094	093 094		094 - LARGE-3-4+	106	101	105	100	
2024-845	102	ACON LAB		093 094	093 094		093 - MOD. (2+)	125	1	125	100	
2024-845	102	ACON LAB		093 094	093 094		094 - LARGE-3-4+	125	124	125	100	
2024-845	131	iCHEM VELO		092 094	093 094		090 - NEGATIVE	33	1	32	0	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-845	131	iCHEM VELO		092 094	093 094		093 - MOD. (2+)	33	16	32	100	
2024-845	131	iCHEM VELO		092 094	093 094		094 - LARGE-3-4+	33	16	32	100	
2024-845	140	MISSION A		093 094	093 094		093 - MOD. (2+)	43	2	43	100	
2024-845	140	MISSION A		093 094	093 094		094 - LARGE-3-4+	43	41	43	100	
2024-845	145	CLINITEK		093 094	093 094		094 - LARGE-3-4+	41	41	41	100	
2024-845	147	Mission120		093 094	093 094		092 - SMALL (1+)	39	1	38	0	
2024-845	147	Mission120		093 094	093 094		094 - LARGE-3-4+	39	38	38	100	
2024-845	148	Mission500		093 094	093 094		093 - MOD. (2+)	135	1	135	100	
2024-845	148	Mission500		093 094	093 094		094 - LARGE-3-4+	135	134	135	100	
2024-845	151	Clari. Uro		093 094	093 094		094 - LARGE-3-4+	23	23	23	100	
061 URINALYSIS-NITRATE												
2024-841	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	34	34	34	100	
2024-841	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	20	20	20	100	
2024-841	067	URISCAN		070 070	070 070		070 - NEGATIVE	54	54	54	100	
2024-841	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	57	57	57	100	
2024-841	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	37	36	36	100	
2024-841	080	ROCHE (CHE		070 070	070 070		072 - POSITIVE	37	1	36	0	
2024-841	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	147	147	147	100	
2024-841	094	CLINITEK		070 070	070 070		070 - NEGATIVE	106	106	106	100	
2024-841	102	ACON LAB		070 070	070 070		070 - NEGATIVE	125	125	125	100	
2024-841	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	33	33	33	100	
2024-841	140	MISSION A		070 070	070 070		070 - NEGATIVE	41	41	41	100	
2024-841	145	CLINITEK		070 070	070 070		070 - NEGATIVE	40	40	40	100	
2024-841	147	Mission120		070 070	070 070		070 - NEGATIVE	40	40	40	100	
2024-841	148	Mission500		070 070	070 070		070 - NEGATIVE	135	135	135	100	
2024-841	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	23	23	23	100	
2024-842	011	AMES NM10S		071 072	071 072		072 - POSITIVE	34	34	34	100	
2024-842	013	BAYER CLI		071 072	071 072		072 - POSITIVE	20	20	20	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-842	067	URISCAN		071 072	071 072		072 - POSITIVE	54	54	54	100	
2024-842	072	URS-9-TECO		071 072	071 072		072 - POSITIVE	57	57	57	100	
2024-842	080	ROCHE (CHE		071 072	071 072		072 - POSITIVE	37	37	37	100	
2024-842	089	AIMSTRIP		071 072	071 072		071 - WEAK POS.	147	2	147	100	
2024-842	089	AIMSTRIP		071 072	071 072		072 - POSITIVE	147	145	147	100	
2024-842	094	CLINITEK		071 072	071 072		072 - POSITIVE	106	106	106	100	
2024-842	102	ACON LAB		071 072	071 072		072 - POSITIVE	125	125	125	100	
2024-842	131	iCHEM VELO		071 072	071 072		072 - POSITIVE	33	33	33	100	
2024-842	140	MISSION A		071 072	071 072		072 - POSITIVE	41	41	41	100	
2024-842	145	CLINITEK		071 072	071 072		072 - POSITIVE	40	40	40	100	
2024-842	147	Mission120		071 072	071 072		072 - POSITIVE	40	40	40	100	
2024-842	148	Mission500		071 072	071 072		072 - POSITIVE	135	135	135	100	
2024-842	151	Clari. Uro		071 072	071 072		072 - POSITIVE	23	23	23	100	
061 URINALYSIS-NITRATE												
2024-843	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	34	34	34	100	
2024-843	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	20	20	20	100	
2024-843	067	URISCAN		070 070	070 070		070 - NEGATIVE	54	54	54	100	
2024-843	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	57	57	57	100	
2024-843	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	37	37	37	100	
2024-843	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	147	147	147	100	
2024-843	094	CLINITEK		070 070	070 070		070 - NEGATIVE	106	106	106	100	
2024-843	102	ACON LAB		070 070	070 070		070 - NEGATIVE	125	125	125	100	
2024-843	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	33	33	33	100	
2024-843	140	MISSION A		070 070	070 070		070 - NEGATIVE	41	41	41	100	
2024-843	145	CLINITEK		070 070	070 070		070 - NEGATIVE	40	40	40	100	
2024-843	147	Mission120		070 070	070 070		070 - NEGATIVE	40	40	40	100	
2024-843	148	Mission500		070 070	070 070		070 - NEGATIVE	135	135	135	100	
2024-843	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	23	23	23	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
061 URINALYSIS-NITRATE													
2024-844	011	AMES NM10S		070	070	070	070	070 - NEGATIVE	34	34	34	100	
2024-844	013	BAYER CLI		070	070	070	070	070 - NEGATIVE	20	20	20	100	
2024-844	067	URISCAN		070	070	070	070	070 - NEGATIVE	54	54	54	100	
2024-844	072	URS-9-TECO		070	070	070	070	070 - NEGATIVE	57	57	57	100	
2024-844	080	ROCHE (CHE		070	070	070	070	070 - NEGATIVE	37	37	37	100	
2024-844	089	AIMSTRIP		070	070	070	070	070 - NEGATIVE	147	147	147	100	
2024-844	094	CLINITEK		070	070	070	070	070 - NEGATIVE	106	106	106	100	
2024-844	102	ACON LAB		070	070	070	070	070 - NEGATIVE	125	125	125	100	
2024-844	131	iCHEM VELO		070	070	070	070	070 - NEGATIVE	33	33	33	100	
2024-844	140	MISSION A		070	070	070	070	070 - NEGATIVE	41	41	41	100	
2024-844	145	CLINITEK		070	070	070	070	070 - NEGATIVE	40	40	40	100	
2024-844	147	Mission120		070	070	070	070	070 - NEGATIVE	40	40	40	100	
2024-844	148	Mission500		070	070	070	070	070 - NEGATIVE	135	135	135	100	
2024-844	151	Clari. Uro		070	070	070	070	070 - NEGATIVE	23	23	23	100	
2024-845	011	AMES NM10S		070	070	070	070	070 - NEGATIVE	34	34	34	100	
2024-845	013	BAYER CLI		070	070	070	070	070 - NEGATIVE	20	20	20	100	
2024-845	067	URISCAN		070	070	070	070	070 - NEGATIVE	54	54	54	100	
2024-845	072	URS-9-TECO		070	070	070	070	070 - NEGATIVE	57	57	57	100	
2024-845	080	ROCHE (CHE		070	070	070	070	070 - NEGATIVE	37	37	37	100	
2024-845	089	AIMSTRIP		070	070	070	070	070 - NEGATIVE	147	147	147	100	
2024-845	094	CLINITEK		070	070	070	070	070 - NEGATIVE	106	106	106	100	
2024-845	102	ACON LAB		070	070	070	070	070 - NEGATIVE	125	125	125	100	
2024-845	131	iCHEM VELO		070	070	070	070	070 - NEGATIVE	33	33	33	100	
2024-845	140	MISSION A		070	070	070	070	070 - NEGATIVE	41	41	41	100	
2024-845	145	CLINITEK		070	070	070	070	070 - NEGATIVE	40	40	40	100	
2024-845	147	Mission120		070	070	070	070	070 - NEGATIVE	40	40	40	100	
2024-845	148	Mission500		070	070	070	070	070 - NEGATIVE	135	135	135	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-845	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	23	23	23	100	
062 URINALYSIS-pH												
2024-841	011	AMES NM10S		084 088	083 087		082 - 5.0	34	1	33	0	
2024-841	011	AMES NM10S		084 088	083 087		084 - 6.0	34	1	33	100	
2024-841	011	AMES NM10S		084 088	083 087		085 - 6.5	34	12	33	100	
2024-841	011	AMES NM10S		084 088	083 087		086 - 7.0	34	20	33	100	
2024-841	013	BAYER CLI		084 088	083 087		085 - 6.5	20	9	20	100	
2024-841	013	BAYER CLI		084 088	083 087		086 - 7.0	20	11	20	100	
2024-841	067	URISCAN		083 087	083 087		082 - 5.0	54	1	53	0	
2024-841	067	URISCAN		083 087	083 087		083 - 5.5	54	1	53	100	
2024-841	067	URISCAN		083 087	083 087		084 - 6.0	54	6	53	100	
2024-841	067	URISCAN		083 087	083 087		085 - 6.5	54	46	53	100	
2024-841	072	URS-9-TECO		083 087	083 087		084 - 6.0	57	5	57	100	
2024-841	072	URS-9-TECO		083 087	083 087		085 - 6.5	57	44	57	100	
2024-841	072	URS-9-TECO		083 087	083 087		086 - 7.0	57	8	57	100	
2024-841	080	ROCHE (CHE		083 087	083 087		085 - 6.5	37	33	37	100	
2024-841	080	ROCHE (CHE		083 087	083 087		086 - 7.0	37	4	37	100	
2024-841	089	AIMSTRIP		083 087	083 087		084 - 6.0	146	16	146	100	
2024-841	089	AIMSTRIP		083 087	083 087		085 - 6.5	146	95	146	100	
2024-841	089	AIMSTRIP		083 087	083 087		086 - 7.0	146	35	146	100	
2024-841	094	CLINITEK		084 088	083 087		084 - 6.0	106	1	106	100	
2024-841	094	CLINITEK		084 088	083 087		085 - 6.5	106	33	106	100	
2024-841	094	CLINITEK		084 088	083 087		086 - 7.0	106	72	106	100	
2024-841	102	ACON LAB		083 087	083 087		084 - 6.0	126	13	126	100	
2024-841	102	ACON LAB		083 087	083 087		085 - 6.5	126	93	126	100	
2024-841	102	ACON LAB		083 087	083 087		086 - 7.0	126	20	126	100	
2024-841	131	iCHEM VELO		082 086	083 087		084 - 6.0	33	31	33	100	
2024-841	131	iCHEM VELO		082 086	083 087		086 - 7.0	33	2	33	100	
2024-841	140	MISSION A		083 087	083 087		084 - 6.0	43	9	43	100	
2024-841	140	MISSION A		083 087	083 087		085 - 6.5	43	32	43	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-841	140	MISSION A		083 087	083 087		086 - 7.0	43	2	43	100	
2024-841	145	CLINITEK		083 087	083 087		085 - 6.5	41	41	41	100	
2024-841	147	Mission120		083 087	083 087		084 - 6.0	39	3	39	100	
2024-841	147	Mission120		083 087	083 087		085 - 6.5	39	36	39	100	
2024-841	148	Mission500		083 087	083 087		084 - 6.0	133	2	133	100	
2024-841	148	Mission500		083 087	083 087		085 - 6.5	133	131	133	100	
2024-841	151	Clari. Uro		082 086	083 087		084 - 6.0	23	11	23	100	
2024-841	151	Clari. Uro		082 086	083 087		085 - 6.5	23	10	23	100	
2024-841	151	Clari. Uro		082 086	083 087		086 - 7.0	23	2	23	100	
062 URINALYSIS-pH												
2024-842	011	AMES NM10S		082 086	082 086		082 - 5.0	34	5	34	100	
2024-842	011	AMES NM10S		082 086	082 086		083 - 5.5	34	12	34	100	
2024-842	011	AMES NM10S		082 086	082 086		084 - 6.0	34	17	34	100	
2024-842	013	BAYER CLI		082 086	082 086		082 - 5.0	20	6	20	100	
2024-842	013	BAYER CLI		082 086	082 086		083 - 5.5	20	6	20	100	
2024-842	013	BAYER CLI		082 086	082 086		084 - 6.0	20	8	20	100	
2024-842	067	URISCAN		080 084	082 086		082 - 5.0	54	46	54	100	
2024-842	067	URISCAN		080 084	082 086		083 - 5.5	54	8	54	100	
2024-842	072	URS-9-TECO		082 086	082 086		082 - 5.0	57	11	57	100	
2024-842	072	URS-9-TECO		082 086	082 086		083 - 5.5	57	8	57	100	
2024-842	072	URS-9-TECO		082 086	082 086		084 - 6.0	57	33	57	100	
2024-842	072	URS-9-TECO		082 086	082 086		085 - 6.5	57	5	57	100	
2024-842	080	ROCHE (CHE		080 084	082 086		082 - 5.0	37	34	37	100	
2024-842	080	ROCHE (CHE		080 084	082 086		084 - 6.0	37	3	37	100	
2024-842	089	AIMSTRIP		082 086	082 086		082 - 5.0	146	40	146	100	
2024-842	089	AIMSTRIP		082 086	082 086		083 - 5.5	146	34	146	100	
2024-842	089	AIMSTRIP		082 086	082 086		084 - 6.0	146	72	146	100	
2024-842	094	CLINITEK		082 086	082 086		082 - 5.0	106	13	106	100	
2024-842	094	CLINITEK		082 086	082 086		083 - 5.5	106	32	106	100	
2024-842	094	CLINITEK		082 086	082 086		084 - 6.0	106	61	106	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-842	102	ACON LAB		082 086	082 086		082 - 5.0	126	23	126	100	
2024-842	102	ACON LAB		082 086	082 086		083 - 5.5	126	24	126	100	
2024-842	102	ACON LAB		082 086	082 086		084 - 6.0	126	79	126	100	
2024-842	131	iCHEM VELO		080 084	082 086		082 - 5.0	33	33	33	100	
2024-842	140	MISSION A		081 085	082 086		082 - 5.0	43	3	43	100	
2024-842	140	MISSION A		081 085	082 086		083 - 5.5	43	20	43	100	
2024-842	140	MISSION A		081 085	082 086		084 - 6.0	43	20	43	100	
2024-842	145	CLINITEK		081 085	082 086		082 - 5.0	41	3	41	100	
2024-842	145	CLINITEK		081 085	082 086		083 - 5.5	41	38	41	100	
2024-842	147	Mission120		081 085	082 086		082 - 5.0	39	9	39	100	
2024-842	147	Mission120		081 085	082 086		083 - 5.5	39	26	39	100	
2024-842	147	Mission120		081 085	082 086		084 - 6.0	39	4	39	100	
2024-842	148	Mission500		082 086	082 086		082 - 5.0	133	1	133	100	
2024-842	148	Mission500		082 086	082 086		083 - 5.5	133	5	133	100	
2024-842	148	Mission500		082 086	082 086		084 - 6.0	133	127	133	100	
2024-842	151	Clari. Uro		082 086	082 086		082 - 5.0	23	4	22	100	
2024-842	151	Clari. Uro		082 086	082 086		083 - 5.5	23	7	22	100	
2024-842	151	Clari. Uro		082 086	082 086		084 - 6.0	23	11	22	100	
2024-842	151	Clari. Uro		082 086	082 086		088 - 8.0OR MORE	23	1	22	0	
062 URINALYSIS-pH												
2024-843	011	AMES NM10S		084 088	084 088		085 - 6.5	34	1	34	100	
2024-843	011	AMES NM10S		084 088	084 088		086 - 7.0	34	30	34	100	
2024-843	011	AMES NM10S		084 088	084 088		087 - 7.5	34	3	34	100	
2024-843	013	BAYER CLI		084 088	084 088		086 - 7.0	20	19	20	100	
2024-843	013	BAYER CLI		084 088	084 088		087 - 7.5	20	1	20	100	
2024-843	067	URISCAN		083 087	084 088		085 - 6.5	54	28	54	100	
2024-843	067	URISCAN		083 087	084 088		086 - 7.0	54	26	54	100	
2024-843	072	URS-9-TECO		084 088	084 088		085 - 6.5	57	9	57	100	
2024-843	072	URS-9-TECO		084 088	084 088		086 - 7.0	57	48	57	100	
2024-843	080	ROCHE (CHE		084 088	084 088		086 - 7.0	37	37	37	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-843	089	AIMSTRIP		084 088	084 088		085 - 6.5	146	8	146	100	
2024-843	089	AIMSTRIP		084 088	084 088		086 - 7.0	146	129	146	100	
2024-843	089	AIMSTRIP		084 088	084 088		087 - 7.5	146	9	146	100	
2024-843	094	CLINITEK		084 088	084 088		086 - 7.0	106	103	106	100	
2024-843	094	CLINITEK		084 088	084 088		087 - 7.5	106	3	106	100	
2024-843	102	ACON LAB		084 088	084 088		084 - 6.0	126	1	126	100	
2024-843	102	ACON LAB		084 088	084 088		085 - 6.5	126	14	126	100	
2024-843	102	ACON LAB		084 088	084 088		086 - 7.0	126	109	126	100	
2024-843	102	ACON LAB		084 088	084 088		087 - 7.5	126	2	126	100	
2024-843	131	iCHEM VELO		084 088	084 088		084 - 6.0	33	1	33	100	
2024-843	131	iCHEM VELO		084 088	084 088		086 - 7.0	33	32	33	100	
2024-843	140	MISSION A		084 088	084 088		085 - 6.5	43	10	43	100	
2024-843	140	MISSION A		084 088	084 088		086 - 7.0	43	33	43	100	
2024-843	145	CLINITEK		084 088	084 088		086 - 7.0	41	41	41	100	
2024-843	147	Mission120		083 087	084 088		084 - 6.0	39	1	39	100	
2024-843	147	Mission120		083 087	084 088		085 - 6.5	39	23	39	100	
2024-843	147	Mission120		083 087	084 088		086 - 7.0	39	15	39	100	
2024-843	148	Mission500		084 088	084 088		086 - 7.0	133	131	133	100	
2024-843	148	Mission500		084 088	084 088		085 - 6.5	133	2	133	100	
2024-843	151	Clari. Uro		084 088	084 088		085 - 6.5	23	4	23	100	
2024-843	151	Clari. Uro		084 088	084 088		086 - 7.0	23	19	23	100	
062 URINALYSIS-pH												
2024-844	011	AMES NM10S		086 088	085 088		087 - 7.5	34	14	34	100	
2024-844	011	AMES NM10S		086 088	085 088		088 - 8.0OR MORE	34	20	34	100	
2024-844	013	BAYER CLI		085 088	085 088		086 - 7.0	20	1	20	100	
2024-844	013	BAYER CLI		085 088	085 088		087 - 7.5	20	12	20	100	
2024-844	013	BAYER CLI		085 088	085 088		088 - 8.0OR MORE	20	7	20	100	
2024-844	067	URISCAN		085 088	085 088		086 - 7.0	54	1	54	100	
2024-844	067	URISCAN		085 088	085 088		087 - 7.5	54	47	54	100	
2024-844	067	URISCAN		085 088	085 088		088 - 8.0OR MORE	54	6	54	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-844	072	URS-9-TECO		085 088	085 088		088 - 8.00R MORE	57	1	56	100		
2024-844	072	URS-9-TECO		085 088	085 088		084 - 6.0	57	1	56	0		
2024-844	072	URS-9-TECO		085 088	085 088		085 - 6.5	57	1	56	100		
2024-844	072	URS-9-TECO		085 088	085 088		086 - 7.0	57	10	56	100		
2024-844	072	URS-9-TECO		085 088	085 088		087 - 7.5	57	44	56	100		
2024-844	080	ROCHE (CHE		084 088	085 088		088 - 8.00R MORE	37	13	37	100		
2024-844	080	ROCHE (CHE		084 088	085 088		085 - 6.5	37	1	37	100		
2024-844	080	ROCHE (CHE		084 088	085 088		086 - 7.0	37	23	37	100		
2024-844	089	AIMSTRIP		085 088	085 088		086 - 7.0	146	5	146	100		
2024-844	089	AIMSTRIP		085 088	085 088		087 - 7.5	146	92	146	100		
2024-844	089	AIMSTRIP		085 088	085 088		088 - 8.00R MORE	146	49	146	100		
2024-844	094	CLINITEK		086 088	085 088		086 - 7.0	106	5	106	100		
2024-844	094	CLINITEK		086 088	085 088		087 - 7.5	106	43	106	100		
2024-844	094	CLINITEK		086 088	085 088		088 - 8.00R MORE	106	58	106	100		
2024-844	102	ACON LAB		085 088	085 088		086 - 7.0	126	7	126	100		
2024-844	102	ACON LAB		085 088	085 088		087 - 7.5	126	97	126	100		
2024-844	102	ACON LAB		085 088	085 088		088 - 8.00R MORE	126	22	126	100		
2024-844	131	iCHEM VELO		084 088	085 088		086 - 7.0	33	25	33	100		
2024-844	131	iCHEM VELO		084 088	085 088		088 - 8.00R MORE	33	8	33	100		
2024-844	140	MISSION A		085 088	085 088		086 - 7.0	43	3	43	100		
2024-844	140	MISSION A		085 088	085 088		087 - 7.5	43	34	43	100		
2024-844	140	MISSION A		085 088	085 088		088 - 8.00R MORE	43	6	43	100		
2024-844	145	CLINITEK		085 088	085 088		087 - 7.5	41	40	41	100		
2024-844	145	CLINITEK		085 088	085 088		088 - 8.00R MORE	41	1	41	100		
2024-844	147	Mission120		085 088	085 088		084 - 6.0	39	1	38	0		
2024-844	147	Mission120		085 088	085 088		086 - 7.0	39	5	38	100		
2024-844	147	Mission120		085 088	085 088		087 - 7.5	39	27	38	100		
2024-844	147	Mission120		085 088	085 088		088 - 8.00R MORE	39	6	38	100		
2024-844	148	Mission500		085 088	085 088		086 - 7.0	133	8	133	100		
2024-844	148	Mission500		085 088	085 088		087 - 7.5	133	116	133	100		

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-844	148	Mission500		085 088	085 088		088 - 8.00R MORE	133	9	133	100		
2024-844	151	Clari. Uro		085 088	085 088		086 - 7.0	23	1	23	100		
2024-844	151	Clari. Uro		085 088	085 088		087 - 7.5	23	21	23	100		
2024-844	151	Clari. Uro		085 088	085 088		088 - 8.00R MORE	23	1	23	100		
062 URINALYSIS-pH													
2024-845	011	AMES NM10S		086 088	085 088		087 - 7.5	34	8	34	100		
2024-845	011	AMES NM10S		086 088	085 088		088 - 8.00R MORE	34	26	34	100		
2024-845	013	BAYER CLI		086 088	085 088		087 - 7.5	20	8	20	100		
2024-845	013	BAYER CLI		086 088	085 088		088 - 8.00R MORE	20	12	20	100		
2024-845	067	URISCAN		085 088	085 088		086 - 7.0	54	1	54	100		
2024-845	067	URISCAN		085 088	085 088		087 - 7.5	54	44	54	100		
2024-845	067	URISCAN		085 088	085 088		088 - 8.00R MORE	54	9	54	100		
2024-845	072	URS-9-TECO		085 088	085 088		086 - 7.0	57	5	57	100		
2024-845	072	URS-9-TECO		085 088	085 088		087 - 7.5	57	45	57	100		
2024-845	072	URS-9-TECO		085 088	085 088		088 - 8.00R MORE	57	7	57	100		
2024-845	080	ROCHE (CHE		084 088	085 088		086 - 7.0	37	23	37	100		
2024-845	080	ROCHE (CHE		084 088	085 088		088 - 8.00R MORE	37	14	37	100		
2024-845	089	AIMSTRIP		086 088	085 088		087 - 7.5	146	52	146	100		
2024-845	089	AIMSTRIP		086 088	085 088		088 - 8.00R MORE	146	94	146	100		
2024-845	094	CLINITEK		086 088	085 088		087 - 7.5	106	28	106	100		
2024-845	094	CLINITEK		086 088	085 088		088 - 8.00R MORE	106	78	106	100		
2024-845	102	ACON LAB		085 088	085 088		086 - 7.0	126	1	126	100		
2024-845	102	ACON LAB		085 088	085 088		087 - 7.5	126	65	126	100		
2024-845	102	ACON LAB		085 088	085 088		088 - 8.00R MORE	126	60	126	100		
2024-845	131	iCHEM VELO		084 088	085 088		082 - 5.0	33	1	32	0		
2024-845	131	iCHEM VELO		084 088	085 088		086 - 7.0	33	27	32	100		
2024-845	131	iCHEM VELO		084 088	085 088		088 - 8.00R MORE	33	5	32	100		
2024-845	140	MISSION A		085 088	085 088		087 - 7.5	43	30	43	100		
2024-845	140	MISSION A		085 088	085 088		088 - 8.00R MORE	43	13	43	100		
2024-845	145	CLINITEK		085 088	085 088		087 - 7.5	41	37	41	100		

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-845	145	CLINITEK		085 088	085 088		088 - 8.00R MORE	41	4	41	100		
2024-845	147	Mission120		085 088	085 088		086 - 7.0	39	2	39	100		
2024-845	147	Mission120		085 088	085 088		087 - 7.5	39	25	39	100		
2024-845	147	Mission120		085 088	085 088		088 - 8.00R MORE	39	12	39	100		
2024-845	148	Mission500		086 088	085 088		086 - 7.0	133	4	133	100		
2024-845	148	Mission500		086 088	085 088		087 - 7.5	133	62	133	100		
2024-845	148	Mission500		086 088	085 088		088 - 8.00R MORE	133	67	133	100		
2024-845	151	Clari. Uro		085 088	085 088		087 - 7.5	23	14	23	100		
2024-845	151	Clari. Uro		085 088	085 088		088 - 8.00R MORE	23	9	23	100		
064 URIN-PROTEIN QUALI.													
2024-841	011	AMES NM10S		053 055	053 055		054 - 2+	34	24	34	100		
2024-841	011	AMES NM10S		053 055	053 055		053 - 1+	34	2	34	100		
2024-841	011	AMES NM10S		053 055	053 055		055 - 3+	34	8	34	100		
2024-841	013	BAYER CLI		053 055	053 055		054 - 2+	20	17	20	100		
2024-841	013	BAYER CLI		053 055	053 055		055 - 3+	20	3	20	100		
2024-841	067	URISCAN		053 055	053 055		054 - 2+	54	44	54	100		
2024-841	067	URISCAN		053 055	053 055		053 - 1+	54	10	54	100		
2024-841	072	URS-9-TECO		053 055	053 055		054 - 2+	57	36	57	100		
2024-841	072	URS-9-TECO		053 055	053 055		053 - 1+	57	1	57	100		
2024-841	072	URS-9-TECO		053 055	053 055		055 - 3+	57	20	57	100		
2024-841	080	ROCHE (CHE		053 055	053 055		053 - 1+	37	1	37	100		
2024-841	080	ROCHE (CHE		053 055	053 055		055 - 3+	37	12	37	100		
2024-841	080	ROCHE (CHE		053 055	053 055		054 - 2+	37	24	37	100		
2024-841	089	AIMSTRIP		053 055	053 055		054 - 2+	145	106	143	100		
2024-841	089	AIMSTRIP		053 055	053 055		052 - TRACES	145	1	143	0		
2024-841	089	AIMSTRIP		053 055	053 055		053 - 1+	145	3	143	100		
2024-841	089	AIMSTRIP		053 055	053 055		055 - 3+	145	34	143	100		
2024-841	089	AIMSTRIP		053 055	053 055		056 - 4+	145	1	143	0		
2024-841	094	CLINITEK		053 055	053 055		054 - 2+	106	96	105	100		
2024-841	094	CLINITEK		053 055	053 055		052 - TRACES	106	1	105	0		

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-841	094	CLINITEK		053 055	053 055		053 - 1+	106	2	105	100	
2024-841	094	CLINITEK		053 055	053 055		055 - 3+	106	7	105	100	
2024-841	102	ACON LAB		053 055	053 055		054 - 2+	127	105	127	100	
2024-841	102	ACON LAB		053 055	053 055		053 - 1+	127	7	127	100	
2024-841	102	ACON LAB		053 055	053 055		055 - 3+	127	15	127	100	
2024-841	131	iCHEM VELO		053 055	053 055		054 - 2+	33	32	33	100	
2024-841	131	iCHEM VELO		053 055	053 055		053 - 1+	33	1	33	100	
2024-841	140	MISSION A		053 055	053 055		054 - 2+	41	39	41	100	
2024-841	140	MISSION A		053 055	053 055		055 - 3+	41	2	41	100	
2024-841	145	CLINITEK		053 055	053 055		054 - 2+	41	39	41	100	
2024-841	145	CLINITEK		053 055	053 055		053 - 1+	41	1	41	100	
2024-841	145	CLINITEK		053 055	053 055		055 - 3+	41	1	41	100	
2024-841	147	Mission120		053 055	053 055		054 - 2+	40	36	40	100	
2024-841	147	Mission120		053 055	053 055		053 - 1+	40	4	40	100	
2024-841	148	Mission500		053 055	053 055		054 - 2+	134	110	134	100	
2024-841	148	Mission500		053 055	053 055		053 - 1+	134	16	134	100	
2024-841	148	Mission500		053 055	053 055		055 - 3+	134	8	134	100	
2024-841	151	Clari. Uro		053 055	053 055		054 - 2+	23	20	23	100	
2024-841	151	Clari. Uro		053 055	053 055		053 - 1+	23	1	23	100	
2024-841	151	Clari. Uro		053 055	053 055		055 - 3+	23	2	23	100	
064 URIN-PROTEIN QUALI.												
2024-842	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	34	34	34	100	
2024-842	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	20	20	20	100	
2024-842	067	URISCAN		051 051	051 051		051 - NEGATIVE	54	54	54	100	
2024-842	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	57	57	57	100	
2024-842	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	37	37	37	100	
2024-842	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	145	144	144	100	
2024-842	089	AIMSTRIP		051 051	051 051		052 - TRACES	145	1	144	0	
2024-842	094	CLINITEK		051 051	051 051		051 - NEGATIVE	106	106	106	100	
2024-842	102	ACON LAB		051 051	051 051		051 - NEGATIVE	127	127	127	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-842	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	33	33	33	100	
2024-842	140	MISSION A		051 051	051 051		051 - NEGATIVE	41	41	41	100	
2024-842	145	CLINITEK		051 051	051 051		051 - NEGATIVE	41	41	41	100	
2024-842	147	Mission120		051 051	051 051		051 - NEGATIVE	40	40	40	100	
2024-842	148	Mission500		051 051	051 051		051 - NEGATIVE	134	134	134	100	
2024-842	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	23	23	23	100	
064 URIN-PROTEIN QUALI.												
2024-843	011	AMES NM10S		053 055	053 055		054 - 2+	34	22	34	100	
2024-843	011	AMES NM10S		053 055	053 055		053 - 1+	34	2	34	100	
2024-843	011	AMES NM10S		053 055	053 055		055 - 3+	34	10	34	100	
2024-843	013	BAYER CLI		053 055	053 055		054 - 2+	20	13	20	100	
2024-843	013	BAYER CLI		053 055	053 055		055 - 3+	20	7	20	100	
2024-843	067	URISCAN		053 055	053 055		054 - 2+	54	48	54	100	
2024-843	067	URISCAN		053 055	053 055		053 - 1+	54	5	54	100	
2024-843	067	URISCAN		053 055	053 055		055 - 3+	54	1	54	100	
2024-843	072	URS-9-TECO		054 056	053 055		054 - 2+	57	24	56	100	
2024-843	072	URS-9-TECO		054 056	053 055		051 - NEGATIVE	57	1	56	0	
2024-843	072	URS-9-TECO		054 056	053 055		053 - 1+	57	2	56	100	
2024-843	072	URS-9-TECO		054 056	053 055		055 - 3+	57	30	56	100	
2024-843	080	ROCHE (CHE		053 055	053 055		054 - 2+	37	26	37	100	
2024-843	080	ROCHE (CHE		053 055	053 055		055 - 3+	37	11	37	100	
2024-843	089	AIMSTRIP		053 055	053 055		054 - 2+	145	86	144	100	
2024-843	089	AIMSTRIP		053 055	053 055		053 - 1+	145	3	144	100	
2024-843	089	AIMSTRIP		053 055	053 055		055 - 3+	145	55	144	100	
2024-843	089	AIMSTRIP		053 055	053 055		056 - 4+	145	1	144	0	
2024-843	094	CLINITEK		053 055	053 055		054 - 2+	106	91	104	100	
2024-843	094	CLINITEK		053 055	053 055		052 - TRACES	106	2	104	0	
2024-843	094	CLINITEK		053 055	053 055		053 - 1+	106	1	104	100	
2024-843	094	CLINITEK		053 055	053 055		055 - 3+	106	12	104	100	
2024-843	102	ACON LAB		053 055	053 055		054 - 2+	127	88	127	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-843	102	ACON LAB		053 055	053 055		053 - 1+	127	4	127	100
2024-843	102	ACON LAB		053 055	053 055		055 - 3+	127	35	127	100
2024-843	131	iCHEM VELO		053 055	053 055		053 - 1+	33	1	32	100
2024-843	131	iCHEM VELO		053 055	053 055		055 - 3+	33	5	32	100
2024-843	131	iCHEM VELO		053 055	053 055		056 - 4+	33	1	32	0
2024-843	131	iCHEM VELO		053 055	053 055		054 - 2+	33	26	32	100
2024-843	140	MISSION A		053 055	053 055		054 - 2+	41	35	41	100
2024-843	140	MISSION A		053 055	053 055		055 - 3+	41	6	41	100
2024-843	145	CLINITEK		053 055	053 055		054 - 2+	41	33	41	100
2024-843	145	CLINITEK		053 055	053 055		053 - 1+	41	1	41	100
2024-843	145	CLINITEK		053 055	053 055		055 - 3+	41	7	41	100
2024-843	147	Mission120		053 055	053 055		055 - 3+	40	1	40	100
2024-843	147	Mission120		053 055	053 055		054 - 2+	40	36	40	100
2024-843	147	Mission120		053 055	053 055		053 - 1+	40	3	40	100
2024-843	148	Mission500		053 055	053 055		054 - 2+	134	101	134	100
2024-843	148	Mission500		053 055	053 055		053 - 1+	134	11	134	100
2024-843	148	Mission500		053 055	053 055		055 - 3+	134	22	134	100
2024-843	151	Clari. Uro		053 055	053 055		054 - 2+	23	17	22	100
2024-843	151	Clari. Uro		053 055	053 055		055 - 3+	23	5	22	100
2024-843	151	Clari. Uro		053 055	053 055		056 - 4+	23	1	22	0
064 URIN-PROTEIN QUALI.											
2024-844	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	34	34	34	100
2024-844	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	20	20	20	100
2024-844	067	URISCAN		051 051	051 051		051 - NEGATIVE	54	50	50	100
2024-844	067	URISCAN		051 051	051 051		052 - TRACES	54	3	50	0
2024-844	067	URISCAN		051 051	051 051		053 - 1+	54	1	50	0
2024-844	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	57	57	57	100
2024-844	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	37	35	35	100
2024-844	080	ROCHE (CHE		051 051	051 051		052 - TRACES	37	2	35	0
2024-844	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	145	137	137	100

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-844	089	AIMSTRIP		051 051	051 051		052 - TRACES	145	7	137	0	
2024-844	089	AIMSTRIP		051 051	051 051		053 - 1+	145	1	137	0	
2024-844	094	CLINITEK		051 051	051 051		051 - NEGATIVE	106	106	106	100	
2024-844	102	ACON LAB		051 051	051 051		051 - NEGATIVE	127	126	126	100	
2024-844	102	ACON LAB		051 051	051 051		052 - TRACES	127	1	126	0	
2024-844	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	33	33	33	100	
2024-844	140	MISSION A		051 051	051 051		051 - NEGATIVE	41	39	39	100	
2024-844	140	MISSION A		051 051	051 051		052 - TRACES	41	2	39	0	
2024-844	145	CLINITEK		051 051	051 051		051 - NEGATIVE	41	41	41	100	
2024-844	147	Mission120		051 051	051 051		051 - NEGATIVE	40	40	40	100	
2024-844	148	Mission500		051 051	051 051		051 - NEGATIVE	134	133	133	100	
2024-844	148	Mission500		051 051	051 051		052 - TRACES	134	1	133	0	
2024-844	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	23	21	21	100	
2024-844	151	Clari. Uro		051 051	051 051		052 - TRACES	23	2	21	0	
064 URIN-PROTEIN QUALI.												
2024-845	011	AMES NM10S		053 055	053 055		054 - 2+	34	22	34	100	
2024-845	011	AMES NM10S		053 055	053 055		055 - 3+	34	12	34	100	
2024-845	013	BAYER CLI		053 055	053 055		054 - 2+	20	12	20	100	
2024-845	013	BAYER CLI		053 055	053 055		055 - 3+	20	8	20	100	
2024-845	067	URISCAN		053 055	053 055		054 - 2+	54	48	54	100	
2024-845	067	URISCAN		053 055	053 055		053 - 1+	54	3	54	100	
2024-845	067	URISCAN		053 055	053 055		055 - 3+	54	3	54	100	
2024-845	072	URS-9-TECO		054 056	053 055		055 - 3+	57	29	57	100	
2024-845	072	URS-9-TECO		054 056	053 055		054 - 2+	57	27	57	100	
2024-845	072	URS-9-TECO		054 056	053 055		053 - 1+	57	1	57	100	
2024-845	080	ROCHE (CHE		053 055	053 055		054 - 2+	37	24	37	100	
2024-845	080	ROCHE (CHE		053 055	053 055		053 - 1+	37	1	37	100	
2024-845	080	ROCHE (CHE		053 055	053 055		055 - 3+	37	12	37	100	
2024-845	089	AIMSTRIP		054 056	053 055		053 - 1+	145	1	144	100	
2024-845	089	AIMSTRIP		054 056	053 055		055 - 3+	145	80	144	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-845	089	AIMSTRIP		054 056	053 055		056 - 4+	145	2	144	100	
2024-845	089	AIMSTRIP		054 056	053 055		054 - 2+	145	61	144	100	
2024-845	089	AIMSTRIP		054 056	053 055		051 - NEGATIVE	145	1	144	0	
2024-845	094	CLINITEK		053 055	053 055		054 - 2+	106	89	104	100	
2024-845	094	CLINITEK		053 055	053 055		052 - TRACES	106	2	104	0	
2024-845	094	CLINITEK		053 055	053 055		053 - 1+	106	1	104	100	
2024-845	094	CLINITEK		053 055	053 055		055 - 3+	106	14	104	100	
2024-845	102	ACON LAB		053 055	053 055		054 - 2+	127	78	127	100	
2024-845	102	ACON LAB		053 055	053 055		053 - 1+	127	3	127	100	
2024-845	102	ACON LAB		053 055	053 055		055 - 3+	127	46	127	100	
2024-845	131	iCHEM VELO		053 055	053 055		054 - 2+	33	19	31	100	
2024-845	131	iCHEM VELO		053 055	053 055		051 - NEGATIVE	33	1	31	0	
2024-845	131	iCHEM VELO		053 055	053 055		053 - 1+	33	1	31	100	
2024-845	131	iCHEM VELO		053 055	053 055		055 - 3+	33	11	31	100	
2024-845	131	iCHEM VELO		053 055	053 055		056 - 4+	33	1	31	0	
2024-845	140	MISSION A		053 055	053 055		054 - 2+	41	34	41	100	
2024-845	140	MISSION A		053 055	053 055		055 - 3+	41	7	41	100	
2024-845	145	CLINITEK		053 055	053 055		054 - 2+	41	26	40	100	
2024-845	145	CLINITEK		053 055	053 055		053 - 1+	41	1	40	100	
2024-845	145	CLINITEK		053 055	053 055		055 - 3+	41	13	40	100	
2024-845	145	CLINITEK		053 055	053 055		056 - 4+	41	1	40	0	
2024-845	147	Mission120		053 055	053 055		054 - 2+	40	37	40	100	
2024-845	147	Mission120		053 055	053 055		053 - 1+	40	3	40	100	
2024-845	148	Mission500		053 055	053 055		056 - 4+	134	1	132	0	
2024-845	148	Mission500		053 055	053 055		054 - 2+	134	82	132	100	
2024-845	148	Mission500		053 055	053 055		051 - NEGATIVE	134	1	132	0	
2024-845	148	Mission500		053 055	053 055		053 - 1+	134	12	132	100	
2024-845	148	Mission500		053 055	053 055		055 - 3+	134	38	132	100	
2024-845	151	Clari. Uro		053 055	053 055		054 - 2+	23	18	22	100	
2024-845	151	Clari. Uro		053 055	053 055		055 - 3+	23	4	22	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-845	151	Clari. Uro		053 055	053 055		056 - 4+	23	1	22	0		
066 URINAL.-UROBILINOGEN													
2024-841	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	34	34	34	100		
2024-841	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	20	20	20	100		
2024-841	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100		
2024-841	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	57	57	57	100		
2024-841	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	37	37	37	100		
2024-841	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	146	146	146	100		
2024-841	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100		
2024-841	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	125	125	125	100		
2024-841	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	33	33	33	100		
2024-841	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100		
2024-841	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	40	40	40	100		
2024-841	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	40	40	40	100		
2024-841	147	Mission120		061 061	061 061		061 - NORMAL,NEG	40	40	40	100		
2024-841	148	Mission500		061 061	061 061		061 - NORMAL,NEG	135	135	135	100		
2024-841	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	22	22	22	100		
2024-842	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	34	34	34	100		
2024-842	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	20	20	20	100		
2024-842	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100		
2024-842	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	57	57	57	100		
2024-842	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	37	37	37	100		
2024-842	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	146	146	146	100		
2024-842	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100		
2024-842	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	125	125	125	100		
2024-842	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	33	33	33	100		
2024-842	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100		
2024-842	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	40	40	40	100		

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-842	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-842	147	Mission120		061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-842	148	Mission500		061 061	061 061		061 - NORMAL,NEG	135	135	135	100	
2024-842	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	22	22	22	100	
066 URINAL.-UROBILINOGEN												
2024-843	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	34	34	34	100	
2024-843	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	20	20	20	100	
2024-843	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100	
2024-843	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	57	57	57	100	
2024-843	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	37	37	37	100	
2024-843	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	146	146	146	100	
2024-843	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100	
2024-843	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	125	125	125	100	
2024-843	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2024-843	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100	
2024-843	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-843	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-843	147	Mission120		061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-843	148	Mission500		061 061	061 061		061 - NORMAL,NEG	135	135	135	100	
2024-843	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	22	22	22	100	
2024-844	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	34	34	34	100	
2024-844	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	20	20	20	100	
2024-844	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100	
2024-844	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	57	57	57	100	
2024-844	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	37	37	37	100	
2024-844	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	146	146	146	100	
2024-844	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100	
2024-844	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	125	125	125	100	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-844	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2024-844	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100	
2024-844	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-844	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-844	147	Mission120		061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-844	148	Mission500		061 061	061 061		061 - NORMAL,NEG	135	135	135	100	
2024-844	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	22	22	22	100	
066 URINAL.-UROBILINOGEN												
2024-845	011	AMES NM10S		061 063	061 063		061 - NORMAL,NEG	34	3	32	100	
2024-845	011	AMES NM10S		061 063	061 063		062 - 2	34	16	32	100	
2024-845	011	AMES NM10S		061 063	061 063		063 - 4	34	13	32	100	
2024-845	011	AMES NM10S		061 063	061 063		064 - 8	34	2	32	0	
2024-845	013	BAYER CLI		061 063	061 063		061 - NORMAL,NEG	20	5	20	100	
2024-845	013	BAYER CLI		061 063	061 063		062 - 2	20	12	20	100	
2024-845	013	BAYER CLI		061 063	061 063		063 - 4	20	3	20	100	
2024-845	067	URISCAN			061 063		061 - NORMAL,NEG	54	16	53	100	
2024-845	067	URISCAN			061 063		062 - 2	54	4	53	100	
2024-845	067	URISCAN			061 063		063 - 4	54	33	53	100	
2024-845	067	URISCAN			061 063		064 - 8	54	1	53	0	
2024-845	072	URS-9-TECO		061 063	061 063		064 - 8	57	1	56	0	
2024-845	072	URS-9-TECO		061 063	061 063		061 - NORMAL,NEG	57	7	56	100	
2024-845	072	URS-9-TECO		061 063	061 063		062 - 2	57	31	56	100	
2024-845	072	URS-9-TECO		061 063	061 063		063 - 4	57	18	56	100	
2024-845	080	ROCHE (CHE		061 061	061 063		061 - NORMAL,NEG	37	33	37	100	
2024-845	080	ROCHE (CHE		061 061	061 063		062 - 2	37	3	37	100	
2024-845	080	ROCHE (CHE		061 061	061 063		063 - 4	37	1	37	100	
2024-845	089	AIMSTRIP			061 063		064 - 8	146	1	145	0	
2024-845	089	AIMSTRIP			061 063		061 - NORMAL,NEG	146	110	145	100	
2024-845	089	AIMSTRIP			061 063		062 - 2	146	29	145	100	
2024-845	089	AIMSTRIP			061 063		063 - 4	146	6	145	100	

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-845	094	CLINITEK		062 064	061 063		061 - NORMAL,NEG	106	13	106	100	
2024-845	094	CLINITEK		062 064	061 063		062 - 2	106	32	106	100	
2024-845	094	CLINITEK		062 064	061 063		063 - 4	106	57	106	100	
2024-845	094	CLINITEK		062 064	061 063		064 - 8	106	4	106	100	
2024-845	102	ACON LAB			061 063		061 - NORMAL,NEG	125	92	125	100	
2024-845	102	ACON LAB			061 063		062 - 2	125	24	125	100	
2024-845	102	ACON LAB			061 063		063 - 4	125	9	125	100	
2024-845	131	iCHEM VELO		062 064	061 063		061 - NORMAL,NEG	33	1	33	100	
2024-845	131	iCHEM VELO		062 064	061 063		063 - 4	33	32	33	100	
2024-845	138	URS-10T		061 063	061 063		061 - NORMAL,NEG	10	2	10	100	
2024-845	138	URS-10T		061 063	061 063		062 - 2	10	6	10	100	
2024-845	138	URS-10T		061 063	061 063		063 - 4	10	2	10	100	
2024-845	140	MISSION A		061 061	061 063		061 - NORMAL,NEG	40	32	40	100	
2024-845	140	MISSION A		061 061	061 063		062 - 2	40	8	40	100	
2024-845	145	CLINITEK		061 063	061 063		061 - NORMAL,NEG	40	1	40	100	
2024-845	145	CLINITEK		061 063	061 063		062 - 2	40	39	40	100	
2024-845	147	Mission120		061 061	061 063		061 - NORMAL,NEG	40	37	40	100	
2024-845	147	Mission120		061 061	061 063		062 - 2	40	3	40	100	
2024-845	148	Mission500		061 061	061 063		061 - NORMAL,NEG	135	130	135	100	
2024-845	148	Mission500		061 061	061 063		062 - 2	135	5	135	100	
2024-845	151	Clari. Uro			061 063		061 - NORMAL,NEG	22	15	22	100	
2024-845	151	Clari. Uro			061 063		062 - 2	22	4	22	100	
2024-845	151	Clari. Uro			061 063		063 - 4	22	3	22	100	
184 URINALYSIS LEUKOCYTE												
2024-841	011	AMES NM10S		001 001	001 001		001 - Negative	34	34	34	100	
2024-841	013	BAYER CLI		001 001	001 001		001 - Negative	20	20	20	100	
2024-841	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100	
2024-841	072	URS-9-TECO		001 001	001 001		001 - Negative	53	53	53	100	
2024-841	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	33	33	100	
2024-841	080	ROCHE (CHE		001 001	001 001		003 - Small	34	1	33	0	

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-841	089 AIMSTRIP			001 001	001 001		001 - Negative	145	145	145	100
2024-841	094 CLINITEK			001 001	001 001		001 - Negative	105	105	105	100
2024-841	102 ACON LAB			001 001	001 001		001 - Negative	120	120	120	100
2024-841	131 iCHEM VELO			001 001	001 001		001 - Negative	33	33	33	100
2024-841	140 MISSION A			001 001	001 001		001 - Negative	46	46	46	100
2024-841	145 CLINITEK			001 001	001 001		001 - Negative	39	39	39	100
2024-841	147 Mission120			001 001	001 001		001 - Negative	39	39	39	100
2024-841	148 Mission500			001 001	001 001		001 - Negative	135	135	135	100
2024-841	151 Clari. Uro			001 001	001 001		001 - Negative	22	22	22	100
184 URINALYSIS LEUKOCYTE											
2024-842	011 AMES NM10S			002 004	003 005		002 - Traces	34	2	34	100
2024-842	011 AMES NM10S			002 004	003 005		003 - Small	34	25	34	100
2024-842	011 AMES NM10S			002 004	003 005		004 - Moderate	34	7	34	100
2024-842	013 BAYER CLI			002 004	003 005		003 - Small	20	17	20	100
2024-842	013 BAYER CLI			002 004	003 005		004 - Moderate	20	3	20	100
2024-842	067 URISCAN			004 005	003 005		003 - Small	54	6	54	100
2024-842	067 URISCAN			004 005	003 005		004 - Moderate	54	22	54	100
2024-842	067 URISCAN			004 005	003 005		005 - Large	54	26	54	100
2024-842	072 URS-9-TECO			003 005	003 005		002 - Traces	53	1	52	0
2024-842	072 URS-9-TECO			003 005	003 005		003 - Small	53	23	52	100
2024-842	072 URS-9-TECO			003 005	003 005		004 - Moderate	53	29	52	100
2024-842	080 ROCHE (CHE			004 005	003 005		004 - Moderate	34	2	34	100
2024-842	080 ROCHE (CHE			004 005	003 005		005 - Large	34	32	34	100
2024-842	089 AIMSTRIP			002 004	003 005		002 - Traces	145	17	145	100
2024-842	089 AIMSTRIP			002 004	003 005		003 - Small	145	84	145	100
2024-842	089 AIMSTRIP			002 004	003 005		004 - Moderate	145	43	145	100
2024-842	089 AIMSTRIP			002 004	003 005		005 - Large	145	1	145	100
2024-842	094 CLINITEK			002 004	003 005		003 - Small	105	89	105	100
2024-842	094 CLINITEK			002 004	003 005		004 - Moderate	105	15	105	100
2024-842	094 CLINITEK			002 004	003 005		005 - Large	105	1	105	100

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-842	102	ACON LAB		002 004	003 005		002 - Traces	120	4	120	100
2024-842	102	ACON LAB		002 004	003 005		003 - Small	120	76	120	100
2024-842	102	ACON LAB		002 004	003 005		004 - Moderate	120	38	120	100
2024-842	102	ACON LAB		002 004	003 005		005 - Large	120	2	120	100
2024-842	131	iCHEM VELO		004 005	003 005		004 - Moderate	33	3	33	100
2024-842	131	iCHEM VELO		004 005	003 005		005 - Large	33	30	33	100
2024-842	140	MISSION A		002 004	003 005		001 - Negative	46	1	45	0
2024-842	140	MISSION A		002 004	003 005		002 - Traces	46	6	45	100
2024-842	140	MISSION A		002 004	003 005		003 - Small	46	25	45	100
2024-842	140	MISSION A		002 004	003 005		004 - Moderate	46	14	45	100
2024-842	145	CLINITEK		003 005	003 005		001 - Negative	39	1	38	0
2024-842	145	CLINITEK		003 005	003 005		004 - Moderate	39	38	38	100
2024-842	147	Mission120		002 004	003 005		001 - Negative	39	1	38	0
2024-842	147	Mission120		002 004	003 005		002 - Traces	39	9	38	100
2024-842	147	Mission120		002 004	003 005		003 - Small	39	26	38	100
2024-842	147	Mission120		002 004	003 005		004 - Moderate	39	3	38	100
2024-842	148	Mission500		002 004	003 005		002 - Traces	135	19	135	100
2024-842	148	Mission500		002 004	003 005		003 - Small	135	67	135	100
2024-842	148	Mission500		002 004	003 005		004 - Moderate	135	49	135	100
2024-842	151	Clari. Uro		002 004	003 005		002 - Traces	22	2	22	100
2024-842	151	Clari. Uro		002 004	003 005		003 - Small	22	11	22	100
2024-842	151	Clari. Uro		002 004	003 005		004 - Moderate	22	9	22	100
184 URINALYSIS LEUKOCYTE											
2024-843	011	AMES NM10S		001 001	001 001		001 - Negative	34	34	34	100
2024-843	013	BAYER CLI		001 001	001 001		001 - Negative	20	20	20	100
2024-843	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100
2024-843	072	URS-9-TECO		001 001	001 001		001 - Negative	53	53	53	100
2024-843	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	34	34	100
2024-843	089	AIMSTRIP		001 001	001 001		001 - Negative	145	145	145	100
2024-843	094	CLINITEK		001 001	001 001		001 - Negative	105	105	105	100

Participant Summary

MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-843	102	ACON LAB		001 001	001 001		001 - Negative	120	120	120	100	
2024-843	131	iCHEM VELO		001 001	001 001		001 - Negative	33	33	33	100	
2024-843	140	MISSION A		001 001	001 001		001 - Negative	46	46	46	100	
2024-843	145	CLINITEK		001 001	001 001		001 - Negative	39	38	38	100	
2024-843	145	CLINITEK		001 001	001 001		004 - Moderate	39	1	38	0	
2024-843	147	Mission120		001 001	001 001		001 - Negative	39	39	39	100	
2024-843	148	Mission500		001 001	001 001		001 - Negative	135	135	135	100	
2024-843	151	Clari. Uro		001 001	001 001		001 - Negative	22	22	22	100	
184 URINALYSIS LEUKOCYTE												
2024-844	011	AMES NM10S		001 001	001 001		001 - Negative	34	34	34	100	
2024-844	013	BAYER CLI		001 001	001 001		001 - Negative	20	20	20	100	
2024-844	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100	
2024-844	072	URS-9-TECO		001 001	001 001		001 - Negative	53	53	53	100	
2024-844	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	34	34	100	
2024-844	089	AIMSTRIP		001 001	001 001		001 - Negative	145	145	145	100	
2024-844	094	CLINITEK		001 001	001 001		001 - Negative	105	105	105	100	
2024-844	102	ACON LAB		001 001	001 001		001 - Negative	120	120	120	100	
2024-844	131	iCHEM VELO		001 001	001 001		001 - Negative	33	33	33	100	
2024-844	140	MISSION A		001 001	001 001		001 - Negative	46	46	46	100	
2024-844	145	CLINITEK		001 001	001 001		001 - Negative	39	39	39	100	
2024-844	147	Mission120		001 001	001 001		001 - Negative	39	39	39	100	
2024-844	148	Mission500		001 001	001 001		001 - Negative	135	135	135	100	
2024-844	151	Clari. Uro		001 001	001 001		001 - Negative	22	22	22	100	
2024-845	011	AMES NM10S		001 001	001 001		001 - Negative	34	34	34	100	
2024-845	013	BAYER CLI		001 001	001 001		001 - Negative	20	20	20	100	
2024-845	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100	
2024-845	072	URS-9-TECO		001 001	001 001		001 - Negative	53	53	53	100	
2024-845	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	34	34	100	

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-845	089	AIMSTRIP		001 001	001 001		001 - Negative	145	145	145	100	
2024-845	094	CLINITEK		001 001	001 001		001 - Negative	105	105	105	100	
2024-845	102	ACON LAB		001 001	001 001		001 - Negative	120	120	120	100	
2024-845	131	iCHEM VELO		001 001	001 001		001 - Negative	33	33	33	100	
2024-845	140	MISSION A		001 001	001 001		001 - Negative	46	46	46	100	
2024-845	145	CLINITEK		001 001	001 001		001 - Negative	39	39	39	100	
2024-845	147	Mission120		001 001	001 001		001 - Negative	39	39	39	100	
2024-845	148	Mission500		001 001	001 001		001 - Negative	135	135	135	100	
2024-845	151	Clari. Uro		001 001	001 001		001 - Negative	22	22	22	100	

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 80 PREGNANCY TEST							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score			
063 URI-PREGNANCY TEST														
2024-841	091	AIM STEP		001	001	001	001	001	-	NEGATIVE	38	38	38	100
2024-841	101	HCG Alere		001	001	001	001	001	-	NEGATIVE	21	21	21	100
2024-842	091	AIM STEP		001	001	001	001	001	-	NEGATIVE	38	38	38	100
2024-842	101	HCG Alere		001	001	001	001	001	-	NEGATIVE	21	21	21	100
2024-843	091	AIM STEP		002	002	002	002	002	-	POSITIVE	38	38	38	100
2024-843	101	HCG Alere		002	002	002	002	002	-	POSITIVE	21	21	21	100
2024-844	091	AIM STEP		001	001	001	001	001	-	NEGATIVE	38	38	38	100
2024-844	101	HCG Alere		001	001	001	001	001	-	NEGATIVE	21	21	21	100
2024-845	091	AIM STEP		002	002	002	002	002	-	POSITIVE	38	38	38	100
2024-845	101	HCG Alere		002	002	002	002	002	-	POSITIVE	21	21	21	100

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS			GRP: 75 URINALYSIS SEDIMENT						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
150 URINAL.- SEDIMENT											
2024-851					023 023		023 - URIC ACID	912	911	911	100
2024-851					023 023		033 - OVAL FAT B	912	1	911	0
2024-852					040 040		039 - E. vermic.	912	1	911	0
2024-852					040 040		040 - S. haemat.	912	911	911	100
2024-853					038 038		038 - YEAST/FUN.	912	912	912	100
2024-854					028 028		028 - TRIPLE PH.	912	912	912	100
2024-855					003 003		003 - GRANULAR C	912	886	886	100
2024-855					003 003		005 - RED CELL C	912	25	886	0
2024-855					003 003		033 - OVAL FAT B	912	1	886	0

Participant Summary
MONTH 10 OF YEAR 2024

SPE: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS				GRP: 98 OCCULT BLOOD					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
154 FECAL OCCULT BLOOD												
2024-861	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	366	366	366	100
2024-861	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	746	746	746	100
2024-862	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	366	366	366	100
2024-862	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	746	745	745	100
2024-862	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	746	1	745	0
2024-863	001	PEROXIDASE		002	002	002	002	001 - NEGATIVE	366	1	365	0
2024-863	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	366	365	365	100
2024-863	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	746	746	746	100
2024-864	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	366	366	366	100
2024-864	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	746	745	745	100
2024-864	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	746	1	745	0
2024-865	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	366	366	366	100
2024-865	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	746	745	745	100
2024-865	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	746	1	745	0

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS				GRP: 90 SPECIAL TEST						
ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. LABS	PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
068 CARCINOE. ANTIG. CEA				CLIA TEST ID #: 0								EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}	
2024-811	29	VITROS		11		0.400	0.000	0.00	0.400	0.400			
2024-811	38	ROCHE E		17		0.682	0.104	15.28	0.500	0.900			
2024-811	44	BECK.COUL.		18		0.533	0.047	8.84	0.400	0.700			

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-811	50	ARC		10	1.090	0.513	47.04	0.800	1.400		
068	CARCINOE. ANTIG. CEA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}								
2024-812	29	VITROS		11	13.355	0.365	2.73	12.300	14.500		
2024-812	38	ROCHE E		17	12.971	0.561	4.33	11.300	14.700		
2024-812	44	BECK.COUL.		18	14.844	0.965	6.50	11.900	17.700		
2024-812	50	ARC		10	15.460	1.188	7.68	11.900	19.000		
2024-813	29	VITROS		11	20.027	0.536	2.68	18.400	21.600		
2024-813	38	ROCHE E		17	18.794	0.887	4.72	16.100	21.500		
2024-813	44	BECK.COUL.		18	22.489	1.355	6.03	18.400	26.600		
2024-813	50	ARC		10	23.720	1.111	4.68	20.400	27.100		
2024-814	29	VITROS		11	8.130	0.190	2.34	7.600	8.700		
2024-814	38	ROCHE E		17	8.053	0.315	3.91	7.100	9.000		
2024-814	44	BECK.COUL.		18	9.041	0.546	6.03	7.400	10.700		
2024-814	50	ARC		10	9.350	0.512	5.48	7.800	10.900		
2024-815	29	VITROS		11	4.190	0.114	2.71	3.800	4.500		
2024-815	38	ROCHE E		17	4.394	0.201	4.58	3.800	5.000		
2024-815	44	BECK.COUL.		18	4.717	0.320	6.79	3.800	5.700		
2024-815	50	ARC		10	4.870	0.471	9.68	3.700	6.100		
069	PROS. SPEC-ANTIG-PSA										
2024-811	29	VITROS		45	0.100	0.000	0.00	0.100	0.100		
2024-811	36	TOSOH AIA		10	0.070	0.046	65.47	0.100	0.100		
2024-811	36	TOSOH AIA		10	0.000	0.000	0.00	0.000	0.000		
2024-811	38	ROCHE E		52	0.073	0.048	66.37	0.100	0.100		
2024-811	38	ROCHE E		52	0.000	0.000	0.00	0.000	0.000		
2024-811	44	BECK.COUL.		51	0.100	0.000	0.00	0.100	0.100		
2024-811	50	ARC		21	0.000	0.000	0.00	0.000	0.000		
2024-811	57	S. EXL 200		59	0.081	0.047	57.58	0.100	0.100		

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024-811	58	ATELLICA		13	0.000	0.000	0.00	0.000	0.000
2024-811	58	ATELLICA		13	0.100	0.000	0.00	0.100	0.100
069	PROS. SPEC-ANTIG-PSA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{LOWER}			
2024-812	29	VITROS		45	6.123	0.288	4.70	5.300	7.000
2024-812	36	TOSOH AIA		10	8.710	0.926	10.63	6.500	10.900
2024-812	38	ROCHE E		52	12.540	0.835	6.66	10.000	15.000
2024-812	44	BECK.COUL.		51	12.614	0.667	5.29	10.600	14.600
2024-812	50	ARC		21	10.210	0.520	5.09	8.600	11.800
2024-812	57	S. EXL 200		59	12.397	0.769	6.20	10.100	14.700
2024-812	58	ATELLICA		13	10.462	0.622	5.95	8.600	12.300
2024-813	29	VITROS		45	8.941	0.447	5.00	7.600	10.300
2024-813	36	TOSOH AIA		10	13.380	2.135	15.96	10.000	16.700
2024-813	38	ROCHE E		52	18.346	1.128	6.15	15.000	21.700
2024-813	44	BECK.COUL.		51	18.610	1.002	5.39	15.600	21.600
2024-813	50	ARC		21	14.915	0.795	5.33	12.500	17.300
2024-813	57	S. EXL 200		59	18.425	1.305	7.08	14.500	22.300
2024-813	58	ATELLICA		13	15.446	0.817	5.29	13.000	17.900
2024-814	29	VITROS		45	3.791	0.178	4.69	3.300	4.300
2024-814	36	TOSOH AIA		10	5.340	0.472	8.83	4.000	6.700
2024-814	38	ROCHE E		52	7.579	0.484	6.39	6.100	9.000
2024-814	44	BECK.COUL.		51	7.690	0.390	5.07	6.500	8.900
2024-814	50	ARC		21	6.057	0.420	6.94	4.800	7.300
2024-814	57	S. EXL 200		59	7.297	0.400	5.49	6.100	8.500
2024-814	58	ATELLICA		13	6.454	0.290	4.49	5.600	7.300
2024-815	29	VITROS		45	2.014	0.088	4.36	1.800	2.300
2024-815	36	TOSOH AIA		10	2.680	0.293	10.92	2.000	3.400
2024-815	38	ROCHE E		52	3.788	0.255	6.74	3.000	4.600

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-815	44	BECK.COUL.		51	3.794	0.176	4.64	3.300	4.300
2024-815	50	ARC		21	2.943	0.181	6.17	2.400	3.500
2024-815	57	S. EXL 200		59	3.604	0.193	5.35	3.000	4.200
2024-815	58	APELLICA		13	3.169	0.190	5.98	2.600	3.700
071 VITAMIN B 12			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}				
2024-811	29	VITROS		27	230.037	9.822	4.27	201.000	260.000
2024-811	38	ROCHE E		38	246.263	43.361	17.61	185.000	308.000
2024-811	44	BECK.COUL.		27	166.037	14.180	8.54	125.000	208.000
2024-811	50	ARC		21	247.950	31.078	12.53	186.000	310.000
2024-811	57	S. EXL 200		20	266.050	31.283	11.76	200.000	333.000
2024-811	58	APELLICA		12	172.167	13.446	7.81	132.000	213.000
2024-812	29	VITROS		27	662.615	25.941	3.91	585.000	740.000
2024-812	38	ROCHE E		38	700.703	44.175	6.30	568.000	833.000
2024-812	44	BECK.COUL.		27	491.630	35.982	7.32	384.000	600.000
2024-812	50	ARC		21	642.762	35.995	5.60	535.000	751.000
2024-812	57	S. EXL 200		20	645.450	34.435	5.33	542.000	749.000
2024-812	58	APELLICA		12	571.000	61.677	10.80	428.000	714.000
2024-813	29	VITROS		27	814.769	30.233	3.71	724.000	905.000
2024-813	38	ROCHE E		38	918.526	55.961	6.09	751.000	1086.000
2024-813	44	BECK.COUL.		27	645.481	48.064	7.45	501.000	790.000
2024-813	50	ARC		21	856.857	67.693	7.90	654.000	1060.000
2024-813	57	S. EXL 200		20	832.600	46.737	5.61	692.000	973.000
2024-813	58	APELLICA		12	764.091	33.419	4.37	664.000	864.000
2024-814	29	VITROS		27	461.115	13.357	2.90	421.000	501.000
2024-814	38	ROCHE E		38	506.919	36.322	7.17	398.000	616.000
2024-814	44	BECK.COUL.		27	363.333	24.249	6.67	291.000	436.000
2024-814	50	ARC		21	474.476	34.074	7.18	372.000	577.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-814	57	S. EXL 200		20	488.400	30.513	6.25	397.000	580.000	
2024-814	58	APELLICA		12	402.833	29.077	7.22	316.000	490.000	
071 VITAMIN B 12			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}					
2024-815	29	VITROS		27	330.692	12.193	3.69	294.000	367.000	
2024-815	38	ROCHE E		38	371.316	39.621	10.67	278.000	464.000	
2024-815	44	BECK.COUL.		27	259.926	20.503	7.89	198.000	321.000	
2024-815	50	ARC		21	360.143	25.514	7.08	284.000	437.000	
2024-815	57	S. EXL 200		20	379.750	33.243	8.75	285.000	475.000	
2024-815	58	APELLICA		12	287.000	31.387	10.94	215.000	359.000	

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 95 GLYCOHEMOGLOBINE				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
146 GLYCOHEMOGLOBIN										
2024-821	12	COBAS/INT.		24	8.783	0.254	2.90	8.000	9.500	
2024-821	14	IMMUNOTUR.		16	8.825	0.286	3.24	8.000	9.700	
2024-821	22	VITROS		54	8.470	0.224	2.65	7.800	9.100	
2024-821	31	IMMUNOTURB		48	8.783	0.254	2.89	8.000	9.500	
2024-821	40	SIEMENS DI		79	8.578	0.193	2.25	8.000	9.200	
2024-821	46	ARCHITECT		18	8.217	0.308	3.75	7.300	9.100	
2024-821	48	APELLICA		15	8.327	0.184	2.21	7.800	8.900	
2024-822	12	COBAS/INT.		24	5.196	0.165	3.18	4.700	5.700	
2024-822	14	IMMUNOTUR.		16	5.300	0.225	4.25	4.600	6.000	
2024-822	22	VITROS		54	5.043	0.077	1.52	4.800	5.300	
2024-822	31	IMMUNOTURB		48	5.100	0.209	4.10	4.500	5.700	
2024-822	40	SIEMENS DI		79	5.095	0.108	2.13	4.800	5.400	
2024-822	46	ARCHITECT		18	5.000	0.205	4.11	4.400	5.600	
2024-822	48	APELLICA		15	4.987	0.154	3.10	4.500	5.400	

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 95 GLYCOHEMOGLOBINE				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
146	GLYCOHEMOGLOBIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{LOWER}				
2024-823	12	COBAS/INT.		24	5.870	0.140	2.38	5.500	6.300	
2024-823	14	IMMUNOTUR.		16	6.006	0.233	3.88	5.300	6.700	
2024-823	22	VITROS		54	5.815	0.099	1.70	5.500	6.100	
2024-823	31	IMMUNOTURB		48	5.874	0.147	2.49	5.400	6.300	
2024-823	40	SIEMENS DI		79	5.784	0.118	2.05	5.400	6.100	
2024-823	46	ARCHITECT		18	5.639	0.226	4.02	5.000	6.300	
2024-823	48	ATELLICA		15	5.687	0.088	1.56	5.400	6.000	
2024-824	12	COBAS/INT.		24	5.200	0.172	3.31	4.700	5.700	
2024-824	14	IMMUNOTUR.		16	5.313	0.223	4.20	4.600	6.000	
2024-824	22	VITROS		54	5.045	0.072	1.42	4.800	5.300	
2024-824	31	IMMUNOTURB		48	5.106	0.172	3.37	4.600	5.600	
2024-824	40	SIEMENS DI		79	5.126	0.097	1.89	4.800	5.400	
2024-824	46	ARCHITECT		18	5.022	0.210	4.17	4.400	5.700	
2024-824	48	ATELLICA		15	5.047	0.102	2.03	4.700	5.400	
2024-825	12	COBAS/INT.		24	5.861	0.128	2.18	5.500	6.200	
2024-825	14	IMMUNOTUR.		16	5.981	0.227	3.79	5.300	6.700	
2024-825	22	VITROS		54	5.789	0.082	1.41	5.500	6.000	
2024-825	31	IMMUNOTURB		48	5.892	0.173	2.94	5.400	6.400	
2024-825	40	SIEMENS DI		79	5.785	0.115	1.99	5.400	6.100	
2024-825	46	ARCHITECT		18	5.628	0.218	3.88	5.000	6.300	
2024-825	48	ATELLICA		15	5.667	0.174	3.07	5.100	6.200	
SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 99 Vitamin D				

Participant Summary
MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
178 Vitamin D		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	20 %					
2024-301	3	VITROS		45	82.682	6.349	7.68	66.000	99.000
2024-301	5	ROCHE E		37	37.361	2.162	5.79	30.000	45.000
2024-301	9	BECK.COUL.		46	58.844	6.182	10.51	47.000	71.000
2024-301	11	ARC		17	42.000	2.372	5.65	34.000	50.000
2024-301	25	S. DIME		34	45.206	4.178	9.24	36.000	54.000
2024-301	27	ATELLICA		12	87.182	2.405	2.76	70.000	105.000
2024-301	27	ATELLICA		12	65.333	6.799	10.41	52.000	78.000
2024-302	3	VITROS		45	103.844	6.254	6.02	83.000	125.000
2024-302	5	ROCHE E		37	57.639	3.449	5.98	46.000	69.000
2024-302	9	BECK.COUL.		46	74.311	6.950	9.35	59.000	89.000
2024-302	11	ARC		17	58.313	3.513	6.02	47.000	70.000
2024-302	25	S. DIME		34	59.455	4.307	7.24	48.000	71.000
2024-302	27	ATELLICA		12	89.000	9.522	10.70	71.000	107.000
2024-302	27	ATELLICA		12	108.250	5.659	5.23	87.000	130.000
2024-303	3	VITROS		45	22.533	3.351	14.87	18.000	27.000
2024-303	5	ROCHE E		37	6.029	0.167	2.76	5.000	7.000
2024-303	9	BECK.COUL.		46	13.533	2.372	17.53	11.000	16.000
2024-303	11	ARC		17	8.938	0.747	8.36	7.000	11.000
2024-303	25	S. DIME		34	11.912	1.669	14.01	10.000	14.000
2024-303	27	ATELLICA		12	12.500	2.432	19.46	10.000	15.000
2024-303	27	ATELLICA		12	15.417	2.431	15.77	12.000	19.000
2024-304	3	VITROS		45	119.422	5.009	4.19	96.000	143.000
2024-304	5	ROCHE E		37	78.444	4.291	5.47	63.000	94.000
2024-304	9	BECK.COUL.		46	89.644	8.652	9.65	72.000	108.000
2024-304	11	ARC		17	73.375	5.872	8.00	59.000	88.000
2024-304	25	S. DIME		34	72.471	5.071	7.00	58.000	87.000

Participant Summary

MONTH 10 OF YEAR 2024

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-304	27	APELLICA		12	130.273	3.840	2.95	104.000	156.000
2024-304	27	APELLICA		12	106.000	11.030	10.41	85.000	127.000
178 Vitamin D		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-305	3	VITROS		45	55.659	4.194	7.53	45.000	67.000
2024-305	5	ROCHE E		37	18.444	1.992	10.80	15.000	22.000
2024-305	9	BECK.COUL.		46	37.244	4.243	11.39	30.000	45.000
2024-305	11	ARC		17	24.813	1.629	6.56	20.000	30.000
2024-305	25	S. DIME		34	27.667	2.878	10.40	22.000	33.000
2024-305	27	APELLICA		12	40.500	6.212	15.34	32.000	49.000
2024-305	27	APELLICA		12	54.273	2.260	4.16	43.000	65.000